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ZUSAMMENFASSUNG FÜR LAIEN 
Krebserkrankungen sind nach wie vor ein Hauptgrund für vorzeitige Sterblichkeit. Während 
Fortschritte im Verständnis von Krebs auf molekularer und genetischer Ebene zur Identifizierung 
neuer potentieller therapeutischer Ansätze geführt haben, gibt es weiterhin viel Potential bei der 
Entwicklung von effizienten und spezifischen Krebstherapien. Viele Wirkstoffe in der frühen 
Entwicklung sind durch schlechte physiko-chemische Eigenschaften charakterisiert (bspw. eine 
schlechte Löslichkeit in Wasser). Als Konsequenz haben diese Wirkstoffe oft eine problematische 
Pharmacokinetik und zeigen eine hohe Anreicherung in Nicht-Tumor Gewebe, welche zu Dosis-
limitierenden Nebenwirkungen führen kann. Neue Ansätze zur Formulierung solcher Wirkstoffe sind 
daher von grossem Nutzen. Nanomedizin stellt eine vielversprechende Strategie dar, um die physiko-
chemischen Eigenschaften von Wirkstoffen zu optimieren, und um Wirkstoffe gezielt an ihren Wirkort 
(die Krebszelle) zu navigieren. Dies kann über passive Akkumulierung oder über aktives Binden der 
Nanopartikel an Rezeptoren auf der Zielzelle passieren. Das Ziel dieses Projektes war die 
Entwicklung von Nanopartikeln für die Formulierung von Zytostatika, sowie die Entwicklung eines 
neuen Ansatzes zur Therapie von Leberkrebs. Diese Arbeit kann deshalb folgendermassen in zwei 
Hauptteile zusammengefasst werden:  
 
Erstens wurden biokompatible und bioabbaubare Polymere verwendet um Nanopartikel herzustellen 
welche als Plattform zum Transport von zytostatischen Medikamenten dienen können. Die Partikel 
wurden in vitro in humanen Zellen sowie im Tiermodell getestet. Die Nanopartikel wurden mit 
Doxorubicin, einem zugelassenen Krebstherapeutikum, beladen und die Stabilität sowie die Effizienz 
der Beladung getestet. Anschliessend wurde die zelluläre Aufnahme der Nanopartikel in humanen 
Krebszellen analysiert und der therapeutische Effekt getestet. In einem nächsten Schritt wurde die 
Pharmacokinetik der Nanopartikel in Ratten getestet und die Plasma-Konzentrations-Zeit Profile mit 
dem Gold-Standard für lang-zirkulierende Nanopartikel (PEGylierte Liposomen) verglichen. Eine lange 
Plasma Halbwertszeit ist eine wichtige Voraussetzung für effiziente Akkumulation im Tumor Gewebe. 
Es wurde zudem ein Protokoll zur Herstellung von sogenannten Gold-Nanohybrid Partikeln entwickelt. 
Diese Nanopartikel eignen sich besonders für die Darstellung der zellulären Aufnahme von 
Nanopartikeln und können somit für die Aufschlüsselung von Aufnahmemechanismen oder bei der 
Diagnose eingesetzt werden. In einem letzten Schritt wurden die Nanopartikel mit einem Antikörper 
funktionalisiert welcher Rezeptoren auf Zielzellen erkennt und bindet. Dies ermöglicht eine effiziente 
und spezifische zelluläre Aufnahme der Nanopartikel. Die Interaktion dieser funktionalisierten 
Nanopartikel mit den Zielzellen wurde in vitro mit verschiedenen Methoden analysiert.    
 
Zweitens wurde das Effektorprotein des onkotoxischen Virus „H-1 Parvovirus“ als neuartige 
Therapie bei Leberkrebs getestet. Dieses Virus wurde in präklinischen Studien bereits gegen 
verschiedene Krebsarten eingesetzt und wird in einer klinischen Studie in Patienten mit Hirntumoren 
getestet. Trotz dieser vielversprechenden Resultate kann die virale Krebstherapie mit einigen 
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Problemen verbunden sein. Ziel dieser Studie war es deshalb, das therapeutische Potential des 
Effektorproteins (NS1) in Leberkrebszellen nach nicht-viralem Gen-Transfer zu untersuchen. In einem 
ersten Schritt wurde die Effizienz der Genexpression in einem Set von Leberkrebszellen untersucht 
und der therapeutische Effekt von NS1 charakterisiert. Um zu zeigen dass die Therapie spezifisch für 
Krebszellen ist und kein Effekt auf gesunde Zellen hat, wurden ebenfalls frisch isolierte humane 
Leberzellen getestet. In weiteren mechanistischen in vitro Experimenten wurde der NS1-induzierte 
Zelltod detailliert untersucht. Zusätzlich wurde ein Biomarker für die Sensitivität von Krebszellen auf 
NS1 getestet und evaluiert. Als letztes wurde die Verträglichkeit dieses neuen therapeutischen 
Ansatzes nach einmaliger oder multipler Dosierung in Mäusen getestet.  
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SUMMARY 
Cancer is still a leading cause of death worldwide. Despite the progress in the molecular 
understanding of cancer diseases, there’s an urgent need in novel therapeutics and drug delivery 
strategies. Many novel anti-cancer compounds in early development are characterized by 
unfavorable physico-chemical properties and lack in drug-like properties. As a result, many of these 
compounds suffer from insufficient pharmacokinetic properties and show a high accumulation in off-
target tissue that can induce dose-limiting side effects. Nanomedicines depict a promising strategy 
to optimize the pharmacokinetics of such compounds and to deliver them to their site of action: The 
cancer cell. The goal of this thesis was to develop nanoparticulate drug delivery platforms for passive 
and active drug targeting. In addition, a novel nanoparticle-based gene therapeutic for the treatment 
of liver cancer was evaluated. This thesis can be summarized in two main parts as follows: 
 
In a first part, a biocompatible and biodegradable polymer was used to prepare micelles for the 
delivery of small molecular anticancer drugs. These micelles were tested subsequently on in vitro and 
in vivo models. A highly reproducible protocol for the formulation of doxorubicin-loaded micelles was 
developed and micelles were characterized extensively for their physico-chemical properties. Cellular 
uptake of micelles was analyzed and their therapeutic potential was assessed in vitro on human 
cancer cells. To passively accumulate in solid tumors, nanoparticles need to be long-circulating and 
must remain in the blood circulation for hours. Therefore, the pharmacokinetic profile and 
biodistribution of doxorubicin-loaded micelles in rats was analyzed and compared to the gold 
standard of long-circulating nanoparticles: PEGylated liposomes. In a next step, a protocol for the 
preparation of so-called gold-nanohybrids was developed. Such nanohybrids are valuable tools to 
analyze nanoparticle-cell interactions and the intracellular fate of nanoparticles in detail. Further, such 
nanoparticles can be used as diagnostic tools. In a last step, micelles were functionalized with an 
antibody for targeted drug delivery. Cellular internalization of these micelles was analyzed using an 
array of methods.  
 
In a second part, a novel therapeutic strategy using the main effector protein of the rat parvovirus 
(H-1) for the treatment of hepatocellular carcinoma (HCC) was developed. H-1 parvovirus showed 
promising results in the preclinical setting and was consequently tested in a clinical trial in patients 
suffering form glioma. Despite this development, viral therapies may be linked with several issues. 
Therefore, the potential of the viral effector protein NS1 for the treatment of liver cancer was analyzed 
after non-viral gene delivery. In a first step, the gene-delivery efficiency and the therapeutic effect 
were analyzed in a panel of human liver cancer-derived cell lines. Various in vitro assays were used to 
study the NS1-induced cell death in detail. To show that this therapeutic approach is specific for 
cancer cells, the treatment was furthermore tested on healthy human liver cells. To identify cells that 
are susceptible for this therapeutic approach, a biomarker for the sensitivity to non-viral NS1 therapy 
was evaluated. Finally, safety of this therapy was analyzed in mice after single and multiple dosing.  
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INTRODUCTION 
1 NANOMEDICINES 
The use of nanoparticulate drug carriers for the delivery of small molecules and biologics (e.g. 
proteins or nucleic acids) gained increasing interest within the last decades. Whereas the principle of 
the “magic bullet” was already introduced by Paul Ehrlich in the beginning of the last century [1], 
recent progress in the development of engineered nanomaterials (ENMs) allows to translate this 
theoretical paradigm into drug therapies. Several nanoparticulate drug delivery platforms were 
approved by health care authorities recently and are successfully used in clinical practice [2,3].  
 
1.1 HISTORY OF NANOMEDICINES 
The development of nanomedicines was revolutionized by the use of liposomes [4]. First used to 
study membrane behavior [5], their potential in the encapsulation and delivery of drugs was 
discovered in the early 1960s [6–8]. At the beginning, major drawbacks of their use were burst drug 
release after dilution and substantial uptake by mononuclear macrophages. To overcome these 
issues, the principle of PEGylation was implemented and resulted in so-called “stealth liposomes” [9]. 
These liposomes show less protein opsonization, reduced uptake by the mononuclear phagocyte 
system (MPS), and as a consequence a prolonged plasma circulation half-life. With the approval of 
Doxil® in the 1990s, the first nanoparticulate (i.e. liposomal) formulation was successfully introduced 
in to clinical practice [10]. This approval paved the way for more advanced systems, e.g. for the 
delivery of complex biologics such as proteins and nucleic acids using nanoparticles (NPs), as 
outlined in the next sections.   
 
1.2 TYPES OF NANOPARTICLES 
According to the European Commission, ENMs are defined as ‘intentionally manufactured material, 
containing particles, in an unbound state or as an aggregate or as an agglomerate and where, for 50% 
or more of the particles in the number size distribution, one or more external dimensions is in the size 
range 1 nm to 100 nm’ [11,12]. ENMs share distinct characteristics such as a minute size, a high 
surface to volume ratio, and unique physico-chemical properties. With respect to pharmaceutical 
applications, NPs can be classified e.g. according to their chemical composition and their 
morphology. Besides lipid-based NPs mentioned above, nanomedicine platforms based on viruses, 
inorganic materials, and polymers were developed and reached market approval in the last decade 
[2]. The following section is providing an overview about the different nanomedicine platforms used in 
drug delivery (Fig. 1).  
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Figure 1 Schematic overview about types of nanomedicines.  
 
Materials such as colloidal gold, iron oxide, silica, and graphene are used for the production of 
inorganic nanoparticles [13]. Characterized by unique physico-chemical properties (e.g. 
photo-thermal features, high electron density, and optical properties), inorganic NPs are of big 
interest as therapeutics, drug carriers, imaging tools, and as theranostics, combining diagnosis and 
treatment of a disease [14]. Quantum dots and nanocrystals, for example, with their size-tunable 
absorption and emission properties, are dominant classes of in vitro and in vivo optical imaging 
probes [13]. Several diagnostic inorganic NPs were approved by health care authorities and some 
therapeutic inorganic constructs such as AuroLaseTM are in clinical development. AuroLaseTM, i.e. 
PEGylated silica-gold nanoshells, are used for the treatment of head and neck cancer via laser-
induced thermal ablation [15]. 
 
Viral nanoparticles are used as gene delivery vectors. Viruses evolved to transfer their nucleic acids 
payload in a highly efficient way to specific cell types [16]. When genetically modified, recombinant 
viral vectors can be used to deliver therapeutic nucleic acids such as DNA or RNA into target cells. 
Retroviruses, adenoviruses, adeno-associated viruses (AAV), and herpes viruses are frequently used 
gene delivery vectors [17]. In addition, some viruses are characterized by an (inherent) ability to 
specifically kill transformed cells. Oncolytic viruses such as the herpes simplex virus and the H-1 
parvovirus are therefore tested as cancer therapeutics [18]. With T-VecTM (talimogene laherparepvec), 
the first oncolytic virus for the treatment of melanoma was approved by health care authorities in 
2015 [19,20].  
 11 
 
Lipid-based nanoparticles were pioneers in the field of nanomedicines [4]. Drug delivery systems 
based on lipids can be classified according to their morphology into liposomes, micelles, lipoplexes, 
and solid-lipid NPs [21,22]. Besides natural occurring lipids such as phosphatidylcholine (PC) or 
phosphatidylinositol, both structural lipids of eukaryotic cell membranes and big libraries containing 
artificial synthetic lipids are used for the formulation of lipid-based NPs [23,24]. With such artificial 
lipids, advanced drug delivery strategies (e.g. triggered drug release and gene delivery platforms) 
were implemented. Until today, more than 10 lipid-based drug carriers for various indications such as 
cancer (e.g. Doxil®), pain (e.g. DepoDurTM), and infectious diseases (e.g. AmBisomeTM) reached 
market approval [25]. 
 
Natural polymers such as polysaccharides (e.g. chitosan or cyclodextrins) and proteins (e.g. gelatin 
or albumin) are used to develop drug delivery systems [26–29]. They are characterized by a high 
biocompatibility and biodegradability, are low in their production costs, and show a high structural 
flexibility [29]. For example, a formulation of albumin-bound paclitaxel (AbraxaneTM) was approved by 
health care authorities and is used in the treatment of several solid tumors [30,31]. Antibodies are 
another class of promising nano-sized therapeutics. They can have an inherent therapeutic effect that 
can be further potentiated by conjugating small molecular drugs to the antibody (antibody drug 
conjugates, ADC) [32].  
 
Because of their versatile chemistry and low batch-to-batch variability as compared to natural 
polymers, synthetic polymers are widely used in pharmaceutical applications. Synthetic polymers 
are used in the production of solid-sphere NPs, polymeric micelles, dendrimers, polymersomes, 
polyplexes, and polymer-drug conjugates [33]. Due to their biocompatibility, biodegradable aliphatic 
polyesters and their copolymers are of special interest. They were successfully used to develop 
medicinal devices, e.g. for tissue engineering and in the production of implants [34–37] and were 
further developed for the implementation of nanoparticulate drug delivery platforms. Typical 
examples are poly(lactic acid) [PLA], poly(glycolic acid) [PGA], poly(lactide-co-glycolide) [PLGA], or 
poly(ε-caprolactone) [PCL] and their copolymers [38,39]. In 2007, PEG-PLA-based polymeric micelles 
(Genexol-PMTM) were approved by health care authorities as delivery vehicle for paclitaxel [40]. A 
recent and promising synthetic polymer, which is of special importance for this PhD thesis project is 
PEG-PCL. A detailed overview about PEG-PCL, including its synthesis, preparation of PEG-PCL NPs, 
and their application is provided in Chapter I of this thesis.  
 
1.3 CLINICAL APPLICATION 
Although the principles of nanomedicine are applicable to a broad range of indications, cancer 
therapy is the most advanced application of NPs. More than 4 out of 5 clinical trials testing NPs are 
registered in the field of cancer therapy [3]. Two main reasons may account for this. First, although 
there was major progress in the development of efficient cancer therapies (e.g. biologics), there is still 
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a high mortality for patients diagnosed with certain tumors [41]. Second, since many 
chemotherapeutic drugs are cytotoxic and lack in specificity, severe, dose limiting off-target effects 
are observed frequently. These side effects dramatically decrease the quality of life for patients and 
may even force therapy stops prior to successful management of the disease [42]. Thus cancer is a 
life-threatening disease and the therapy of cancer is still an unmet medical need. Since many drug 
candidates in development pipelines that show promising results in preclinical trials lack in drug-like 
properties (e.g. metabolic stability, solubility, unfavorable pharmacokinetics), their application is 
challenging and clinical translation is inefficient [43,44]. Therefore, advanced drug delivery systems 
and novel therapeutic strategies are of urgent need. The following section of this PhD thesis is 
focusing on the application of nanomedicines in cancer therapy. 
 
2 CANCER THERAPY 
2.1 BASICS 
Cancer remains a major cause of death worldwide [41]. According to the World Health Organization 
(WHO), cancer is defined as the uncontrolled growth and spread of cells. Since cancer can develop in 
various cell types throughout the body and may metastasize to other organs during progression of 
the disease, cancer is characterized by a high heterogeneity [45,46]. However, a set of general 
hallmarks of cancer such as unlimited replication and proliferation, evading of apoptosis, and 
sustained angiogenesis was defined [47,48]. These cancer-cell related features were targeted by 
various therapeutic strategies [49]. Current options to treat cancer can be classified into surgical 
resection, radiation, and chemotherapy including immunotherapy. Whereas surgery and radiation 
depict first-line choice for some solid cancers, by far not all types of cancer can be treated this way. 
Especially when cancer becomes a systemic rather than a localized disease, chemotherapy becomes 
an important treatment option [50].  
 
2.2 DELIVERY OF SMALL MOLECULAR DRUGS 
The development of chemotherapeutics was launched in the 1940s with the clinical use of alkylating 
agents developed during World War I [51]. Conventional chemotherapeutics are often unspecifically 
targeting rapidly growing and dividing cells and can therefore cause severe off-target effects [42]. 
These non-specific therapies are often characterized by a small therapeutic window and are thus 
limited in their clinical use despite potential benefits. With increasing understanding of cancer biology 
as well as major progress in combinatory chemistry and high-throughput screening techniques, big 
libraries of more specific chemotherapeutics (i.e. molecularly targeted therapies) were identified 
[52,53]. However, these compounds often have unfavorable physico-chemical characteristics and are 
lacking drug-like properties as defined by Lipinski and coworkers [43,54,55]. This often results in 
problems regarding drug formulation and negatively influences pharmacokinetics (PK). After systemic 
administration of these low molecular weight compounds, a rapid clearance from the systemic 
circulation, a large volume of distribution, a high tissue accumulation, and efficient metabolism and 
inactivation (e.g. by the liver) can be observed [56]. Such unfavorable PK may result in a low tumor 
 13 
accumulation and increased off-target effects. Consequently, toxicity concerns and non-favorable PK 
properties are major reasons for the high attrition rate during clinical development of new 
chemotherapeutics: The likelihood of oncology drugs to be approved by health care authorities after 
reaching Phase-I clinical trials is less than 10% [55,57,58]. Nanomedicines depict a promising 
strategy to overcome these drawbacks and to dramatically increase the therapeutic index of potent 
chemotherapeutics. Nanoparticles can (I) increase the solubility of hardly soluble drugs, (II) prolong 
the plasma circulation time of drugs, (III) passively or (IV) actively target diseased cells, tissues, or 
organs, (V) increase efficiency of combination therapies and reduce drug resistances, (VI) release 
their drug payload upon internal or externally applied triggers, and (VII) be combined with diagnostic 
tools (i.e. theranostics). The following section is giving an overview. More detailed information with a 
major emphasis on PEG-PCL-based drug delivery systems is proved in Chapter I of this thesis.  
 
(I) Unfavorable physico-chemical properties of promising therapeutic compounds are often resulting 
in drug formulation problems and are limiting their clinical use. NPs can improve the solubility of 
highly potent compounds and are thus sound candidates for the formulation of such drugs. Paclitaxel, 
for example, has a very low solubility in water (<0.3 μg/mL).  Conventional marketed products contain 
emulsifiers like Cremophor® EL that can provoke undesirable side effects [59]. Therefore, PEG-PLA 
biodegradable polymeric micelles were developed for the delivery of paclitaxel [60]. This formulation 
(Genexol-PM®) was successfully tested in clinics and received market approval in 2007 [40]. In 
another approach, paclitaxel was conjugated to the protein albumin, a naturally occurring polymer. 
Again, albumin-based NPs showed promising clinical results and were approved by health care 
authorities in 2005 under the brand name Abraxane® [30,31].  
 
(II) After encapsulation, nanoparticulate drug delivery systems can change pharmacokinetics and 
biodistribution of their drug payload. A long plasma half-life (t1/2) and a high area under the plasma 
concentration curve (AUC) are prerequisites for efficient delivery of drugs since the dose reaching the 
target tissue increases with the number of passages through the organ and the organ permeability-
surface area (see passive targeting) [39,61]. In addition, by preventing accumulation in e.g. 
metabolizing organs such as spleen and liver or fat tissue, off-target effects can be reduced. 
Anthracyclines, for example, are characterized by a high plasma clearance (CL), a low AUC, and a 
short plasma half-life after i.v. administration. However, encapsulation in PEG-liposomes results in a 
prominent increase in AUC and a significant prolongation of t1/2 as shown in various preclinical and 
clinical studies [62]. This formulation was approved by health care authorities and was the first 
nanoparticulate drug delivery system to reach the market.  
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Figure 2 Passive targeting of solid tumors.  
 
(III) The rapid cell proliferation of cancer cells increases the local demand for oxygen and nutrients 
supply that requires growth of new blood vessels. These fast growing blood vessels are often 
characterized by endothelial fenestration [63]. Long-circulating NPs can extravasate from such leaky 
blood vessels and can passively accumulate in solid tumors. In addition, many solid tumor lack in 
sufficient lymphatic drainage resulting in reduced clearance of macromolecules and NPs from the 
interstitial space [64]. In sum, this phenomenon is called enhanced permeability and retention (EPR) 
effect [65,66]. The extent of passive drug targeting (Fig. 2) strongly depends on tumor biology (e.g. 
blood flow, intratumoral pressure, and pore size of vascular fenestration) as well as key 
characteristics of the NPs such as size, shape, and surface charge [63,67]. The choice of the tumor 
model strongly influences the outcome of preclinical testing and establishment of relevant animal 
models depicts a major issue in the development of NPs for tumor therapy [68,69]. For example, a 
long-circulating liposomal formulation of the anticancer drug lurtotecan (NK 211) was evaluated in an 
ovary cell carcinoma xenograft model. Delivery of lurtotecan using liposomes resulted in a 9 to 
67-fold increase in tumor exposure and superior therapeutic efficacy as compared to administration 
as free drug [70]. As a consequence, liposomal lurtotecan was tested in several clinical trials [71,72]. 
 
 
Figure 3 Active targeting of cancer cells. Schematic drawing of (A) targeted nanoparticles and (B) targeting ligands.  
 
(IV) To specifically target cells and to improve cellular uptake, active drug targeting strategies were 
implemented. Active targeting takes advantage of specific surface-accessible receptors or epitopes 
overexpressed on target cells (Fig. 3A) [67]. Small molecular ligands (e.g. vitamins or carbohydrates) 
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as well as biologics (e.g. antibodies and aptamers) are therefore conjugated to the nanocarrier 
surface (Fig. 3B) [73]. Ligands should have sufficient binding affinity to their target, should be non-
immunogenic, and not exceed certain size ranges [74]. Moreover, the amount of ligand per NP 
dramatically influences the drug targeting efficiency. On one hand, multivalent binding with high 
ligand densities can enhance the binding and uptake to target cells (i.e. avidity) [75]. On the other 
hand, loss of camouflage (i.e. stealth properties) and subsequent increase of NP uptake by 
mononuclear macrophages may decrease the circulation half-life and by this the targeting 
efficiency [76]. Cetuximab, a chimeric monoclonal antibody against the epidermal growth factor 
receptor (EGFR), was conjugated to FDA approved doxorubicin-loaded PEG-liposomes (Caelyx®) to 
treat patients with advanced solid tumors. The targeted delivery system successfully completed a 
Phase-I clinical trial recently and exceeded the therapeutic potential of free drug or drug 
encapsulated into non-targeted PEG-liposomes due to dramatically increased intracellular drug 
concentrations in tumor cells [77,78].  
 
(V) For certain diseases, single drug therapies may not be sufficient and therefore combination 
therapies are often superior. Synergistic effects, that overwhelm simple additive effects of two drugs, 
can only occur at certain defined drug-to-drug ratios [79]. These ratios are often determined in vitro 
but translation of these results to the in vivo situation is difficult because of differences in drug 
metabolism and PK (DMPK) of the compounds. The synchronized delivery of a certain drug-to-drug 
ratio using NPs may help to translate these preclinical results into clinically relevant therapies [80,81]. 
A liposomal formulation combining the chemotherapeutics cytarabine and daunorubicin in a molar 
ratio of 5:1 (CPX-351) showed promising results in a Phase-III clinical trial treating patients suffering 
from acute myeloid leukemia [82–84]. Delivery of chemosensitizing agents (e.g. inhibitors of efflux 
transporters) and chemotherapeutics in the same delivery vehicle may in addition be a powerful tool 
to tackle multi-drug resistance [80].  
 
(VI) Nanosized drug delivery systems can be tuned to efficiently release their drug cargo at the site of 
action. Stimuli responsive (“smart”) nanomedicines sensitive to internal (e.g. enzymes) or external 
(e.g. radiation) triggers were designed [85]. Matrix metalloprotease 2/-9 (MMP-2 and MMP-9) 
cleavable linkers, for example, are widely used. MMP-2 and MMP-9 are overexpressed in the 
extracellular matrix of several tumors. MMP-2 and MMP-9-cleavable linkers can thus be used to 
activate NPs in the tumor microenvironment [86]. For example, a PEG-PCL copolymer linked by an 
enzyme-cleavable linker was synthesized. Upon exposure to MMP-2 and MMP-9, PEG is cleaved 
and “stealth” properties are lost. This results in a high tumor uptake and superior therapeutic effects 
as compared to conventional PEG-PCL micelles [86] 
 
(VI) Nanomedicines have the great potential to combine diagnostic tools and therapeutic compounds 
in a single agent. These multifunctional systems are called theranostics [87]. Imaging probes 
suitable for non-invasive imaging techniques such as optical imaging (e.g. near-infrared (NIR) 
imaging), computer tomography (CT), magnetic resonance (MR) imaging, or positron-emission 
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spectroscopy (PET) are therefore used [87]. Some of these probes can be activated as therapeutics 
by external stimuli e.g. in photodynamic or photothermal therapy, others are combined with 
conventional chemotherapeutics or biologics such as nucleic acids [88–91]. For example, PEG-PCL-
tethered gold NPs (GNPs) were tested as theranostics in vivo. Dense packaging of GNPs resulted in a 
strong NIR absorption due to plasmon coupling. When injected in melanoma-bearing mice, tumor 
imaging and prolongation of the mean survival time was achieved [89].  
 
2.3 DELIVERY OF MACROMOLECULES 
2.3.1 DELIVERY OF PROTEINS AND PEPTIDES 
Peptide and protein therapeutics are of increasing interest. Whereas in the early 1990s only a few 
biotechnology products were available, more than 200 products were approved by health care 
authorities in 2012 [92]. However, the administration of proteins in vivo is linked with major issues. 
Proteins often show inadequate stability, can be excreted via glomerular filtration, and can induce 
immunogenic reactions. As a result, therapeutic proteins are often characterized by unfavorable PK 
properties, i.e. a short plasma circulation half-life [93].  
 
In order to overcome this issue, modification of therapeutic proteins via PEGylation is a frequently 
used and well-established concept. The hydrophilic polymer PEG is approved by health care 
authorities and is non-toxic. Conjugation of PEG to proteins increases their size and PEGylated 
proteins can be considered as nanomedicines. For example, type I interferon (IFN) that regulates the 
expression of genes linked with cancer growth, proliferation, differentiation, and migration [94]. 
PEGylation of IFN increases the hydrodynamic diameter of the protein from 2.73 nm to 9.46 nm, 
decreases the systemic clearance of IFN, and reduces IFN side effects while remaining the 
therapeutic activity of IFN [94,95]. A class of therapeutic proteins with increasing interest is 
monoclonal antibody fragments (Fab’). However, they show a relatively short plasma half-life and 
their application is therefore limited [96]. A Fab’ directed against the vascular endothelial growth 
factor receptor 2 (VEGFR-2) was modified with a 40 kDa PEG fragment (CDP791) and was tested in a 
clinical trial in patients with solid tumors. Whereas the free Fab’ was rapidly cleared from the 
systemic blood circulation, the PEG-protein conjugate showed a prolonged plasma half-life after 
injection [97]. A PEG-conjugate of the enzyme asparaginase (OncasparTM) received market approval 
in 2006 for the treatment of leukemia [98]. In contrast to the free enzyme that frequently induces 
hypersensitivity reactions due to anti-asparaginase antibody production requiring adaptation or even 
stop of therapy, the PEG-protein conjugate decreases the risk for these side effects and shows a 
prolonged therapeutic effect [99,100]. In summary, PEG-protein conjugates show reduced 
immunogenicity and toxicity, a prolonged blood circulation time, and an optimized biodistribution 
[9,101–106].  
To further improve chemical stability of therapeutic proteins (e.g. to prevent proteolysis in plasma and 
after cellular internalization), they were encapsulated in nanoparticulate drug delivery systems. PLGA-
lipid hybrid NPs were developed for the simultaneous delivery of the immunostimulant interleukin-2 
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(IL-2) and a small molecule inhibitor of the transforming growth factor β (TGF-β). This formulation 
showed promising results against melanoma [107]. Another interesting approach is the use of 
phosphatase and tensin homolog deleted on chromosome 10 (PTEN), a tumor suppressor that is 
inactivated in many human tumors. Restoring the function of PTEN may therefore depict a promising 
therapeutic option for these cancers. However, PTEN is an intracellular protein and artificial PTEN 
thus needs to be internalized. Encapsulation of recombinant PTEN in lipidoids resulted in efficient 
intracellular delivery of this therapeutic protein and induced apoptosis in prostate cancer cells [108]. 
In addition, nanomedicines are promising candidates for the oral delivery of peptides and proteins. 
Liposomal formulations containing tetraether lipids that naturally occur in archaea bacteria were 
successfully used to deliver peptides such as ocreotide or myrcludex B after oral dosage [109,110]. 
Keeping in mind that peptide and protein therapeutics are a rapidly growing class of therapeutics, 
such non-invasive drug delivery strategies are of high importance [111]. 
 
2.3.2 DELIVERY OF NUCLEIC ACIDS 
Gene therapy is a promising strategy for the treatment of cancer diseases. However, the delivery of 
nucleic acids such as micro RNA (miRNA), small interfering RNA (siRNA), messenger RNA (mRNA), 
and plasmid DNA (pDNA) remains challenging [112]. Unprotected nucleic acids are prone to 
degradation and hardly cross biological membranes due to their hydrophilicity and negative charge 
[113]. Thus, advanced delivery systems are currently under investigation in preclinical and clinical 
studies. These nanosized carriers can mainly be divided into two classes: (I) viral and (II) non-viral 
gene delivery systems.  
 
(I) Viruses are natural occurring vectors for nucleic acids and are therefore used to deliver therapeutic 
genes [16]. Various genetically engineered viral vectors can be used, each with its strengths and 
weaknesses. Frequently used viruses for gene delivery are retroviruses, adenoviruses, AAVs, and 
herpes viruses, amongst others [17]. The choice of the viral vectors depends on the type of genetic 
material, packaging capacity, and tropism of the virus. In addition, some viruses are able to insert 
therapeutic genes into the host cellular chromatin, whereas others persist in the nucleus as 
extrachromosomal nucleic acids [114]. Pexa-Vec (JX-594), a replication competent poxvirus 
expressing granulocyte-monocyte colony-stimulating factor (GM-CSF), for example, was used in the 
treatment of renal cell caner, colorectal cancer, and advanced hepatocellular carcinoma [115–118]. 
Via oncolysis and immunotherapy, this virus showed promising results in clinical trials in solid tumors. 
However, several hurdles limit the clinical use of viral gene delivery vectors. First, immunological 
defense mechanisms decrease the therapeutic benefit of viral agents. Second, recombinant viral 
vectors may not show the same tropism as their natural occurring counterparts and can therefore 
infect a broad range of host cells [114]. Whereas this may depict a benefit in some cases, lack of 
specificity may provoke severe side effects to other organs and may be fatal [119]. Third, integrating 
vectors (e.g. retroviruses) may randomly integrate their genome in the host cell chromatin and may in 
long-term induce cancer [114]. Forth, although viral vectors for gene delivery are rendered non-
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replicative, there remains the possibility of reversion to a pathogenic wild-type (i.e. replication 
competent) virus [120].  
 
(II) To address the potential drawbacks of viruses, non-viral gene delivery systems for therapeutic 
applications are of increasing interest. In comparison to viral vectors, non-viral gene delivery systems 
have several advantages. Non-viral delivery systems reduce risks for insertional mutagenesis, are 
less immunogenic, can carry larger genetic payloads, and are more flexible [113,120–122]. Most 
systems for the delivery of genes are based on cationic lipids (e.g. LipofectamineTM) or polymers such 
as poly(ethyleneimine) [PEI]. In addition, positively charged peptides such as poly-lysine were tested 
for their potential as gene carriers [113,121,122]. However, due to their positive charge, these carriers 
accumulate in the lung after i.v. administration and are rapidly cleared from the systemic circulation 
[123,124]. Therefore, long-circulating delivery systems such as liposomes or polymeric micelles with 
a gene delivery capacity are developed. For example, a PEG-PCL-PEI tri-block copolymer construct 
was used for the simultaneous delivery of siRNA and quantum dots [125]. An increase of the plasma 
half-life was observed upon systemic administration as compared to non-modified PEI. When 
modified with folic acid, in vivo targeted delivery of siRNA to tumors was achieved [126]. Despite their 
benefits as compared to viral vectors, several problems need to be solved to enable clinical 
translation of non-viral gene delivery systems [121]. Overall, these systems are characterized by a 
poor transfection efficiency in vivo [122]. Recent efforts were focusing on enhancing endosomal 
escape, unpacking, and nuclear transport [120]. In addition, special tools are needed to confer long-
term gene expression by gene editing techniques such as CRISPR/Cas9 or to decrease the 
epigenetic shutdown of extra-chromosomal DNA [121].  
 
2.4 FUTURE TRENDS AND PERSPECTIVES: ONCOLYTIC VIRUSES 
Whereas the development of specific drugs interfering with single pathways may be effective for 
some tumors, the high frequency of acquired resistances and inefficient therapies resulted in a 
change in paradigm in cancer therapy. In tumors, abnormal cell growth hardly depends on single 
dysregulations [127]. In addition, acquired drug resistances caused by mutations during drug therapy 
can occur and render tumor cells non-permissive for these drugs [128,129]. Thus, targeting various 
signaling pathways (e.g. kinases) either by compounds such as multi-kinase inhibitors or by the 
combination of multiple highly specific drugs may help to increase therapeutic success and to 
bypass acquired resistances [130,131]. Whereas this concept still needs to be implemented in the 
drug discovery process and therapeutic dosage schemes, some natural occurring infectious agents 
such as bacteria and viruses have already developed strategies to avoid cellular defense 
mechanisms by interacting with multiple cellular targets. If targeted towards transformed cells, these 
pathogens can be potent weapons for the treatment of cancer [132,133]. Viral infections are closely 
related to cancer. On one hand, 20% of all human cancers can be associated with infectious 
diseases. Viruses, such as the Rous-Sarcoma Virus, can induce uncontrolled cell proliferation and it’s 
infection can therefore result in neoplastic tissue and subsequently tumor formation [134]. On the 
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other hand, some naturally acquired viral infections were linked with tumor regression in patients with 
hematological malignancies. As a consequence, oncolytic viruses were tested for their therapeutic 
potential in preclinical and clinical trials [19,135–137]. These studies revealed the encouraging 
potential of viral cancer therapy and T-VEC®, a viral cancer therapeutic gained market approval 
recently.  
 
 
Figure 4 Effects of the H-1PV large non-structural protein NS1 on cancer cells. Adapted from [138]. 
 
A virus that successfully reached clinical trials for the treatment of recurrent glioblastoma multiforma 
(GBM) is the rat parvovirus H-1 (H-1PV). Rodent parvoviruses (PV), such as the minute virus of mice 
(MVM) and the H1-PV, belong to the smallest mammalian viruses known. The diameter of the 
icosahedral capsid is around 25 nm and the genetic information is stored on a small 5.1 kb linear 
single strand DNA (ssDNA) [139]. Due to this limited coding capacity (2 structural proteins, at least 6 
non-structural proteins) [138], expressed proteins need to exert several functions in a timely highly 
coordinated manner throughout the viral life cycle. Only a handful of non-structural proteins are 
sufficient to hijack the host cell and take control of its functions [140]. The large non-structural protein 
(NS1) plays essential roles in viral propagation and the induction of H-1PV-mediated cell death [141]. 
NS1 is highly regulated by phosphorylation throughout the viral life cycle. At least 10 different 
phosphorylated species of NS1 were identified [141,142]. Interestingly, cytotoxic effects induced by 
NS1 can be switched on and off by site-directed mutagenesis at potential phosphorylation sites 
without interfering with viral replication [143]. Regulation of NS1 via phosphorylation (e.g. by protein 
kinase C isoforms, PKC) is dependent on phosphoinositide-dependent kinase-1 (PDK1) signaling and 
was shown to be a major reason for H-1PV oncotropism [143–148]. A mutant, constitutive active 
isoform of PDK1 was identified in human glioma samples permissive for H-1PV-induced toxicity and 
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was proposed as a marker for sensitivity to H-1PV therapy [149]. After infection, H-1PV can induce 
apoptosis, necrosis, and so-called lysosomal death resulting in killing of permissive cells (Fig. 4) 
[138,150,151]. NS1 was identified to be a major driver of these oncotoxic effects. Despite the 
promising preclinical and clinical results in the treatment of GBM, several issues need to be ruled out 
regarding viral therapies as mentioned above. Lack in patient safety (e.g. carcinogenesis), inherent 
immunogenicity, environmental toxicity, and difficulties in viral production are major obstacles in the 
development and approval of viral therapies [122,133,137]. Delivery of therapeutic genes (e.g. coding 
for NS1) by non-viral vectors can therefore improve the therapeutic performance and rule out 
potential safety drawbacks [152].  
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AIM OF THE THESIS 
The use of advanced drug delivery systems may improve the performance of established 
chemotherapeutics and may open the door for novel therapeutic approaches such as gene therapy. 
Therefore, the aim of this PhD thesis was to develop a biocompatible nanoparticulate drug delivery 
platform and a novel therapeutic approach for liver cancer using a virus-derived anticancer gene. 
Major project milestones were defined as followed: 
 
 
Evaluation of nanoparticulate drug delivery platforms based on PEG-PCL 
• What are the characteristics of PEG-PCL nanoparticles? 
• How can PEG-PCL nanoparticles be used for drug delivery? 
 
 
 
Preparation of long-circulating PEG-PCL micelles 
• How can PEG-PCL micelles be produced? 
• Do PEG-PCL micelles show stealth properties comparable to established PEG-liposomes? 
 
 
 
Modification of nanoparticles for cellular imaging and diagnosis 
• How can nanoparticles be tracked after cellular uptake? 
• How can the preparation protocol be modified to improve labeling efficiency and 
reproducibility?  
 
 
 
Active targeting of PEG-PCL micelles  
• How can PEG-PCL micelles be modified to target specific cell types? 
• Do modified PEG-PCL micelles show specific and enhanced cellular uptake as compared to 
non-modified PEG-PCL micelles? 
 
 
 
Non-viral gene delivery of a virus-derived anticancer gene 
• Can the parvovirus-derived anticancer gene be delivered via non-viral gene delivery 
methods? 
• Can this therapeutic approach be used to specifically treat liver cancer? 
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CHAPTER I 
 
PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application 
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Highlights: Nanoparticulate drug delivery platforms are promising strategies to improve the 
therapeutic performance of drugs by changing their PK and pharmacodynamic properties. This 
review article highlights the great potential of nanoparticulate drug delivery systems based on the 
biodegradable and non-toxic synthetic polymer PEG-PCL. Established synthesis routes are 
described and state-of-the-art preparation methods are highlighted. An overview about the diverse 
range of encapsulated drugs ranging from lipophilic small molecules to hydrophilic high molecular 
weight biologics is given. Furthermore, recent advances in the application of PEG-PCL drug delivery 
systems for passive and active drug targeting, trigged drug release, theranostics, and gene delivery 
are outlined.  
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A B S T R A C T
The lack of eﬃcient therapeutic options for many severe disorders including cancer spurs demand for improved
drug delivery technologies. Nanoscale drug delivery systems based on poly(ethylene glycol)-poly(ε-caprolac-
tone) copolymers (PEG-PCL) represent a strategy to implement therapies with enhanced drug accumulation at
the site of action and decreased oﬀ-target eﬀects. In this review, we discuss state-of-the-art nanomedicines based
on PEG-PCL that have been investigated in a preclinical setting. We summarize the various synthesis routes and
diﬀerent preparation methods used for the production of PEG-PCL nanoparticles. Additionally, we review
physico-chemical properties including biodegradability, biocompatibility, and drug loading. Finally, we high-
light recent therapeutic applications investigated in vitro and in vivo using advanced systems such as triggered
release, multi-component therapies, theranostics, or gene delivery systems.
1. Introduction
Nanomedicine is an emerging discipline in pharmaceutical science.
Engineered nanomaterials (ENM), deﬁned by one or more external
dimension in the size range of 1 nm to 100 nm, are used to implement
various drug delivery platforms [1,2]. Many promising candidates are
in clinical and preclinical research and some nanoparticle (NP)
formulations, e.g. Genexol-PM™, recently gained market approval by
health care authorities such as the FDA [3–5]. Diﬀerent materials are
used for the production of such nanoparticulate drug delivery systems
(nanoDDS) including inorganic NPs, viral NPs, lipid based NPs, and
polymer based NPs [3]. Among these, synthetic copolymers gained
much attention due to their versatile and tunable chemistry. Synthetic
copolymers can be used to produce solid sphere nanoparticles, micelles,
vesicular polymersomes, polyplexes, polymer-drug conjugates, and
dendrimers [6]. A schematic overview about polymer-based nano-
structures is given in Fig. 1A. Notably, copolymers of the hydrophilic
PEG and hydrophobic PCL are characterized by a high biocompatibility
and biodegradability (Fig. 1B). PEG has a long history of use in
therapeutic strategies. PEGylation of therapeutic proteins or liposomes
is used to reduce immunogenicity and toxicity, prolong blood circula-
tion time, change biodistribution, and optimize protein activities
[4,7–12]. PCL, a semi-crystalline and biodegradable polymer, was
successfully used in medical devices and tissue engineering [13–16].
In this review, we will focus on the synthesis, production, characteriza-
tion, and application of PEG-PCL-based nanomedicines. Therapeutic
eﬀects induced in vivo via targeted and non-targeted drug delivery,
application routes, triggered drug release, theranostic NPs, and progress
in PEG-PCL-based gene delivery strategies will be discussed. For the
sake of simplicity, PEG-b-PCL will be used for di-block copolymers of
PEG and PCL, whereas PEG-PCL will be used for copolymers of PEG and
PCL (and others) with various architectures.
2. Synthesis
During the last decades a vast number of diﬀerent PEG-PCL-based
copolymers have been developed and various synthetic routes have
been investigated. The most established method to synthesize PEG-b-
PCL di-block copolymers is the ring-opening polymerization of ε-
caprolactone (CL) with methoxy poly(ethylene glycol) (mPEG) as an
initiator using catalysts such as stannous octate (Sn(Oct)2), calcium, or
aluminum complexes [17–23]. Alternative synthesis routes using
biocatalysts (e.g. enzymes) or using “click” chemistry were described
[24,25]. For the synthesis of PEG-b-PCL di-block copolymers, various
block lengths of PEG and PCL were combined. The molecular weight of
the PCL block is mainly controlled by the molar ratio of CL to the
initiator mPEG [26]. The mass or volume fraction (f) of each block and
the molecular weight of the copolymer mainly dictate the resulting
structure of the NP [27–31]. Amphiphilic block copolymers with a
hydrophilic weight fraction similar to phospholipids (f≈ 25–45%) tend
to form vesicular structures, a hydrophilic weight fraction of f > 50%
usually results in micellar structures [27,30,32]. The composition of the
http://dx.doi.org/10.1016/j.jconrel.2017.05.028
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block copolymers can be optimized using methods such as full factorial
design [33]. In addition to di-block copolymers, tri-block copolymers,
i.e. PCL-b-PEG-b-PCL (PCEC) and PEG-b-PCL-b-PEG (PECE), as well as
branched, brushed, and star-shaped PEG-PCL copolymers were gener-
ated. Synthesis strategies using diﬀerent PEG variants as initiator,
“click” chemistry, or coupling reagents such as hexamethylendiisocya-
nate (HMDI) or N-hydroxysuccinimide (NHS) and N,N′-dicyclohexyl-
carbodiimide (DCC) resulted in a big arsenal of PEG-PCL copolymers for
the potential use in drug delivery [23,34–41]. These polymers show
diﬀerent assembly behavior, drug loading properties, and cellular
uptake behavior and can thus be chosen according to the therapeutic
strategy [40,42]. PEG-PCL graft copolymers (PEG-g-PCL) were synthe-
sized via a thiol-yne approach [43]. Polymer amphilicity was highly
tunable and easy to control. Thus, PEG-PCL copolymers with a broad
range of molecular weights, various architectures, and tunable amphi-
philicity can be synthesized. Using systematic approaches such as
design of experiments (DoE), tailor-made polymers for speciﬁc drugs
can be produced and NPs with a homogeneous size distribution can be
prepared.
3. Nanoparticle preparation methods
PEG-PCL NPs for biomedical applications can be produced using
various types of methods. Mostly, these are based either on spontaneous
self-assembly or emulsiﬁcation. A suitable protocol depending e.g. on
stability of the drug or the targeting ligand in organic solvents or at
high temperatures can be chosen.
In solvent-displacement, also called nanoprecipitation, the polymer
is dissolved in a water-miscible organic solvent and subsequently, an
aqueous phase (i.e. non-solvent) is added dropwise. Due to reduced
polymer solubility and interfacial hydrodynamic phenomena (i.e.
Marangoni eﬀect), spontaneous NP formation is induced. The organic
solvent is subsequently removed by evaporation [44,45]. Various
organic solvents such as acetone, dimethylformamide (DMF), or tetra-
hydrofuran (THF) were used in the production of PEG-PCL NPs
[17,18,42,46–50]. The type of organic solvent, the ratio of organic to
aqueous phase, and the order of phase addition can be changed to
control NP size, morphology, and to optimize drug loading [51].
Recently, PEG-b-PCL micelles with mean diameters of 82.9 nm,
87.8 nm, and 109.0 nm were prepared by using either acetonitrile,
acetone, or THF as organic phase [51]. A modiﬁcation of the solvent-
displacement method is the so-called dialysis method. In this method,
the polymer is dissolved in a water-miscible organic solvent, mixed
with an aqueous phase, and then dialyzed against aqueous media
[22,52,53]. Film rehydration is widely used in the production of
liposomes and was also used for the production of polymer NPs
[54–57]. In ﬁlm rehydration, the polymer is dissolved in an organic
solvent (e.g. chloroform, methanol, or acetone) that is subsequently
removed by evaporation to obtain a thin polymer ﬁlm. After rehydra-
tion of the polymer ﬁlm, small micelles are formed that can further
rearrange to form spherical micelle-like NPs or vesicles (i.e. polymer-
somes) [58]. An adaptation of ﬁlm rehydration, melting/sonication,
was developed [59]. Heating of the sample above the polymer melting
temperature (Tm) and subsequent sonication after rehydration of the
polymer thin ﬁlm led to the formation of mono-disperse PEG-b-PCL
micelles [59–62]. Several approaches for the preparation of NPs using
emulsiﬁcation or double emulsiﬁcation for the encapsulation of hydro-
philic drugs were described. In the so-called emulsion solvent evapora-
tion technique, the polymer is dissolved in a volatile and water-
immiscible organic solvent such as dichloromethane (DCM) or chloro-
form. This solution is emulsiﬁed in an aqueous phase containing
stabilizers (e.g. polyvinyl alcohol (PVA), trehalose, or sodium cholate)
in combination with ultrasonication or other methods. The organic
solvent is then removed by heat and NP formation is induced
[44,45,63–67]. Especially, novel methods such as microﬂuidics have
gained much attention for the preparation of PEG-PCL NPs. Micro-
ﬂuidic mixing of PEG-b-PCL-b-poly(ethylene imine) (PEI) for siRNA
complexation resulted in smaller and more homogeneous micelles,
enhanced siRNA stability, and higher transfection eﬃciency as com-
pared to micelles produced by bulk mixing (i.e. solvent-displacement)
[68]. Interestingly, this technique can be used for scale-up production
as well as in process-sterilization of NPs which is a prerequisite for the
preparation of clinical trial samples [69–71]. Importantly, the great
variety of preparation methods for the production of PEG-PCL NPs
oﬀers the possibility to choose the ideal strategy, e.g. depending on the
drug stability in organic solvents or at diﬀerent temperatures. Recently
developed preparation methods for diﬀerent drugs and PEG-PCL
copolymers are summarized in Table 1.
4. Degradation and colloidal stability
4.1. Stability and degradation
In order to improve the therapeutic value (i.e., biocompatibility and
excretion of nanoparticles), the degradability of polymer nanoparticles
is a major issue. During the last years, the biodegradation of PCL and
PEG-PCL-based medical devices was studied extensively [16,72–75]. It
has been shown that controllable factors such as polymer composition
and molecular weight as well as other factors like temperature and pH
strongly inﬂuence the degradation rate, reﬂected by a decreasing
molecular weight of the polymer [76–79]. Mainly, polymers can
degrade and erode via surface or bulk process [80,81]. The latter is
deﬁned by polymer loss from the entire volume and seems to be the
mechanism highly contributing to the degradation of PCL-based ﬁlms
and medical devices [82]. In an initial phase, a random hydrolytic chain
scission can be observed followed by polymer weight loss and diﬀusion
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Fig. 1. Types of polymer-based nanoparticles. (A) Schematic representation of polymer-based nanomedicines. (B) Chemical structure of PEG, PCL, and PEG-b-PCL.
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of small CL oligomers out of the polymer bulk. This process is
autocatalytic, i.e. free carboxylic groups catalyze the cleavage of
remaining ester groups [82]. Consequently, water-soluble and insoluble
CL oligomers as well as PEG segments were identiﬁed as ﬁrst degrada-
tion products of PEG-PCL [83]. Additionally, enzymes such as lipases
increase PEG-PCL degradation in vitro. These enzymes are present
intra- and extracellularly and catalyze the hydrolysis of triglycerids.
However, their contribution for the in vivo degradation is still unclear
[80,82,84]. Regarding PEG-PCL NPs, several other factors such as route
of administration and NP characteristics (e.g. size, shape, and zeta
potential) strongly inﬂuence the degradation and elimination from the
body. A study on the in vivo degradation of di-block copolymer micelles
showed, that in vitro degradation kinetics should be used with
precaution to predict the in vivo situation. The in vivo degradation
was much faster than the weight decrease measured in vitro [84,85].
Polymer bioresorption, degradation, and subsequent elimination or
metabolism of the degradation products will determine the residual
time in the body after administration [73]. Colloidal stability and
biodistribution of the NP will therefore dramatically inﬂuence the mean
residual time (MRT) of the polymer [85,86]. PEG-PCL micelles are
stable in phosphate buﬀered saline (PBS) for months [67]. However, in
biological media such as cell culture medium or blood, protein
Table 1
PEG-PCL-based drug carriers. Selected PEG-PCL-based nanoparticles (NP) are shown. NP formulations are sorted according to increasing lipophilicity of their drug payload.
aDrug bXLogP3b cMw [g/mol] dPolymer ePreparation method fNP size [nm] gDLE [%] hDLC [% w/w] iRef.
Ovalbumin −9.9 1773.4 PEG-b-PCL EM 220 15.7 1.2 [199]
Goserelin −1.5 1269.4 PEG-b-PCL EM 174 44.2 – [110]
NAPVSIPQ −5.6 824.4 PEG-b-PCL EM 76.2 54.3 0.7 [214]
Etoposide 0.6 588.6 PEG-b-PCL CS 36.5–90.2 61.4–96.8 2.7–5.3 [248]
Oxymatrine 1 264.4 PEG-b-PCL TF 96.7 34.0 6.7 [54]
Camptothecin 1 348.4 PEG-b-PCL EM 116 71.7 6.0 [220]
Ocreotide 1 1019.2 PEG/PCL EM [249]
Doxorubicin 1.3 543.5 PEG-b-PCL CS 110–202 81–95.5 – [164]
PEG-b-PCL OT 30.1 93.6 4.5 [106]
PEG-b-PCL CS 104.9 – 4.3 [17]
PCEC MS 130.8 86.7 8.7 [62]
PEG-b-PCL CS 37.7 70 7 [222]
Sulforaphane 1.4 177.3 PEG-b-PCL EM 118 86.0 20.0 [111]
Luteolin 1.4 286.2 PEG-b-PCL TF 38.6 98.3 3.9 [107]
SN38 1.4 392.4 PEG-b-PCL TF 128.3 83.8 20.7 [108]
Docetaxel 1.6 807.9 PEG-b-PCL
PCEC
MS 53–87 41–90 4.9–8.7 [61]
PEG-b-PCL CS 85.7 80.7 20.3 [48]
PEG-b-PCL DL 51.4 64.2 8.2 [22]
TGX-221 and
BL05-HA
1.9 364.5 PEG-b-PCL CS 54.5 74.5 9.5 [145]
Dexamethasone 1.9 392.5 PEG-b-PCL TF 45.2 94.2 2.2 [116]
Chetomin 1.9 710.9 PECE TF 26.5 98.4 4.92 [57]
Triamcinolone 2.5 434.5 PEG-b-PCL CS 130 97.0 10.0 [250]
Paclitaxel 2.5 853.9 PEG-b-PCL EM < 100 – – [142]
PEG-b-PCL EM 72.5 90.4 8.2 [66]
PEG-b-PCL CS 19.6 85.5 4.6 [143]
PEG-b-PCL EM 107 49.8 1.3 [64]
PEG-b-PCL EM 102.81 47.7 0.9 [63]
Noscapin 2.7 413.4 PEG-b-PCL CS 65.61 3.2 34.6 [50]
Curcumin 3.2 368.4 PEG-b-PCL CS 65.3–196 5.7–40.9 0.1–4.7 [mol/mol] [47]
PEG-b-PCL TF 27.4 99.0 14.9 [109]
PCEC EM 38.9 95.5 11.9 [166]
Capsaicin 3.6 305.4 PEG-b-PCL EM 82.5 81.5 14.0 [67]
Dasatinib 3.6 488.0 PEG-b-PCL CS 54.3 95.4 1.9 [192]
Tetradine (Disulﬁram) 3.9 296.5 PEG-b-PCL
PCEC
EM 190.3–444.3 29.9–91.4 0.9–2.5 [65]
Indometacin 4.3 357.8 PEG-b-PCL DL 191 77.5 – [52]
Honokiol 5 266.3 PEG-b-PCL OT 29.19–165 56.9–95.8 4.6–27.4 [21]
Rapamycin 6 914.2 PEG-b-PCL CS 76 50.0 11.0 [144]
Cyclosporin A 7.5 1202.6 PEG-b-PCL CS 98.6 63.8 1.9 [18]
Paclitaxel
Cyclopamine
Gossypol
2.5
3.5
6.9
853.9
411.6
518.6
PEG-b-PCL CS 80 9.4 3.2
3.1
3.1
[189]
VAAP – – PEG-b-PCL DL 106 – 4.2 [251]
RU 58668 – 658.8 PEG-b-PCL CS 100 – – [104]
Cisplatin – 300.1 PEG-b-PCL CS 78.8 86.7 – [46]
PC-4 – 717.0 PEG-b-PCL CS 88 – 5 [208,209]
NC-1900 – – PEG-b-PCL DL 107 20.6 – [20]
a Name of the drug. VAAP: cis,cis,trans-diaminedichlorobisvalproato-platinum(IV).
b Calculated octanol-water partition coeﬃcients (XlogP3) [139], from [pubchem.ncbi.nlm.nih.gov].
c Molecular weight (Mw) of the drug in [g/mol], from [pubchem.ncbi.nlm.nih.gov].
d Type of copolymer used.
e Preparation method: solvent-displacement (SD), thin-ﬁlm rehydration (TF), dialysis (DL), oil-in-water (OW) or WOW emulsiﬁcation (EM), melting/sonication (MS), and others (OT).
f Diameter of the drug loaded NP in [nm].
g Drug-loading eﬃciency (DLE) expressed as [%] of the initial drug concentration recovered after preparation and puriﬁcation.
h Drug-loading content (DLC) expressed as [% w/w] drug to polymer.
i References.
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opsonization can aﬀect the micelle stability [87–89]. It is thus
recommended, that the colloidal stability should be tested in an
environment similar to in vivo conditions [89,90]. For example,
stability of PEG-PCL micelles was tested in serum containing medium.
In contrast to the high stability in PBS, micelles showed changes in size
and size distribution in a time and serum-concentration dependent
manner [91–93]. Large NP aggregates can be taken up by the mono-
nuclear phagocyte system (MPS) [94,95]. In contrast, individual PEG-
PCL block copolymers (unimers) that may occur after NP disassembly
can be cleared via diﬀerent mechanisms. When PEG-b-PCL was injected
into experimental animals as unimers (i.e. below the critical aggrega-
tion concentration; CAC), a high uptake by liver, spleen, and kidney
already after one hour of injection was observed as indicated by high
tissue to plasma concentration ratios of 1.90, 1.30, and 1.70, respec-
tively [96]. As a consequence, PEG-b-PCL unimers were rapidly
removed from the plasma compartment (half-life: 10.2 h), whereas
PEG-b-PCL micelles remained three times longer in the blood circula-
tion [96]. Importantly, resulting metabolites did not accumulate and
were cleared from the body via feces and urine eﬃciently [97]. A
schematic overview about PEG-PCL NP behavior after injection is given
in Fig. 2.
4.2. Shelf half-life
To prolong the shelf half-life of PEG-PCL-based formulations and to
prevent premature nanoparticle degradation, NPs can be freeze-dried.
This technique is widely used in pharmaceutical industry to increase
storage stability of drugs, especially biologics. In order to preserve the
physico-chemical characteristics of the NP formulation after reconstitu-
tion, cryoprotectants and stabilizers can be added to the formulation to
optimize freeze drying [98]. Layre and colleagues analyzed the eﬀect of
diﬀerent additives on the lyophilization of PEG-b-PCL micelles. Best
results with only little aggregation of micelles after reconstitution were
obtained by adding the surfactant Poloxamer 188 and trehalose to the
micelle formulation before freeze-drying [99]. Importantly, reconsti-
tuted samples were still able to exert their biologic activities [100].
5. Biocompatibility and safety
The repeated use of nanomedicine products bears the risk of
unwanted side-eﬀects. Thus, an important step in the development of a
nanomedicine product is the assessment of any safety risk. Especially, the
biocompatibility and cytotoxicity of the nanocarrier on an acute and
chronic level (i.e. short and long-term eﬀects) have to be evaluated. PEG,
PCL, and PEG-PCL products were approved by health care authorities
such as the FDA [97,101,102]. Long-term experience with medical
products consisting of these materials revealed a high biocompatibility
and no concerns about toxic side eﬀects [15,16,72]. In nanotoxicology,
however, additional factors such as particle size, geometry and morphol-
ogy, surface-to-volume ratio, and protein adsorption capacity of NPs
have to be considered. Thus, each new NP formulation should be tested
individually for toxic eﬀects [103]. A precise physico-chemical char-
acterization of NP properties is a prerequisite for any nanotoxicity
proﬁling. Many PEG-PCL NPs in vitro toxicity studies (i.e. MTT cell
viability assays or cell growth assays) using various established cell lines
were performed. PEG-PCL-based NPs within a size range of around
20 nm to 200 nm and slightly negative zeta potentials were tested. No or
only minor toxic eﬀects on cell viability were detected up to concentra-
tions of 1.5 mg/mL [22,42,49,61,104–111]. Shi and coworkers incu-
bated human umbilical vein endothelial cells (HUVEC) with 0.2 mg/mL
up to 1.2 mg/mL of PEG-b-PCL micelles for 48 h and observed no
decrease in cell viability when analyzed using the MTT assay [105]. A
slight elevation of reactive oxygen species (ROS) levels in macrophages
was observed in vitro, whereas no induction of nitric oxide (NO) was
detected [112,113]. In addition, PEG-PCL micelles did not induced
hemolysis when incubated with freshly isolated human blood or rabbit
erythrocytes [61,106,113]. Although in vitro studies revealed no cyto-
toxic eﬀects of PEG-PCL NPs, data from experimental animals are needed
to conﬁrm such ﬁndings [114]. Several studies on the in vivo toxicity of
PEG-PCL micelles were conducted in mice and rats. In vivo studies using
high single doses of PEG-PCL micelles up to 2.4 g/kg injected i.v. did not
reveal any signs of acute toxicity. No histological changes in heart, liver,
spleen, lung, and kidney were observed. Behavior and food consumption
of the animals were comparable to untreated animals [21,113]. PCEC
was injected s.c. at a dose of 5 g/kg. Again, no toxic eﬀects or behavioral
changes were observed in BALB/c mice [115]. It should be noted that
BALB/c mice are frequently used for immunological studies due to their
potential to develop (Th2-biased) immune responses. No changes in
plasma levels of serum aspartate transaminase (AST) and alanine
transaminase (ALT) were measured in animals treated i.v. with a single
dose of 36 mg/kg dexamethasone-loaded PEG-b-PCL micelles (the used
concentration of the model compound dexamethasone was 0.8 mg/kg).
A slight activation of the complement system was observed as measured
by elevated C3a levels in treated rats [116]. PEG-b-PCL micelles induced
no changes in levels of inﬂammatory factors in mice plasma when
injected i.v. at a dose of 8 mg/kg. IL-6, IL-10, IL-12p70, IFN-γ, TNF, and
MCP-1 levels were comparable to control animals treated with saline
[112]. PCEC micelles did not induce any mutagenic eﬀects in vitro and in
vivo [117]. PEG-b-PCL micelles were also tested for sub-chronic toxicity
in vivo. Daily i.v. administration of 100 mg/kg for one week in rats and
mice did not induce any changes in weight gain. No acute inﬂammation
or toxic eﬀects on liver, kidney, or the brain parenchyma were observed
[117,118]. AST, ALT, total bilirubin, ureanitrogen (BUN), and creatinin
levels were comparable to those of control animals treated with saline
[118]. PEG-PCL NPs are well tolerated and have not induced any acute
toxicity in experimental animals in vivo after single or multiple dosing.
No changes in histology or markers of inﬂammation were detected. Thus,
it is expected that PEG-PCL based nanomedicines should be safe and well
tolerated in human. As of today, long-term toxicity studies were
performed in experimental animals only.
6. Drug loading and release
6.1. General principles
In order to induce a desired pharmacological eﬀect, drugs of interest
can be combined with PEG-PCL-based formulations. Therefore, non-
covalent drug encapsulation (based on hydrogen bonding, hydrophobic
interactions, or ionic interactions) or covalent drug conjugation can be
used [119]. Several factors such as the solubility of the drug, the
aﬃnity of the drug to the polymer, the NP core volume, and the ability
of the drug to self-aggregate can inﬂuence the drug loading content
(DLC), i.e. the mass ratio of drug to polymer [120]. Paclitaxel loading
Disassembly
Opsonization/
Aggregation
Elimination
Degradation
Uptake by
MPS
Fig. 2. Degradation and biodistribution of PEG-PCL-based nanoparticles. Schematic
representation of nanoparticle (NP) stability, degradation, and biodistribution. Stability
and degradation are summarized in Section 4, NP pharmacokinetics and biodistribution
are reviewed in Section 7. MPS: mononuclear phagocyte system.
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content in PEG-b-PCL micelles for example increased with increasing
length of the hydrophobic PCL block [121]. In contrast, no signiﬁcant
increase was observed when a similar experiment was performed with
the less hydrophobic compound doxorubicin [17]. Besides experimen-
tal approaches, physico-chemical models were used to predict drug
loading and stability based on polymer-drug compatibility parameters
[122]. The Flory-Huggins interaction parameter (ΧFH), for example,
was successfully used to characterize drug polymer compatibilities
[123–125]. Methods to calculate interaction parameters of PEG-PCL
copolymers and various drugs based on molecular dynamics were
developed [126,127]. A rational coarse grain model for the partitioning
of paclitaxel in PEG-b-PCL micelles and worm-like nanocarriers was
generated. The authors showed that not only the composition of the
polymer, but also the NP shape heavily inﬂuences drug loading [32].
Worm-like structures are characterized by increased polymer packaging
constraints: PEG moieties show a higher packaging density on surfaces
with a reduced curvature. Under this condition, PEG chains extend
resulting in an increased thickness of the outer PEG layer [32].
Consequently, worm-like structures showed a two fold increase in drug
loading as compared to spherical NPs [32]. Such methods can facilitate
formulation screening and can be used for the rational design of novel
drug-speciﬁc polymers and nanocarriers [122,128–131]. It should be
noted that combination of a given drug with a nanocarriers can strongly
inﬂuence the PK proﬁle of the drug and its pharmacological eﬀect
[132].
Encapsulated drugs can be released from NPs via diﬀusion through
the polymer matrix or water ﬁlled pores or after erosion of the polymer
micelle [133]. In addition to passive release, triggered release of drugs
may be favorable as discussed in Section 8.3 of this review. For the
analysis of drug release from PEG-PCL-based nanomedicines in vitro,
diﬀerent methods can be applied: The gold standard is dialysis against
an appropriate recipient medium. Alternative methods make use of
continuous ﬂow systems or microdialysis [134,135]. Due to missing
sink conditions, extrapolation of these in vitro results to the in vivo
situation is diﬃcult. Other approaches, such as determination of the
unbound fraction (fu) of the drug when drug loaded PEG-PCL micelles
are incubated with red blood cells are therefore good alternatives to
simulate in vivo stability and release behavior [136]. Methods to
measure the intracellular drug release after NP uptake [137] can
additionally be of particular interest when “smart” drug formulations
with triggered release kinetics upon intracellular stimuli exposure (e.g.
pH) are designed. Scarpa and colleagues established a method to
quantify the real-time intracellular release of a ﬂuorescent dye from
PEG-b-PCL NPs after in vitro cell uptake [138].
6.2. Examples
PEG-PCL block copolymers and their derivatives oﬀer a large
variety of physico-chemical features including variable hydrophilic
and lipophilic properties and self-assembly into nano-sized structures.
A vast number of active compounds can be encapsulated into PEG-PCL-
based nanoDDS. Drugs with molecular weights ranging from 177 g/mol
up to 1269 g/mol and a wide range of XLogP3 [139] values (−9.9 to
7.5) were successfully incorporated into PEG-PCL NPs. XLogP3 is a
method for LogP computation (i.e. prediction of octanol-water partition
coeﬃcients) and can thus be used to characterize the lipophilicity of
compounds [139]. A detailed overview about drug-loaded PEG-PCL-
based nanoDDS is given in Table 1. The following section highlights
some examples from the preclinical setting.
Sulforaphane, a potent natural compound against various cancers
lacks of chemical stability (i.e. sensitivity to heat and oxygen) and
suﬀers from poor water solubility. Sulphoraphane was encapsulated in
PEG-b-PCL micelles with a homogeneous size distribution around
120 nm and a high encapsulation eﬃciency (EE) [111]. This formula-
tion showed therapeutic activity in MCF-7 breast cancer cells in vitro.
Paclitaxel, an inhibitor of the microtubule rearrangement, is widely
used in cancer therapy. Due to its low water solubility, the excipient
Cremophor EL is used in the approved formulation (Taxol™). However,
this excipient has certain limitations and is characterized by severe
toxic side eﬀects [140,141]. To overcome this issue, PEG-b-PCL micelles
were successfully used in various experimental settings for the encap-
sulation of paclitaxel [63,64,66,118,142,143]. Xin and coworkers
produced PEG-b-PCL NPs with a high EE of> 90% and a DLC of
8.2% that were tested in vitro and in vivo in experimental animals and
showed promising results [66,118,142]. Another PEG-b-PCL-based
formulation of paclitaxel showed a remarkable stability with< 50%
of the initial drug content released within 24 h [64].
Co-encapsulation strategies, chemical optimization of the drug, and
active drug loading strategies were successfully used to improve EE and
DLC of PEG-PCL NPs. Rapamycin, used for immunosuppression and
cancer treatment, was encapsulated in PEG-b-PCL micelles.
Interestingly, optimization of the encapsulation protocol by co-incor-
poration of the excipient α-tocopherol increased the EE and the release
half-life of rapamycin [144]. A high EE of 11% and a slow drug release
(50% released after 31 h) were achieved. The authors speculated that
similar chemical motifs in α-tocopherol and rapamycin as well as their
high lipophilicity were major reasons for this phenomenon. In another
study, a PEG-b-PCL micelle formulation of TGX-221, a PI3K inhibitor,
was developed. A fast release half-life of< 1 h was observed. In sharp
contrast, synthesis of a TGX-221 prodrug, i.e. BL05-HA, resulted in
signiﬁcantly improved micelle stability and an increase of the release
half-life to 6.5 days. Still, the micelle formulation showed selective
inhibition of prostate cancer cells in vitro [145]. Active drug loading
strategies using e.g. transmembrane pH gradients were developed for
liposomal formulations [146–148] and adopted to PEG-PCL NPs. For
example, active loading of doxorubicin into PEG-b-PCL polymersomes
was performed using proton gradients. Despite the high membrane
thickness of 16 nm, a high EE of 96% was achieved [149]. It can be
concluded that various parameters can inﬂuence loading eﬃciency into
PEG-PCL NPs and drug release. Optimized PEG-PCL copolymers can be
designed and preparation protocols adapted to improve encapsulation
of speciﬁc drugs. Application of PEG-PCL-based nanoDDS inducing
therapeutic eﬀects in both in vitro and in vivo settings will be
highlighted in the following sections.
7. Pharmacokinetics and biodistribution
A prerequisite for successful active or passive drug targeting is a long
plasma half-life. To obtain long circulating formulations, several factors
such as size, shape, and surface characteristics need to be considered in the
design of NPs [150,151]. NPs with a size below 5–6 nm can be excreted by
renal ﬁltration, while NPs with> 500 nm in diameter or with a positive
surface charge are recognized and removed from the blood circulation by
the reticulo-endothelial system (i.e. MPS) [152–156]. Especially, protein
opsonization plays a critical role in cellular uptake of NPs [157].
PEGylation of NPs was shown to inﬂuence the total amount and composi-
tion of adsorbed proteins on the NP surface; thus, changing NP-cell
interactions as well as NP PK properties [8,11,158–160]. Most PEG-PCL
NPs used in in vitro or in vivo studies showed a size between 20 and
200 nm and a slightly negative zeta potential, both indicators for long
circulating nanocarriers [161,162]. Several in vivo PK and biodistribution
studies in experimental animals (i.e. rats and mice) were performed
[20,50,64,96,106,136,142,163–165]. Diﬀerent strategies for the labeling
and detection of PEG-PCL NPs were applied, i.e. tracking the drug or the
nanocarrier in vivo. In most experimental settings, drug loaded PEG-PCL
NPs were produced. Drug concentrations were analyzed by high perfor-
mance liquid chromatography (HPLC), mass spectrometry (LC-MS/MS), or
liquid scintillation counting (LSC) and used to determine the PK parameters
of the drug carrier [20,50,64,107,136,165].
As noted above, morphology and polymer characteristics of PEG-
PCL NPs can vary considerably. Consequently, a certain variability of
PK parameters can be observed as summarized below. PEG-b-PCL
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micelles with an average hydrodynamic diameter of 89.3 ± 15.3 nm
loaded with cyclosporine A were injected i.v. into male Sprague-Dawley
rats at a dose of 5 mg/kg. A low volume of distribution (VD) of 0.167 L/
kg, a slow clearance (CL) of 0.0223 L/kg/h, and a high mean residual
time (MRT) of 11.1 h were measured [163]. Similar results were
observed for paclitaxel-loaded PEG-b-PCL micelles with a size
of≈ 100 nm [20]. PCEC NPs loaded with curcumin and a size of
38.9 nm were administered in Wistar rats at a dose of 15 mg/kg via
single tail vein injection. The PK parameters of curcumin were
dramatically changed. A VD of 0.216 L/kg, a CL of 0.005 L/kg/h, and
a long MRT of 30.07 h were observed [166]. Capsaicin-loaded PEG-b-
PCL micelles were administered orally to Sprague-Dawley rats. Capsai-
cin is characterized by a high hepatic ﬁrst pass metabolism and a short
plasma half-life. Encapsulation in PEG-b-PCL micelles with an average
diameter of 82.5 ± 0.5 nm resulted in a 6-fold increase in AUC and
prolonged the MRT by a factor of 3 [67]. Whereas these studies aimed
to detect changes in PK parameters of the encapsulated drug, covalent
labeling of PEG-PCL by tritium or gamma emitters such as 99mTC was
used to analyze polymer concentration by scintillation counting
[96,164]. Tritium labeled PEG-b-PCL micelles with a size of
56 ± 6 nm were injected i.v. into female BALB/c mice at a dose of
250 mg/kg. Comparable to the results obtained in rats (see above), a
low VD of 1.75 mL (corresponding to 0.6 L/kg), a low CL, and a high
MRT of 43.3 h were observed [96]. Up to 12 h after i.v. injection, only
small fractions of PEG-PCL micelles were detected in liver, spleen, and
kidney [96,163,164]. Near-infrared (NIR) imaging is a promising non-
invasive imaging technique to study NP distribution in vivo using NIR
dyes such as DiR. NIR imaging was used to further analyze accumula-
tion of NPs in various tissues and tumors [64,116,167–172]. Moreover,
NIR dye loaded PEG-b-PCL NPs were proposed as tools to guide surgical
resection in cancer patients suﬀering from tumors with pronounced
EPR eﬀects [169]. Due to their favorable pharmacokinetic proﬁle, i.e.
long-circulating properties, PEG-PCL NPs oﬀer a promising option for
nano-based drug formulations. In addition, this characteristic is an
important prerequisite for further implementation of drug targeting
strategies. Notably, a big toolbox of labeling and detection strategies of
PEG-PCL NPs was developed that is applicable for various PEG-PCL
constructs. Nevertheless, comparison of PEG-PCL NPs to the gold
standard long-circulating drug delivery system, i.e. PEGylated lipo-
somes, should be performed in the same experimental settings.
8. Applications in the preclinical setting
In order to improve the therapeutic index of a drug, diﬀerent
approaches in combination with PEG-PCL copolymers were developed.
The following section will focus on non-targeted (i.e. passive) and
targeted (i.e. active) delivery systems. In addition, advanced technol-
ogies such as stimuli-responsive systems, theranostics, and gene
therapeutics will be highlighted. In each section, examples will be
given with increasing complexity from small molecules to macromole-
cules or from single drug applications to drug combinations. Fig. 3
summarizes various applications of PEG-PCL-based NPs.
8.1. Non-targeted drug delivery
In contrast to some organs (e.g. the brain) that are highly protected
by tightly sealed endothelial cell layers, other tissues are characterized
by fenestrated (i.e. permeable) blood vessels (e.g. the liver).
Interestingly, diseases such as cancer and inﬂammatory states are also
linked with leaky vasculature [173,174]. In cancer for example, rapid
cell proliferation increases the local demand for oxygen and nutrients
that requires the generation of new blood supply. These fast growing
blood vessels are often irregular and can have fenestrations of 100 nm
up to 2 μm, depending on the localization and type of tumor [175–177].
As a consequence, macromolecules or long-circulating NPs can extra-
vasate and can therefore passively accumulate in the tumor. Addition-
ally, many solid tumors lack in suﬃcient lymphatic drainage and thus
clearance of nanoparticles from the interstitial space is reduced [178].
This phenomenon is called enhanced permeability and retention (EPR)
eﬀect [179]. The eﬃciency of passive tumor targeting strongly depends
on tumor biology (e.g. the type and location of the tumor, the
extracellular matrix, and the presence of necrotic domains) and the
physico-chemical properties of the NP such as size, shape, and zeta
potential [175,180,181]. Because of signiﬁcant inter- and intra-indivi-
dual diﬀerences in tumor biology, screening of patients that could
potentially beneﬁt from long-circulating NPs using diagnostic tools
needs to be considered [182,183]. Furthermore, detailed characteriza-
tion of NPs is required, since even small diﬀerences in e.g. the particle
diameter can dramatically inﬂuence the potential tumor accumulation
[167]. A non-targeted micellar PEG-b-PCL formulation of paclitaxel was
injected i.v. in mice carrying MDA-MB-468 breast cancer cells in their
mammary fat pad and compared to the approved formulation Taxol™.
Mice were treated twice per week at a dose of 15 mg/kg via i.v.
injection and the tumor volume was measured. Whereas a relapse in
tumor growth was observed in animals treated with Taxol™, a constant
reduction of the tumor volume was achieved in animals treated with
paclitaxel PEG-b-PCL micelles [143]. PEG-b-PCL micelles loaded with
doxorubicin and a size around 100 nm preferentially accumulated in
tumor tissue when administered i.v. in Ehrlich-ascites tumor (EAT)-
bearing mice. Animals treated with the micelle formulation showed a
reduced tumor size as compared to animals treated with free doxor-
ubicin [164]. Doxorubicin-loaded PCEC with a size of 130.8 nm showed
a 2.38-fold higher accumulation after 24 h in tumor tissue as compared
to free doxorubicin after single i.v. injection in EMT-6 breast cancer-
bearing mice [62]. Chemotin, a hydrophobic anti-cancer compound,
was encapsulated in PECE micelles. PECE NPs were injected in
transgenic zebraﬁsh, xenograft-bearing zebraﬁsh, and mice. Chemotin
showed increased intratumoral accumulation when injected as micelle
formulation and inhibited angiogenesis and tumor growth in vivo [57].
Goserelin is a synthetic analogue of luteinizing hormone-releasing
hormone, used in the treatment of prostate cancer. Its half-life is rather
short, so continuous application is needed to reach therapeutic relevant
plasma concentrations in patients. Encapsulation into PEG-b-PCL
micelles resulted in a depot eﬀect with constant goserelin plasma levels
and long-term suppression of serum testosterone over 28 days when
administered s.c [110]. The use of combination therapies is a major
strategy in the treatment of resistant cancers. The combination of
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Fig. 3. Application of PEG-PCL-based nanoparticles. Schematic representation of PEG-
PCL nanoparticle (NP) application: Passive and active drug delivery (Section 8.1 and 8.2),
triggered drug release (Section 8.3), theranostics (Section 8.4), and the delivery of nucleic
acids to target cells (Section 8.5).
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potent inhibitors of eﬄux transporters and chemotherapeutics, for
example, can increase the exposure of cancer cells to the cytotoxic
drug and by this restore therapeutic eﬀects [184]. At certain drug-to-
drug ratios, synergistic eﬀects (in contrast to simple additive eﬀects)
can occur [185]. Whereas these combinations of drugs are often tested
on in vitro cell culture models, the translation of results into the patient
situation is diﬃcult due to inter- and intra-individual diﬀerences in
drug metabolism and pharmacokinetics (DMPK). The encapsulation of a
speciﬁc combinations of drugs into a NP formulation and the subse-
quent synchronized delivery of this drug payload to the cancer cell can
overcome this hurdle [184,186–188]. Paclitaxel, cyclopamine, and
gossypol were loaded in PEG-b-PCL micelles and used for the treatment
of ovarian cancer xenografts. All tumor-bearing animals treated with
the triple therapy NP survived (58 days), whereas 75% of all animals in
the control group died during this period [189]. Local delivery of PEG-
PCL NPs on e.g. the skin [60,190,191] or the eye [192] was used to
increase the therapeutic eﬀect at the site of action.
8.2. Targeted drug delivery
In contrast to non-targeted delivery systems, active targeting is
directed towards speciﬁc, accessible receptors or epitopes preferentially
(over)-expressed on target cells. The NP is designed to speciﬁcally
interact with the cellular surface, increasing the NP binding to its target
cell, retention at the site of action, and cellular uptake [174]. Various
types of ligands such as antibodies or antibody fragments, aptamers,
proteins, peptides, carbohydrates, and small molecules such as vitamins
can be used for targeted drug delivery [193]. An overview of ligands
used in combination with PEG-PCL NPs is shown in Table 2 and Fig. 4.
Diﬀerent strategies were applied to conjugate targeting ligands to PEG-
Table 2
Ligands and ligand-conjugation strategies for the preparation of targeted PEG-PCL-based drug carriers. Selected strategies for the implementation of targeted PEG-PCL nanoparticles are
highlighted. Ligands are sorted by decreasing average molecular weight.
aClass bName cTarget dDisease ePolymer fConjugation gRef.
Antibodies 83–14 Insulin receptor CNS disorders NH2-PEG-b-
PCL
Bifunctional linker
Maleimide-/NHS
chemistry
[49]
OX26 Transferin Receptor CNS disorders Mal-PEG-b-PCL Maleimide chemistry [20]
Nanobodies VHH1 HER2 receptor Breast cancer Mal-PEG-b-PCL Maleimide chemistry [56]
Proteins Low molecular weight
protamine
– Glioma Mal-PEG-PCL Maleimide chemistry [64]
Polymers Poly-dopamine – Malignant melanoma PEG-b-PCL Oxidative-self
polymerization
[252]
Peptides RGD beta1-integrins M cells for oral vaccination PEG-b-PCL Photografting
RGDp
cRGD
LDVd
LDVp
CGKRK Heparan sulfate Tumors/blood vessels Mal-PEG-b-PCL Maleimide chemistry [63]
Angiopep LRP receptor Glioma Mal-PEG-b-PCL Maleimide chemistry [118,142]
cRGD Alpha 5-beta3 integrins Glioma COOH-PEG-
PCL
NHS chemistry [171]
cRGD Alpha 5-beta3 integrins Glioma COOH-PEG-
PCL
NHS chemistry [223]
TGN (12mer peptide) – CNS disorders Mal-PEG-b-PCL Maleimide chemistry [172]
GE11 EGFR Epidermioid carcinoma Mal-PEG-b-PCL Maleimide chemistry [208,209]
Nucleic acids PSMAa10 Prostate speciﬁc membrane antigen
(PSMA)
Prostate cancer N3-PEG-b-PCL “Click” chemistry [145]
AS1411 Nucleolin Glioma COOH-PEG-b-
PCL
NHS chemistry [172]
Carbohydrates Hyaluronic acid (HA) HA receptors
(CD44, RHAMM)
Ehrlich ascites carcinoma NH2-PEG-b-
PCL
Carbodiimide chemistry [164]
Galactose Asialoglycoprotein receptor Hepatocellular carcinoma
(HCC)
NH2-PEG-b-
PCL
NHS chemistry [196]
Mannan Mannan receptor Dendritic cells/vaccination PCEC Non-covalent adsoprtion [194]
Small molecules Manose beta1-integrins M cells for oral vaccination PEG-b-PCL Photografting [199]
Galactose ASGPR HCC NH2-PEG-b-
PCL
NHS chemistry [196]
Folate Folate receptor HCC NH2-PEG-b-
PCL
NHS chemistry [239]
Epidermiod carcinoma NH2-PEG-b-
PCL
NHS chemistry [253]
Retinal cells NH2-PEG-b-
PCL
Carbodiimide chemistry [250]
– NH2-PEG-b-
PCL
NHS chemistry [60]
Pancreas tumors NH2-PEG-b-
PCL
Carbodiimide chemistry [254]
Small molecular ligand
PSMA
PSMA Prostate cancer COOH-PEG-b-
PCL
NHS chemistry [22]
a Classiﬁcation of ligands in antibodies, nanobodies, proteins, peptides, sugars, nucleic acids, and small molecules.
b Name of the ligands.
c Molecular target.
d Disease or target organ.
e Type of copolymer used.
f Conjugation strategy applied.
g References.
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PCL NPs. Gou and coworkers produced mannan-functionalized PCEC
NPs by passively adsorbing this linear polysaccharide to the NP surface
[194]. Such non-covalent conjugation techniques were largely replaced
by covalent conjugation [195]. A widely used strategy is the conjuga-
tion of ligands to amino-terminated PEG-PCL (e.g. NH2-PEG-b-PCL),
carboxyl-terminated PEG-PCL, or maleimide-terminated PEG-PCL
[49,54,56,60,64,196,197]. Pourcelle and coworkers developed a photo-
imobilization-based conjugation strategy using aryl azide “molecular
clip”. NHS-activated PEG-b-PCL was generated by light-induced con-
jugation of a bi-functional “molecular clip” (O-Succinimidyl-4-(p-azi-
dophenyl)-N-butanoate) to PEG-b-PCL [198,199]. Azide-modiﬁed PEG-
b-PCL was synthesized for the conjugation of alkyne-modiﬁed aptamers
using “click” chemistry [145]. Typical conjugation strategies for PEG-
PCL NPs are summarized in Fig. 5.
Doxorubicin was encapsulated into PEG-b-PCL micelles functiona-
lized with hyaluronic acid (HA), a linear polysaccharide that can be
used to target a variety of tumor. Ehrlich ascites tumor (EAT)-bearing
mice were treated via tail vein injection over 7 days at a dose of
0.24 mg/kg/day. Tumor size was measured over 20 days. A 2.6-fold
reduction in tumor volume after 20 days as compared to free doxor-
ubicin was observed [164]. Paclitaxel-loaded PEG-b-PCL micelles
decorated with aniopep-2, a speciﬁc ligand to low density lipoprotein
receptor related protein 1 (LRP1) expressed on endothelial cells of the
blood-brain barrier (BBB), were tested in an intracranial glioma mouse
model [142,200,201]. PEG-b-PCL micelles were injected daily at dose of
10 mg/kg three times within 9 days and compared to Taxol™, the
approved formulation of paclitaxel. Tumor volume in animals treated
with targeted PEG-b-PCL micelles was reduced> 2-fold as compared to
Taxol™. In addition, mean survival time (MST) was prolonged to
37 days, whereas mean survival time in animals treated with Taxol™
was 25 days only [118]. Dual targeted docetaxel loaded PEG-b-PCL
micelles were modiﬁed with TGN, a peptide obtained by phage display
to enhance BBB permeability, and with the aptamer AS1411, targeted
against nucleolin, a protein highly expressed in glioma cells [91,172].
Targeted PEG-b-PCL micelles showed an increased therapeutic eﬃ-
ciency in vivo as compared to free drug and non-targeted NPs. The MST
of orthotropic glioma bearing mice was prolonged to 32 days, whereas
animals treated with free drug had a MST of 18 days [172]. The density
of the ligand on the NP surface is a critical characteristic for successful
targeting. Quantiﬁcation of the ligand/NP ratio was performed using
radio-, ﬂuorescent-, and immunogold-labeling of the targeting moiety
[49,160,198,202–204]. Scanning transmission electron microscopy can
additionally give insight into the spatial organization of immunogold-
labeled ligands on the NP surface [205]. Multivalent binding enabled
by high ligand densities on the NP surface can enhance binding aﬃnity
to the target receptor [206]. For example, PEG-b-PCL micelles were
prepared with diﬀerent ratios of PEG-b-PCL and folate-modiﬁed PEG-b-
PCL. Cellular uptake was enhanced with increasing amounts of folate
per micelle [207]. Similarly, PEG-b-PCL micelles decorated with a
peptide ligand of the endothelial growth factor receptor (EGFR) showed
maximal cellular uptake in EGFR overexpressing cells in vitro for
micelles with the highest peptide surface density [208,209]. However,
loss of stealth properties by high ligand surface densities can reduce the
NP targeting eﬃciency in vivo [202]. NC-1900, a vasopressin fragment
analog with a great potential in the treatment of neurological disorders
(i.e. spatial memory impairments) but with a poor permeation across
the BBB, was encapsulated within PEG-b-PCL NPs [20,210]. OX26, an
antibody against the transferrin receptor that was used in brain-
targeting in various studies, was conjugated to these PEG-b-PCL NPs
[20,203,211–213]. NPs with a high surface density of OX26 (i.e. 92 per
NP) showed a signiﬁcantly reduced AUC and no increase in brain
delivery capacity. In contrast, the optimized formulation with 34
molecules of OX26 per NP was able to deliver its payload 2.6-fold
more eﬃcient to the brain as compared with non-modiﬁed NPs and
improved scopolamine-induced learning and memory deﬁcits when
injected i.v. in Sprague-Dawley rats [20]. In another study, the
neuroprotective peptide NAP was encapsulated in lactoferrin-modiﬁed
PEG-b-PCL micelles. After intranasal administration in an in vivo
Alzheimer model of mice, a neuroprotective eﬀect was reached as
shown by behavioral improvements and histological analysis [214].
PEG-b-PCL micelles were conjugated to a cell penetrating peptide (Tat).
Modiﬁed micelles were able to deliver siRNA and ﬂuorescently labeled
dextran more eﬃcient to the brain than non-modiﬁed PEG-b-PCL
micelles or free dextran after intranasal administration [215,216].
Antibodies
<1 nm
~ 12 nm
Antibody fragments
Fab/scFv
Peptides
Aptamers
Small molecules
~ 30-250 nm
Fig. 4. Targeting ligands used in combination with PEG-PCL-based nanoparticles.
Schematic representation of various ligands used for targeted delivery based on PEG-
PCL nanoparticles. Targeting strategies are summarized in Section 8.2 and on Table 2.
Adsorption Click chemistry
Carboxyl-PEG/PCL
NHS chemistry
Maleimide-PEG/PCL
Maleimide chemistry
Azide-PEG/PCL
Triazole conjugate
Thioether conjugate
Amide conjugate
Non-covalent
interaction
EDC/NHS
+
–
Fig. 5. Conjugation of targeting ligands to PEG-PCL-based nanoparticles. Schematic representation of selected ligand conjugation strategies (Section 8.2 and Table 2).
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PEG-b-PCL poly(lactic acid)-hydrid micelles were designed for oral
vaccination. Modiﬁcation of the NP surface with diﬀerent peptidic and
small molecular peptides resulted in enhanced cellular uptake and
transport in vitro and increased immune response when administered
orally in experimental animals [199]. The ease of chemical modiﬁca-
tion of PEG-PCL copolymers can thus be exploited to conjugate various
ligands to the surface of PEG-PCL NPs and to implement drug targeting
strategies. Detailed understanding of the NP-cell interaction as well as
optimization of the ligand density is furthermore needed to improve the
performance of these systems.
8.3. Stimuli-responsive nanoparticles and triggered drug release
Stimuli-responsive “smart” NPs, e.g. controlled drug release for-
mulations, can improve therapeutic eﬃciency by increasing the drug
release at the site of action. In such systems, drug release can be
triggered by either externally applied or internal stimuli. Systems
responsive to changes in e.g. pH, temperature, irradiation, magnetism,
concentration gradients, or enzymatic activity were designed [217]. A
schematic overview about PEG-PCL-based stimuli-responsive NPs is
given in Fig. 6 and Table 3.
Overexpression of matrix metalloproteases (MMP), especially MMP-
2 and MMP-9, are linked with progression of cancer [218]. Thus,
prodrug strategies depending on MMP activity are promising candi-
dates to increase therapeutic selectivity to tumors [219]. A PEG-PCL
copolymer with a MMP-cleavable peptide linker (PEG-b-Pep-b-PCL) was
synthesized and used to produce campothecin-loaded micelles. After
passive accumulation in the tumor, loss of stealth properties as a
consequence of MMP-mediated detachment of PEG should lead to
increased cellular uptake by tumor cells. Indeed, this formulation
showed superior eﬀects as compared to PEG-b-PCL micelles or free
drug as shown by a high tumor accumulation of the drug and a reduced
tumor volume in treated xenograft-bearing mice [220]. In another
study, a cell-penetrating peptide with a MMP-cleavable protection
e-
H+
PEG/PCL NP
Chemical stimuli
e.g. electrons or 
protons
Enzyme
e.g. MMP-2/9
Inorganic NP
e.g. Au-NP
Drug
External stimuli
e.g. NIR radiation
e-
e-
H+
pH or redox 
triggered
Enzyme 
triggered
NIR triggered
Triggered 
drug release
Passive 
drug release
Erosion
Diffusion
Fig. 6. Triggered drug release. Schematic representation of strategies for triggered drug release using PEG-PCL-based nanoparticles. Strategies are reviewed in Section 8.3 and Table 3.
Table 3
Design of stimuli-sensitive nanoparticles using PEG-PCL polymers. Strategies for triggered drug release and stimuli-responsive targeting are highlighted.
aTrigger bPolymer cDrug dStimuli eStimuli-responsive mechanism fRef.
Internal triggers
Enzymatic cleavage PEG-Pep-PCL Campothecin Matrix metalloprotease 2/9 Disruption of PEG-Pep-PCL in the presence of MMP 2/9 and
subsequent enhanced drug release
[220]
Pep-PEG-b-PCL Paclitaxel Matrix metalloprotease 2/9 Activation of the cell penetrating peptide low molecular weight
protamine (LMWP) after MMP 2/9 exposure
[64]
pH PEG-b-PCL(COOH) Ibuprofen/
campothecin
pH≥ 7 Vesicle disruption and drug release at pH≥ 7 (i.e. small
intestine), stable at pH < 6
[221]
Redox PEG-SS-PCL Doxorubicin Reduction (10 mM DTT) Disruption of PEG-SS-PCL at a reductive environment similar to
cytosol and enhanced subsequent drug release
[222]
Reduction (10 mM glutathione) [223]
Temperature PEG-b-PCL/PCL-b-
PNIPAM
– Temperature (37 °C) Collapse of PNIPAM chains due to hydrophilic to hydrophobic
transformation at physiological temperatures and subsequent
adsorption of Aβ mono- and small oligomers
[228]
pH/Redox/
Temperature
(Multi trigger)
PEG-b-(PCL2/
PNIPAM2)
PEG-b-(PCL2/PAA2)
Doxorubicin pH (5.3), reduction (10 mM
DTT), and temperature (37 °C)
Disruption of mixed micelles composed of PEG-PCL-based star-
shaped copolymers and subsequent drug release after changes in
temperature, reductive environment, and/or pH.
[229]
External triggers
Light PEG-b-PCL/Gold-
nanorod hydrid NPs
Doxorubicin Near infrared (NIR) Phase transition of PCL from crystalline to amorphous after NIR
exposure and subsequent enhanced drug release
[171]
[224]
[225]
a Classiﬁcation of triggers.
b Type of copolymer used.
c Name of encapsulated drugs.
d Stimuli and experimental conditions applied.
e Stimuli-responsive mechanism and eﬀect after stimuli exposure.
f References.
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group was conjugated to PEG-b-PCL micelles loaded with paclitaxel.
Again, enzyme-triggered activation resulted in higher anti-tumor
activity in vitro as well as in vivo [64].
PEG-b-PCL NPs with carboxylic functionalized PCL were synthe-
sized for pH-responsive drug release, e.g. after oral administration.
Vesicles were produced and loaded with various drugs. Whereas a slow
and incomplete drug release was observed in acidic conditions, a burst
release was obtained at pH > 7 [221]. Such systems could be used to
implement targeting strategies for speciﬁc sections of the gastro-
intestinal tract (GIT) after oral application although a proof-of-concept
in vivo is still missing.
Zhong and coworkers synthesized PEG-PCL copolymers containing a
disulﬁde linkage (PEG-SS-PCL). Reductive sensitive micelles were
produced and loaded with doxorubicin. At redox potentials similar to
the physiological intracellular level, a complete release of doxorubicin
was observed within 10 h, whereas only 20% of the drug was released
in PBS [222]. Furthermore, PEG-SS-PCL micelles showed increased
anti-tumor activity in experimental animals as compared to PEG-b-PCL
micelles [223].
PEG-b-PCL-gold nanorods loaded with doxorubicin were prepared
for NIR triggered thermochemotherapy. When hybrid nanorods were
irradiated with a NIR laser source, an increase in temperature and a
triggered release of doxorubicin was observed [171,224,225]. The core
of PEG-b-PCL micelles is crystalline at temperatures below the melting
point of PCL. As soon as the temperature is elevated above the melting
point of the micelle core (e.g. by NIR irradiation), increased drug
release can be observed [226,227].
Huang and colleagues produced mixed micelles consisting of PEG-b-
PCL and poly(N-isopropylacrylamide)-b-PCL (PNIPAM-PCL). Due to its
spontaneous hydrophilic to hydrophobic transformation at physiologi-
cal temperatures, PNIPAM builds hydrophobic domains on the micelle
surface that have high aﬃnity for toxic Aβ oligomers. These micelles
were capable to inhibit the Aβ ﬁbrillation process and to enhance
proteolytic degradation of Aβ in vitro. They could thus be used as
artiﬁcial scavengers in the therapy of Alzheimer's disease [228].
Another group synthesized star-shaped PEG-PCL-poly(acrylic acid)
(PEG-PCL-PAA) and PEG-PCL-PNIPAM copolymers. These particles
were sensitive to temperature, pH, and chemical reduction. Release of
doxorubicin was enhanced upon exposure to those stimuli [229].
Covalent chemical modiﬁcation of PEG-PCL copolymers, synthesis
of PEG-PCL tri-block copolymers, and production of PEG-PCL mixed-
micelles was used to develop stimuli-responsive PEG-PCL NPs. Upon
exposure to disease-related or externally applied triggers, these NPs
showed increased drug release or cellular uptake in vitro and superior
therapeutic eﬀects induced in animal models.
8.4. Theranostics
Theranostics combine diagnosis, treatment, and monitoring of the
therapeutic eﬀect using a single nanocarrier system [230–234]. A
variety of non-invasive diagnostic imaging tools such as NIR ﬂuores-
cence imaging, magnetic resonance imaging (MRI), computed tomo-
graphy (CT), or positron emission tomography (PET) is in use [235].
These methods require contrast agents or probes, e.g. quantum dots
(QDs), inorganic dyes, supramagnetic iron oxide NPs (SPIONs), gold
NPs (GNPs), or radioisotopes [230,235]. Some of these probes can be
activated by external stimuli to exert an inherent therapeutic eﬀect, e.g.
in photodynamic or photothermal therapy [230]. Vesicles of PEG-b-
PCL-tethered GNPs were used for photoacoustic imaging and enhanced
photothermal therapy [236]. Dense packaging and speciﬁc orientation
of GNPs in PEG-b-PCL nanohybrid vesicles induced strong NIR absorp-
tion by plasmon coupling and enabled tumor ablation and prolongation
of the mean survival time in MDA-MB-435 tumor-bearing mice [236].
BBTe2FT, a small molecule with strong absorbance in the NIR window,
was encapsulated in PEG-b-PCL micelles. A strong photoacoustic signal
and a high photothermal conversion eﬃciency upon NIR laser irradia-
tion resulted in a high anti-tumor eﬃciency in vitro and a high
penetration depth of 4 cm in ex vivo tissue [237]. Alternatively, drugs
(e.g. cytostatic compounds) can be administered simultaneously.
SPIONs and doxorubicin were encapsulated in folate-targeted PEG-b-
PCL micelles. These micelles showed eﬃcient uptake in hepatoma cells
and enhanced MRI T2-weighed signal in vitro and in vivo [238,239]. In
highly heterogeneous diseases such as cancer, patients could beneﬁt
from such personalized therapies. Inter- and intra-individual variability
of tumors require adequate diagnosis and an adapted treatment, as for
example the selection of patient populations that beneﬁt from passive
tumor accumulation (i.e. EPR eﬀect) upon NP treatment. PEG-PCL-
based theranostics were successfully used for the simultaneous detec-
tion and treatment of cancer diseases in vivo. Future challenges include
the adaptation of this promising strategy to various diseases in
combination with established biomarkers.
8.5. Delivery of nucleic acids
Nucleic acids are promising therapeutics for many diseases. Their
metabolic instability requires drug delivery systems that protect them
from rapid degradation in the circulation to enable eﬃcient delivery to
the target cells. Several strategies were used to implement gene delivery
platforms using PEG-PCL NPs. Synthesis of tri-block copolymers by
chemical modiﬁcation of PEG-PCL or the preparation of mixed micelles
using various copolymers showed promising results. Conjugation of
positively charged cationic segments such as linear or branched poly
(ethylene imine) (PEI) and poly(aminoethyl methacrylate) (PAMA) to
PEG-b-PCL di-block copolymers results in PEG-b-PCL-b-PEI or PEG-b-
PCL-b-PAMA tri-block copolymers. Alternatively, esteriﬁcation of the
mPEG-b-PCL hydroxyl group by acryloyl chloride and subsequent
Michael-type addition of PEI was used [240,241]. Optimizations in
the self-assembly process and the molecular composition of the tri-
block copolymer resulted in eﬃcient encapsulation of small interfering
RNA (siRNA) and high gene delivery capacity [68,241,242]. PEG-b-
PCL-b-PEI micelles loaded with siRNA, targeted against GAPDH,
showed high transfection eﬃciency and were able to knock down
target gene expression in vitro and in vivo when administered
intratracheally [240]. Another PEG-PCL-PEI tri-block copolymer tar-
geted to the folate receptor was used to simultaneously deliver
doxorubicin and to knock down P-glycoprotein (P-gp) expression using
siRNA. Micelles were able to restore sensitivity of MCF-7/ADR cells to
doxorubicin in an attempt to treat multi-drug resistant (MDR) cancer
[243]. Mixed micelles composed of PEG-b-PCL, poly(2-(dimethylami-
no)ethyl methacrylate)-b-PCL (PDMA-b-PCL), and pegylated anti-VEGF
siRNA were produced. In addition, micelles were loaded with SN-38, a
cytotoxic drug, and iron oxide nanoparticles for MRI contrast enhance-
ment. This multi-component formulation was able to knock down VEGF
expression, served as MRI contrast agent, and showed promising anti-
tumor eﬃciency in vivo [244]. The high chemical stability of PEG-PCL
copolymers can eﬃciently prevent the extracellular degradation of
nucleic acid-based therapeutics: The future challenges lay in the
extrapolation from test systems and animal models to possible clinical
applications in human.
9. Conclusion
PEG-PCL NPs are promising candidates as drug delivery tools
characterized by a high biocompatibility, biodegradability, and long-
circulating properties. Chemical versatility and ease of modiﬁcation led
to the development of drug carriers for targeted and non-targeted
delivery of various drugs ranging from small molecules to macromole-
cules such as proteins or nucleic acids. Although no candidate reached
market approval from regulatory authorities so far, further improve-
ment and research on PEG-PCL-based nanomedicines will increase the
chance for a clinical application in humans. As lesson from history, the
development of liposomal drug delivery systems have shown that
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transferring novel technologies from bench to bedside needs to over-
come several hurdles and can take decades [245]. The implication of
scalable and reproducible production processes using e.g. microﬂuidics
and extensive physico-chemical characterization should therefore be
addressed. With this knowledge, disease-driven design and develop-
ment of PEG-PCL nanoDDS can enhance the therapeutic eﬃcacy and
potential patient beneﬁt. Long-term safety and eﬃcacy studies in vivo
need to be performed. Suitable preclinical models should be selected
carefully and used for the development of patient pre-selection tools
[246,247]. This will open up paths for ﬁrst in human trials and clinical
implication of promising PEG-PCL-based nanoDDS candidates. At
present, a vast number of synthetic polymers are developed in
preclinical research. PEG-b-PCL-based micelles are among the most
advanced and best-characterized systems and therefore have a great
potential to successfully enter translational research in the near future.
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Biodegradable PEG-PCL Micelles as Long-Circulating Drug Carriers 
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Highlights: While successful therapeutic options are available for many diseases, cancer remains a 
leading cause of death worldwide. Long-circulating drug delivery system may increase the 
performance of established drug therapies and decrease the high attrition rate of new chemical 
entities for the treatment of cancer entering clinical trials. In this study, a nanoparticulate drug 
delivery system based on PEG-PCL was developed and used for the delivery of doxorubicin. 
Therapeutic effects were analyzed in vitro and accumulation of doxorubicin at its site of action was 
studied. To assess the potential of doxorubicin-loaded PEG-PCL micelles for passive tumor targeting, 
PK properties and tissue distribution were analyzed in a high-trough put-screening model (i.e. 
zebrafish embryos) and in rats. Results were compared to doxorubicin administered as free drug and 
encapsulated in PEG-liposomes, the gold standard for long circulating NPs.  
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Abstract 
The use of nanomedicines for delivery of anti-cancer drugs is a promising 
strategy to increase the therapeutic efficiency of these compounds. Whereas 
PEGylated liposomes (PEG-liposomes) are gold standards for long-circulating 
drug carriers, other systems such as polymeric micelles are promising 
alternatives.   
In this study, doxorubicin-loaded poly(ethylene glycol)-b-poly(ε-caprolactone) 
(PEG-PCL) micelles were compared to doxorubicin-loaded PEG-liposomes. 
Dox-PEG-PCL micelles were characterized by similar pharmacological effects 
as compared to doxorubicin administered as free drug or encapsulated in 
PEG-liposomes. Biodistribution studies in an in vivo screening tool (i.e. 
zebrafish embryos) revealed long circulating properties of PEG-PCL micelles. 
To further confirm these findings, pharmacokinetics of doxorubicin as free drug 
or encapsulated in PEG-liposomes or PEG-PCL micelles was assessed in 
vivo. Whereas free doxorubicin was rapidly cleared form the blood circulation, 
encapsulation in PEG-PCL micelles dramatically increased the area under the 
plasma concentration curve and decreased the systemic volume of distribution. 
These results highlight the long-circulating properties of doxorubicin-loaded 
PEG-PCL micelles and thus their potential application for the delivery of anti-
cancer drugs via passive tumor targeting.  
 
Introduction 
Despite great progress in the understanding of cancer biology, this group of 
diseases still remains a leading cause of death. With the discovery of novel 
potential drug targets, a variety of promising new chemical entities entered 
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preclinical and clinical research. Nevertheless, attrition during clinical 
development of oncology drugs is high: Less than one out of ten compounds 
receives market approval after reaching Phase-I clinical trials [1]. Major causes 
of failure are lack in clinical safety and non-favorable pharmacokinetics of the 
investigational compounds [2,3]. Nanocarriers can increase drug solubility, 
protect metabolically labile drugs, improve the pharmacokinetics of their drug 
payload (i.e. prolong the blood-circulation time), and by this reduce off-target 
effects, increase therapeutic efficiency, and improve drug safety [4]. They can 
therefore be used to implement drug delivery strategies of highly potent drugs 
lacking in drug-like properties to cancer cells. Moreover, some solid tumors are 
characterized by fenestrated blood vessels and reduced lymphatic drainage. 
Long-circulating nanoparticles (NPs) can therefore extravasate and passively 
accumulate in the tumor tissue, a phenomenon called the enhanced 
permeability and retention (EPR) effect [5]. The efficiency of passive tumor 
targeting mainly depends on tumor biology (e.g. blood flow and pore size of the 
fenestration) as well as particle-related features such as size and surface 
charge [6,7]. Doxorubicin entrapped in PEG-liposomes, for example, remain in 
the plasma for hours and accumulates in solid tumors when injected i.v., 
whereas free drug is rapidly cleared from the central blood compartment [8–
10]. Although PEG-liposomes remain the most advanced nanocarriers (i.e. 
gold standard for long-circulating drug carriers), they are not suitable for all 
therapeutic strategies. Therefore, a big arsenal of NPs was developed using 
various building materials during the last decades. Some showed encouraging 
preclinical results and successfully proceeded to clinical trials [11]. 
Genexol-PM™, a polymeric micelle encapsulating paclitaxel reached market 
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approval in 2007 [12]. Micelles consisting of FDA approved, biodegradable 
PEG-PCL block copolymers are promising candidates for the delivery of anti-
cancer drugs [13–15]. The hydrophobic PCL core can serve as a reservoir for 
drugs, the hydrophilic PEG corona sterically stabilizes the micelle, minimizes 
protein opsonization, and by this, prolongs the blood circulation-time of the 
drug carrier [16–19]. They can easily be chemically modified, are 
biodegradable, and non-toxic. When paclitaxel was entrapped in PEG-PCL 
micelles, a high tumor accumulation was observed and mean survival time of 
xenograft-bearing animals was prolonged 1.5-fold as compared to animals 
treated with an approved paclitaxel formulation (TaxolTM) [14]. The aim of this 
experiment was to produce PEG-PCL micelles loaded with the model drug 
doxorubicin. Pharmacological effects of doxorubicin were analyzed in vitro on 
the hepatocellular carcinoma (HCC)-derived cell line HepG2. Cellular uptake 
and nuclear translocation of doxorubicin was analyzed using confocal 
microscopy. To assess the potential of PEG-PCL micelles for passive drug 
targeting, the pharmacokinetic profile of doxorubicin as free drug and 
encapsulated in PEG-liposomes or PEG-PCL micelles was assessed in vivo. 
To the best of our knowledge this is the first time that PEG-PLC micelles are 
compared to PEG-liposomes in the same experimental setting.  
 
Results 
Physico-chemical characterization of doxorubicin-loaded nanoparticles  
PEG-PCL micelles were prepared and loaded with doxorubicin using a 
modified cosolvent method [20]. PEG-PCL micelles had a mean hydrodynamic 
diameter of 73.4 ± 4.2 nm and a monodisperse size distribution (PDI 
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0.083 ± 0.029) as determined by DLS (n = 3) (Table 1). TEM analysis showed 
spherical particles with a diameter of 77.3 ± 20.9 nm (n = 50) as shown in 
Figure 1. PEG-PCL micelles were stable over 2 months as indicated by 
constant size and size distribution (data not shown). A drug loading content 
(DLC) of 1.9 ± 0.04% [w/w] was achieved with a drug loading efficiency (DLC) 
of 5.0 ± 0.1%. Drug release at 37 °C was analyzed with PBS (pH 7.4, 3% BSA) 
as a receiver medium. A slow release of doxorubicin was observed. Only 5.1 % 
of the initial drug content was detected in the receiver medium after 24 hours 
(Fig. 2). Similar results were obtained for Dox-PEG-liposomes (Table 1 and 
Fig. 2)  
 
In vitro characterization of doxorubicin-loaded nanoparticles 
A cell viability assay was used to study the pharmacological effect of 
Dox-PEG-PCL micelles. A human HCC-derived cell line (HepG2) was 
incubated with equal concentrations of free doxorubicin or doxorubicin 
encapsulated in PEG-liposomes or PEG-PCL micelles. Cell viability was then 
determined using the MTT assay (Fig. 3B). A similar decrease in cell viability 
was detected in cells incubated with doxorubicin administered as free drug or 
encapsulated in PEG-liposomes or PEG-PCL micelles. In addition, cellular 
uptake and intracellular distribution of doxorubicin was analyzed qualitatively 
using confocal microscopy. After 24 hours of incubation with either free drug or 
doxorubicin encapsulated in PEG-PCL micelles, doxorubicin fluorescence (red) 
merged with stained nuclei (blue) as shown in Figure 3A. However, a slower 
uptake of doxorubicin was observed when encapsulated in PEG-PCL micelles 
as indicated by lower intracellular red fluorescence after 2 hours of incubation 
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(data not shown). In addition to qualitative analysis, Pearson’s Correlation 
Coefficients (PCC) were calculated. Free doxorubicin showed a high 
correlation with stained nuclei after 2 hours (PCC 0.853) whereas doxorubicin 
encapsulated in PEG-PCL micelles showed a low correlation (PCC 0.165). 
After 24 hours, both formulations showed similar PCCs with values of 0.536 for 
free doxorubicin and 0.657 for doxorubicin encapsulated in PEG-PCL micelles.  
 
Biodistribution in zebrafish embryos 
The biodistribution and blood circulation of fluorescently labeled PEG-PCL 
micelles and PEG-liposomes were tested in zebrafish embryos. Formulations 
were injected in the duct of cuvier using a micromanipulator device. For both 
formulations, DiI (carbocyanine dye) fluorescence was found evenly distributed 
in tail vein areas without signs of agglomeration or uptake by macrophages 
(Fig. 4)  
 
In vivo pharmacokinetics and biodistribution 
Plasma concentration of free doxorubicin and doxorubicin encapsulated in 
PEG-liposomes or PEG-PCL micelles was analyzed after i.v. injection using a 
jugular vein catheter. To prevent adsorption and loss of doxorubicin to plastic 
tubing during preparation and injection, free drug formulation was prepared 
using 0.1% BSA. The area under the plasma concentration curve (AUC0∞) 
increased significantly (Table 2 and Fig. 5) when doxorubicin was 
encapsulated in PEG-liposomes (16-fold) or PEG-PCL micelles (14-fold). From 
these data, the systemic volume of distribution at steady state (VD) and the 
plasma clearance were calculated (Table 2). As described previously, a 
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pronounced difference was revealed for PEG-liposomes as compared to free 
drug [21,22]. Free doxorubicin disappeared rapidly from the plasma 
compartment with a plasma clearance of 44.5 ± 10.5 mL/min/kg and a high VD 
of 1182.0 ± 311.9 mL/kg. Encapsulation of doxorubicin in PEG-liposomes 
decreased plasma clearance 90-fold (0.5 ± 0.1 mL/min/kg). A similar effect on 
the plasma clearance was obtained when doxorubicin was entrapped in 
PEG-PCL micelles (0.6 ± 0.2 mL/min/kg). VD of doxorubicin was decreased 
dramatically when encapsulated in PEG-liposomes (44.0 ± 8.9 mL/kg) or 
PEG-PCL micelles (77.0 ± 9.1 mL/kg). In addition to the plasma concentration 
over time, recovery of doxorubicin from liver, spleen, kidneys, lung, and heart 
after 60 min was analyzed (Fig. 6). Encapsulation of doxorubicin in 
PEG-liposomes and PEG-PCL micelles significantly reduced accumulation in 
kidneys. 
 
Discussion 
Physico-chemical characterization of doxorubicin-loaded nanoparticles  
PEG-PCL micelles used in this study were characterized by a monodisperse 
size distribution, a hydrodynamic diameter below 100 nm, and a slightly 
negative zeta potential (Table 1). Ideally, long-circulating nanocarriers should 
be within a size range of 10-500 nm to avoid renal filtration and uptake by 
mononuclear macrophage system (MPS) [23–25]. Doxorubicin was stably 
incorporated in PEG-PCL micelles as indicated by a slow drug release profile 
(Fig. 2). Stable drug incorporation is important regarding two issues. First, 
premature drug release may reverse the positive effects of NP encapsulation 
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on the drug. It was shown that the release rate of doxorubicin from liposomes 
negatively correlates with intratumoral accumulation and therapeutic activity 
[26]. Second, stable encapsulation is a prerequisite for further in vivo testing of 
PEG-PCL micelles using doxorubicin as model drug. Total recovery of 
doxorubicin after 72 hours was 79.3 ± 8.8%. A high affinity of doxorubicin to 
plastic devices (e.g. polypropylene) was described previously [27]. Although 
3% BSA was added to the receiver medium, adsorption of doxorubicin to 
plastic could thus reduce the total recovery obtained in the release 
experiments.  
 
In vitro characterization of doxorubicin-loaded nanoparticles 
The pharmacological effect of doxorubicin encapsulated in PEG-PCL micelles 
was analyzed on HepG2 cells. Similar therapeutic effects (i.e. decrease in cell 
viability) were obtained when cells were incubated with doxorubicin as free 
drug or encapsulated in PEG-liposomes or PEG-PCL micelles (Fig. 3B). These 
results indicate that although doxorubicin was stably encapsulated in 
PEG-PCL micelles, cellular uptake results in efficient release of the drug from 
its carrier. These findings were further supported qualitatively by confocal 
microscopy. One mode of action that was described for doxorubicin is the 
intercalation with DNA and disturbance of DNA repair mechanisms [28]. Thus, 
to induce its pharmacological effects, doxorubicin needs to enter the cell 
nucleus. After 2 hours of incubation, doxorubicin fluorescence was observed 
as condensed spots in the cytoplasm, indicating uptake of doxorubicin 
incorporated in PEG-PCL micelles (PCC 0.165). In contrast, doxorubicin 
fluorescence was observed in the cell nucleus when doxorubicin was 
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administered as free drug (PCC 0.853). After 24 hours of incubation, 
doxorubicin fluorescence merged with stained cell nuclei in cells incubated with 
free drug (PCC 0.536) or Dox-PEG-PCL micelles (PCC 0.657) as shown in 
Fig. 3A. Higher fluorescence intensity for cells incubated with free drug as 
compared to cells incubated with Dox-PEG-PCL micelles indicates slower 
cellular uptake due to stealth properties of PEG-PCL micelles. Decrease in 
PCC for free doxorubicin may be explained due to morphological changes 
such as blebbing of incubated cells due to initiation of apoptosis as described 
previously [29]. 
 
Biodistribution in zebrafish embryos 
Invertebrate models such as zebrafish embryos are valuable screening tools to 
predict in vivo behavior of nanomedicines as shown previously [30]. In 
comparison with mammalian in vivo models, these screening models (i.e. 
zebrafish embryos) have several advantages. They can be used in 96-well 
formats and thus are prawn to high-trough put screening, they are transparent 
and allow fluorescent imaging, and they are cheap. Additionally, there are 
major benefits on animal welfar.  Whereas non-circulating particles are rapidly 
removed from the central blood compartment, fluorescence of long-circulating 
NPs remains in the blood compartment for hours [30]. One hour after injection 
into the duct of cuvier, both formulations tested in this work showed evenly 
distributed fluorescence signals in the vasculature (Fig. 4). No agglomerations 
or extravascular signal were detected indicating the long-circulating properties 
of PEG-PCL micelles, comparable to PEG-liposomes.  
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In vivo pharmacokinetics and biodistribution 
The goal of this study was to assess the potential of PEG-PCL micelles as long 
circulating drug delivery system using the model drug doxorubicin. Although 
the pharmacokinetic profile of PEG-PCL micelles was analyzed previously [31–
33], factors such as polymer composition and NP preparation may influence 
the in vivo faith of NPs. In addition, parameters related to the in vivo model and 
study design (e.g. choice of analytics, dose, and animal species) can highly 
influence the outcome of the experiment. Due to these reasons, the 
pharmacokinetic profiles of doxorubicin as free drug or encapsulated in PEG-
liposomes or PEG-PCL micelles were analyzed in the same experimental 
setting. With this approach, PEG-PCL micelles can be compared to the gold 
standard of long circulating NPs, i.e. PEG-liposomes. Plasma concentration 
data were analyzed using PK solver [34]. A one (Dox-PEG-liposomes and Dox-
PEG-PCL micelles) and two compartment model (free doxorubicin) were used 
for fitting and interpretation of data. The best model for each formulation was 
selected using the Akaike Information Criterion [35] and the Schwarz Criterion 
[36] as described previously [37]. To validate the experimental animal model, a 
design that was used in previous experiments using anthracyclines in 
combination with PEG-liposomes was chosen. Data obtained for doxorubicin 
as free drug or entrapped in PEG-liposomes were comparable to the reference 
data indicating the validity of the experimental procedure used in this study 
[21,22]. Encapsulation of doxorubicin in PEG-liposomes or in 
PEG-PCL micelles reduced the total clearance from plasma compartment 
dramatically. Both formulations increased the AUC0∞ (16-fold increase vs. 14-
fold increase) and the plasma clearance (89-fold decrease vs. 74-fold 
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decrease) of doxorubicin (Table 2). However, the VD of doxorubicin 
encapsulated in PEG-PCL micelles was almost 2-fold higher as compared to 
PEG-liposomes. Several reasons could account for this difference. First, traces 
of non-encapsulated doxorubicin characterized by a high VD could influence 
the experimental outcome. Second, differences in NP characteristics could 
result in differences in tissue distribution as it was shown for lipid NPs [38]. 
Indeed, slightly higher doses of doxorubicin were recovered from liver and 
kidneys when encapsulated in Dox-PEG-PCL micelles as compared to PEG-
liposomes (Fig. 6).  
 
Conclusion 
PEG-PCL micelles prepared in this study are characterized by physico-
chemical properties that are favorable for long-circulating drug carriers. Using a 
powerful screening tool for the biodistribution and blood circulation (i.e. 
zebrafish embryos), a long plasma half-life of PEG-PCL micelles was 
predicted. These results were further confirmed in experimental animals (i.e. 
rats). PEG-PCL micelles were compared to PEG-liposomes, the gold standard 
for long circulating NPs, in the same experimental setting. PEG-PCL micelles 
remained in the central blood compartment for hours and reduced the 
accumulation of doxorubicin in off-target tissue such as the liver and kidney. 
Thus, PEG-PCL micelles are suitable carriers for anti-cancer drugs and can be 
used to increase the therapeutic performance drugs that lack in drug-like 
properties and that are characterized by unfavorable pharmacokinetics.  
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Figure 1 Transmission electron micrographs of doxorubicin-loaded (A) PEG-liposomes and (B) 
PEG-PCL micelles. Nanoparticles were negatively stained using uranyl acetate. Scale bar: 
500 nm; Insert: 100 nm. 
 
 
 
Figure 2 Cumulative drug release. Release of doxorubicin as free drug (dashed line, black 
squares), incorporated in PEG-liposomes (dotted line, black dots), or PEG-PCL micelles (solid 
line, black squares) was analyzed by dialysis against PBS (pH 7.4, BSA 3%, 37°C). For free 
doxorubicin and PEG-PCL micelles values represent means ± S.D. of n = 3 experiments. 
Transmission electron micrographs of Dox-PEG-PCL micelles and Dox-PEG-liposomes after 
drug release (72 hours). Scale bare: 100 nm.  
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 Figure 3 In vitro characterization of Dox-PEG-PCL micelles. (A) Cellular uptake and nuclear 
localization of doxorubicin in HepG2 after incubation for 24 hours as free drug or encapsulated 
in PEG-PCL micelles. Red: doxorubicin; Blue: cell nuclei (Hoechst 33342). Pearson’s 
correlation coefficients (PCC) for doxorubicin and Hoechst 33342 after 2 hours and 24 hours 
are shown. (B) Cell viability assay of HepG2 cells 24 hours after incubation with free drug 
(white) or doxorubicin encapsulated in PEG-liposomes (grey), or PEG-PCL micelles (black). 
Values represent means ± S.D. of n = 3 experiments.  
 
 
 
Figure 4 Circulation behavior of fluorescently labeled PEG-liposomes and PEG-PCL micelles 
in zebrafish embryos was analyzed one hour post infection (hpi). Upper panel: 10 x; lower 
panels: 20 x. Green: GFP signal in vasculature; Red: DiI; Grey; DiI. 
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Figure 5 Plasma-concentration curve of doxorubicin after injection of free drug (black 
squares), drug incorporated in PEG-liposomes (white squares) and PEG-PCL micelles (grey 
dots). Results represent means ± S.D. of n = 3 experiments. 
 
 
 
Figure 6 Tissue distribution of doxorubicin as free drug (black), drug incorporated in PEG-
liposomes (grey) and PEG-PCL micelles (white) analyzed at 60 minutes after injection. Values 
represent means ± S.D. of n = 3 experiments. Statistical significance was tested using one-
way analysis of variance (ANOVA) followed by Tukey’s post hoc test at a level if significance of 
p < 0.05 (*).  
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Table 1 Physico-chemical characterization of Dox-PEG-PCL micelles and Dox-PEG-Liposomes. 
 
Dox-PEG-PCL micelles Dox-PEG-Liposomes 
Hydrodynamic diameter [nm]a 73.4 ± 4.2 85.1 ± 2.6 
Polydispersity index (PDI)a 0.08 ± 0.03 0.13 ± 0.03 
Diameter [nm]b 77.3 ± 20.9 72.2 ± 15.6 
Morphologyc Solid spheres Hollow spheres 
a Determined by dynamic light scattering. Values represent means ± S.D. of n = 3 experiments.  
b Determined by transmission electron microscopy (TEM). Values represent means ± S.D. of n = 50 
counts.  
c Determined by SLS and Cyro-EM.  
 
 
Table 2 Plasma clearance, systemic volume of distribution (VD), and area under the plasma 
concentration curve (AUC) of doxorubicin after injection of free drug or drug incorporated in PEG-
liposomes or PEG-PCL micelles.  
 
Clearance 
[mL/min/kg]a 
VD 
[mL/kg]a 
AUC
t
0  
[%ID/mL*min]a 
AUC
∞
0  
[%ID/mL*min]a 
Doxorubicin HCl 44.5 ± 10.5 1182.0 ± 311.9 21.1 ± 5.3 59.2 ± 19.9 
Dox-PEG-liposomes 0.5 ± 0.1 44.0 ± 8.9 405.9 ± 24.9 970.3 ± 310.8 
Dox-PEG-PCL micelles 0.6 ± 0.2 77.0 ± 9.1 256.6 ± 26.6 818.0 ± 260.0 
a Values represent means ± S.D. of n = 3 experiments.  
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Experimental section 
Materials. PEG-b-PCL (PCL average Mn 13 000, PEG average Mn 5 000), anhydrous 
tetrahydrofuran (THF; ≥99.9%), triethylamine (TEA), cholesterol, anhydrous dimethyl sulfoxide 
(DMSO; ≥99.9%), ethyl 3-aminobenzoate methane sulfonate (tricaine), N-phenylthiourea 
(PTU), methylene blue, halocarbon oil 27, and hydrogen peroxide (35% [w/v]) were purchased 
from Sigma-Aldrich (Buchs, Switzerland). Thiazolyl blue (MTT reagent; ≥98%) was purchased 
from Carl Roth GmbH (Karlsruhe, Germany). 1,2-Distearoyl-sn-glycero-3-phosphocholine 
(DSPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(methoxy(polyethylene 
glycol)-2000) (DSPE-PEG-2000)  were purchased from Avanti Polar-Lipids (Alabaster, AL, 
USA). Amicon Ultra-4 centrifugal filter units (100 kDa MWCO) were purchased from Merck 
Millipore (Darmstadt, Germany). Regenerated cellulose dialysis membrane tubing (6-8 kDa 
MWCO) was purchased from Spectrum Laboratories Inc. (Rancho Dominguez, CA, USA). 
Tritium-labeled Dox ([3H]-Dox; 0.5-3 Ci/mmol, in EtOH) was purchased from Campro Scientific 
GmbH (Berlin, Germany). Econo-Pac 10DG desalting columns and agarose standard low were 
purchased from BioRad (Hercules, CA, USA). Ultima-Gold XR and Solvable were purchased 
from PerkinElmer (Schwerzenbach, Switzerland). Doxorubicin (Doxorubicin Sandoz eco, 
2 mg/mL in NaCl 0.9%) and doxorubicin-loaded PEG-liposomes (CaelyxTM) were purchased in 
a public pharmacy. Tg(kdrl:EGFP) zebrafish were kindly provided by Prof. Dr. Markus Affolter 
(Biozentrum, University of Basel, Basel, Switzerland).  
 
Preparation of doxorubicin loaded PEG-PCL micelles. Doxorubicin-loaded 
PEG-PCL micelles were prepared using a modified cosolvent method [20]. PEG-PCL (5 mg) 
was dissolved in THF (50 μL). Doxorubicin (1 mL; 2 mg/mL) was mixed with an equivalent 
molar ratio of TEA and was added dropwise to the polymer solution under constant stirring 
(700 rpm). After overnight stirring at room temperature, free doxorubicin was removed by gel 
filtration chromatography using a Superose 6 Prep column eluting with PBS (0.01 M, 0.15 M 
NaCl, pH 7.4). Samples were concentrated using Amicon Ultra-4 centrifugal filter units 
(100 kDa MWCO).  
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Preparation of [3H]-doxorubicin-loaded PEG-PCL micelles. For pharmacokinetic 
experiments, tritium-labeled PEG-PCL micelles were prepared. Therefore, [3H]-doxorubicin 
(30 μCi) in EtOH was placed in a glass vial and EtOH was evaporated under nitrogen. 
[3H]-doxorubicin was dissolved in THF (50 μL) and mixed with a 1:1 molar ratio of TEA. 
PEG-PCL (3 mg) was added. MiliQ water (1 mL) was added dropwise under constant stirring 
at 700 rpm. After 2 horus, free [3H]-doxorubicin was removed by gel filtration chromatography 
using Econo-Pac® 10DG desalting columns eluting with PBS (0.001 M, 0.15 M NaCl, pH 7.4). 
Fractions containing [3H]-doxorubicin-loaded PEG-PCL micelles were concentrated using 
Amicon Ultra-4 centrifugal filter units (100 kDa MWCO). 
 
Preparation of fluorescently labeled PEG-PCL micelles. Fluorescently labeled 
PEG-PCL micelles were prepared as described previously [20]. In brief, PEG-PCL (5 mg) was 
dissolved in THF (50 μL) and DiI (10 μg) was added. The mixture was stirred at 700 rpm and 
room temperature. PBS (0.01 M, pH 7.4, 0.15 M NaCl; 1 mL) was added dropwise under 
constant stirring at 700 rpm. The mixture was stirred for 24 h at room temperature. Free DiI 
was removed by gel filtration chromatography using Superose 6 prep column eluting with PBS 
(0.01 M, 0.15 M NaCl, pH 7.4). Samples were concentrated using Amicon Ultra-4 centrifugal 
filter units (100 kDa MWCO). 
 
Preparation of [3H]-doxorubicin-loaded PEG-liposomes. PEG-liposomes were prepared 
using a microfluidics device (NanoAssemblr Benchtop, Precision Nanosystems, Vancouver, 
BC, Canada). A lipid mix (20 mM tot) containing DSPC (10.45 mM), cholesterol (8.55 mM) and 
DSPE-PEG (1 mM) in EtOH was prepared. Lipids in EtOH were mixed with acetate buffer 
(0.3 M, pH 4.0) at a flow-rate ratio (FRR) of 2.5:1 and a total flow rate (TFR) of 6 mL/min. PEG-
liposomes were dialyzed over night against PBS (0.01 M, 0.15 M NaCl, pH 7.8). PEG-
liposomes were loaded with [3H]-doxorubicin using a remote loading strategy (i.e. pH gradient) 
as described previously [21]. In brief, [3H]-doxorubicin was placed in a glass vial and EtOH was 
removed under nitrogen. [3H]-doxorubicin was reconstituted in 20 μL of MiliQ water. PEG-
liposomes were added and the mixture was incubated at 60°C for 10 min. Excess of 
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[3H]-doxorubicin was removed by gel filtration chromatography using Econo-Pac® 10DG 
desalting columns eluting with PBS (0.001 M, 0.15 M NaCl, pH 7.4). Fractions containing 
[3H]-doxorubicin-loaded PEG-liposomes were concentrated using Amicon Ultra-4 centrifugal 
filter units (100 kDa MWCO). For the preparation of DiI-labeled PEG-liposomes, DiI was added 
to lipids (1% [mol/mol]) and PEG-liposomes were prepared and purified as described above.  
 
Physico-chemical characterization. PEG-PCL micelles and PEG-liposomes were 
characterized using transmission electron microscopy (TEM) and dynamic light scattering 
(DLS). For TEM analysis, 5 μL of the NP suspension were mounted on a copper-carbon grid 
(400 mesh per grid) and negatively stained with a 2% uranyl acetate solution. Samples were 
then analyzed using a Philips Morgagni 268D transmission electron microscope. Average 
nanoparticle size was determined by dynamic using a Delsa Nano C (Beckman Coulter, Nyon, 
Switzerland). The laser was adjusted to 658 nm and scattered light was detected at a 165° 
angle. Data was converted using CONTIN particle size distribution analysis. 
 
Determination of the drug loading content and drug loading efficiency. Doxorubicin 
content was determined by absorption measurement. In brief, a calibration curve of 
doxorubicin in PBS/DMSO (1:1 v/v) was prepared and absorbance was measured at a 
wavelength of 493 nm using a Spectrramax M2 microplate reader (Molecular Devices, 
Sunnyvale, CA, USA). Doxorubicin-loaded PEG-PCL micelles were mixed with DMSO at a 
ratio of 1:1 [v/v] and the doxorubicin content was determined. Drug loading content was 
calculated as percentage [m/m] of doxorubicin to PEG-PCL. Drug loading efficiency was 
calculated as percantage of the initial doxorubicin concentration (i.e. before purification). 
Concentration of [3H]-doxorubicin was determined by liquid scintillation counting.  
 
Analysis of drug release. Drug release was measured by dialysis. Either 1 mL of 
doxorubicin as free drug and encapsulated in PEG-liposomes or PEG-PCL micelles was 
placed in dialysis membrane tubing (6-8 kDa MWCO) and dialyzed against 10 mL of PBS 
(pH 7.4, 3% BSA) at 37 °C. Samples were taken at time points indicated from the recipient 
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medium and replaced by fresh medium. Doxorubicin concetration in receiver medium was 
determined using absorbance measurments as described above. Total recovery was 
calculated by measuring the remaining doxorubicin concetration in the donor medium at the 
end of the release experiment and is expressed as percentage of the initial doxorubicin 
concentration.  
 
Cell culture. The human hepatoma cell line HepG2 was kindly provided by Prof. Dr. 
Dietrich von Schweinitz (University Hospital of Basel, Basel, Switzerland). Cells were cultured 
in Dulbecco’s modified eagle medium (DMEM, Sigma-Aldrich, Buchs, Switzerland; glucose 
4500 g/L) supplemented with 10% fetal calf serum (FCS, Amimed BioConcept, Allschwil, 
Switzerland), 100 U/mL penicillin (Sigma-Aldrich, Buchs, Switzerland), and 100 mg/mL 
streptomycin (Sigma-Aldrich, Buchs, Switzerland).  
 
In vitro cell viability studies. In vitro cell viability was determined using a modified MTT 
assay as described previously [39]. In brief, HepG2 cells were seeded at a density of 1 x 104 
cells/well in a 96-well plate (TPP, Trasadingen, Switzerland) coated with poly-D lysine 
(0.04 mg/mL; Sigma-Aldrich, Buchs, Switzerland). Cells were allowed to adhere over night and 
were washed twice with Dulbecco’s phosphate-buffered saline (DPBS). Then, doxorubicin as 
free drug, encapsulated in PEG-liposomes, or PEG-PCL micelles was added at 1-10 μM. 
DMEM was used as negative control, terfenadine (20 μM) as positive control. After 24 hours of 
incubation, cells were washed three times with DPBS and MTT working solution (100 μL, 
thiazolyl blue 5 mg/mL) was added. MTT working solution was aspirated after 2-3 hours of 
incubation at 37 °C and formazan crystals were solubilized with acidified isopropyl alcohol 
(100 μL) and SDS (3%, 20 μL) for 2 hours at room temperatue under light protection. 
Absorption was read at 570 nm and 670 nm using a Spectrramax M2 microplate reader 
(Molecular Devices, Sunnyvale, CA, USA). Cell viability is expressed as relative cell viability 
compared to control cells (DMEM only). Experiments were performed in triplicates and 
statistical analysis was performed as described below.  
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In vitro cell uptake. In vitro uptake of doxorubicin as free drug or encapsulated in 
PEG-PCL micelles by HepG2 cells was analyzed by confocal laser scanning microscopy 
(CLSM). Glass coverslips (♯1.5, Menzel, Braunschweig, Germany) were coated with poly-D 
lysine (0.4 mg/mL) and placed in a 12-well plate (TPP, Trasadingen, Switzerland). HepG2 cells 
were seeded at a density of 2.5 x 104 cells/cm2 and were allowed to adhere over night. Cells 
were then washed twice with DPBS and were incubated with free doxorubicin or doxorubicin 
encapsulated in PEG-PCL micelles for indicated times. To stain cell nuclei, Hoechst 33342 dye 
(0.2 μg/mL; Eugene, OR, USA) was added 10 min prior to end of incubation time. Cells were 
then washed three times with ice-cold DPBS and were fixed with paraformaldehyde (4%) for 
15 min at 4 °C. Paraformaldehyde was removed and cell were washed three times with ice-
cold DPBS. Coverslips were mounted with Prolong Gold (Thermo Fisher Scientific, Waltham, 
MA, USA). Cells were analyzed using an Olympus FV 1000 inverted laser scanning 
microscope equiped with a 40x (NA 1.30) and a 60x (NA 1.40) oil immersion objective 
(Olympus, Tokyo, Japan). Doxorubicin was excited at 488 nm and emitted signal was detected 
using a 530/30 bandpass filter. Colocalization of Hoechst 33342 and doxorubicin was 
calculated was determined by Pearson’s Correlation Coefficient (PCC) using ImagJ 1.46 
software (National Institutes of Health). 
 
Zebrafish biodistribution studies. All experiments using zebrafish were performed in 
accordance with Swiss animal welfare regulations. Experiments were performed as described 
previously [30]. In brief, zebrafish embryo (ZFE) culture medium at pH 7.4 was prepared at 
final concentrations of sodium chloride (5 mM), potassium chloride (0.25 mM), magnesium 
sulfate (0.5 mM), potassium dihydrogen phosphate (0.15 mM), sodium phosphate dibasic 
(0.05 mM), calcium chloride (0.5 mM), sodium bicarbonate (0.71 mM), and methylene blue 
(0.001% w/v). Zebrafish eggs of Tg(kdrl:EGFP) zebrafishes were incubated at 28°C in ZFE 
culture medium and bleached 1-day post fertilization (dpf) using PTU (0.03 mg/mL). ZFE were 
anesthetized using tricaine (0.01% w/v) and immobilized using agarose (0.3% w/v) containing 
the same amount of tricaine.  DiI labelled PEG-liposomes and PEG-PCL micelles were injected 
at 2 dpf via the duct of cuvier using a micromanipulator (Wagner Instrumentenbau KG, 
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Schöffengrund, Germany), a pneumatic Pico Pump PV830 (WPI, Sarasota, FL), and a Leica 
S8AP0 microscope (Leica, Wetzlar, Germany) according to an adapted protocol [40]. Injection 
volumes were calibrated to 1 nL using halocarbon oil. Fluorescence imaging of injected ZFE 
was performed 1-hour post injection using an Olympus FV1000 confocal microscope 
(Olympus, Tokyo, Jpaan) equiped with a 10x water immersion objective (NA 0.4; Tokyo, 
Japan). Samples were excited at 488 and 520 nm and fluorescence was detected at 559 and 
569 nm.  
 
In vivo pharmacokinetic studies. Pharmacokinetic profiles of [3H]-doxorubicin as free 
drug and encapsulated in PEG-liposomes or PEG-PCL micelles were determined in female 
wistar rats (250-280 g) as described previously [21,22]. The protocol for animal experiments 
was approved by Swiss animal welfare authorities and experiments were performed in 
accordance with Swiss animal welfare regulations. In brief, rats were anesthetized by 
isoflurane (2-5%) and the jugular vein was cannulated. [3H]-doxorubicin (4 μCi) was injected as 
free drug, encapsulated in PEG-liposomes, or PEG-PCL micelles. Blood samples (200 μL) 
were collected at indicated time points, mixed with EDTA (0.5 M, 10 uL), and centrifuged for 
5 min at 1 000 rcf and 4 °C to seperate plasma. The blood volume collected was replaced by 
sterile normal saline containing heparin (100 U/mL). After 1 hour, animals were sacrificed and 
organs (liver, kidney, spleen, heart, and lung) were removed. Plasma aliquots (40 μL) and 
tissue samples (50-100 mg) were mixed with Solvable (1 mL) and solubilized according to the 
manufacturers protocol. Tissue samples were bleached with hydrogen peroxide (30%, 200 μL). 
Samples were then mixed with 10 mL of Ultima-Gold XR scintillation cocktail and activity was 
determined using liquid scintillation counting. Plasma-concentration time data were analyzed 
using PK Solver software [34]. One or two compartmental models were used to fit the data. 
Statistical significance of tissue distribution was determined by performing one-way analysis of 
variance (ANOVA) followed by Tukey’s post hoc test using OriginPro (Version 9.1.0, OriginLab 
Corporation, Northampton, MA, USA). 
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Highlights: To further understand uptake mechanisms of NPs and to analyze intracellular trafficking 
after cellular uptake, labeling techniques are of great interest. This article highlights the development 
of gold-nanohybrids using a novel strategy that is applicable to a broad range of engineered 
nanomaterials (i.e. lipids and polymers) and that is highly reproducible. These gold-nanohybrids exert 
unique physico-chemical properties and can be visualized in complex biological scaffolds such as 
mammalian cells using electron microscopy. This technique is a promising tool for the analysis of 
cellular uptake mechanisms and intracellular trafficking and may further be used for diagnostic 
purposes.  
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Formation of lipid and polymer based gold
nanohybrids using a nanoreactor approach†
Dominik Witzigmann,a Sandro Sieber,a Fabiola Porta,a Philip Grossen,a Andrej Bieri,b
Natalja Strelnikova,c Thomas Pfohl,c Cristina Prescianotto-Baschongd
and Jo¨rg Huwyler*a
Nanocarriers encapsulating gold nanoparticles (AuNPs) hold tremendous promise for numerous biomedical
applications. So far only a few fabrication strategies have been investigated and eﬃcient processes for the
manufacturing of gold nanohybrids (AuNHybs) are still missing. We encapsulated a tetrachloroaurate/citrate
mixture within nanocarriers and initiated the AuNP formation after self-assembly of the nanomaterial by a
temperature shift. This nanoreactor approach was successfully combined with the ﬁlm-rehydration,
nanoprecipitation, or microﬂuidics method. Diﬀerent nanomaterials were validated including
phospholipids and copolymers and the process was optimized towards encapsulation eﬃciency and
physico-chemical homogeneity of AuNHybs. Our nanoreactor technology is versatile, eﬃcient, and
highly reproducible. Dynamic light scattering and electron microscopy techniques conﬁrmed that
generated lipid and polymer based AuNHybs were of uniform size below 130 nm and contained a single
AuNP. The AuNHyb solutions had a deep-red color and exhibited the speciﬁc surface plasmon
absorption of AuNPs. The unique optical properties of AuNHybs were used to visualize cellular uptake of
nanocarriers in vitro demonstrating the promising applicability of AuNHybs as a bioimaging tool.
1. Introduction
Gold nanoparticles (AuNPs) have attracted great interest since
Michael Faraday rst described them in 1857.1,2 The application
of AuNPs in the eld of imaging and therapy were based on
their unique properties, which include; (I) advantageous
physico-chemical characteristics, (II) non-toxic and inert prop-
erties, (III) facile preparation of monodisperse AuNPs, and (IV)
various modication options.3–5 Diﬀerent methods for the
synthesis of AuNPs have been described.6,7 The most widely
used approach is the chemical reduction of gold salt (Au3+) such
as tetrachloroaurate (HAuCl4) to metallic gold (Au0) using the
Turkevich8,9 or Brust-Schiﬀrin10 method. Moreover, synthesis
methods using microwaves, UV irradiation, microuidics, or
biologic approaches were examined.3,11 Ultimately, AuNPs have
to be modied with capping agents to avoid aggregation,
provide solubility in aqueous media, and improve stability.12
Encapsulation of AuNPs into diﬀerent nanocarriers such as
liposomes or polymeric nanoparticles is an interesting option
for a wide range of applications such as smart drug delivery,
imaging, or photothermal therapy.13–18 In recent decades, great
progress has been made in the eld of hybrid nanocarriers
using AuNPs and several strategies for their synthesis have been
investigated. For example, lipid based gold nanohybrids (lipid-
AuNHybs) have been prepared using the following methods:
improved cholate dialysis,19 incorporation of hydrophobic
AuNPs,20–22 physical absorption,23,24 or precipitation of gold
within liposomes using either, glycerol including formation or
reverse-phase evaporation.25,26
However, these strategies exhibited marked variability in
homogeneity, reproducibility, size distribution, and
morphology of gold nanohybrids (AuNHybs). To overcome these
challenges, we developed a novel and versatile strategy to
encapsulate AuNPs into diﬀerent nanocarriers with high
reproducibility using a nanoreactor approach. The goal of the
present study was, (I) the encapsulation of a tetrachloroaurate/
citrate mixture within nanocarriers and (II) the initiation of
AuNP formation aer self-assembly of the nanomaterial.
Selected nanomaterials (i.e. lipid and polymer based) were
validated and the encapsulation eﬃciency, homogeneity, and
robustness of our approach were optimized. Nanocarriers
loaded with AuNPs were prepared by three diﬀerent methods
depending on the physico-chemical properties of the nano-
carrier material.
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The lm-rehydration–extrusion method27 was used for
conventional (non-PEGylated) liposomes, the nano-
precipitation method28 was used for di-block copolymer
nanoparticles, and the microuidics method29,30 was used for
PEGylated (sterically stabilized) liposomes (Fig. 1). The most
important feature of our nanoreactor approach is the
production of nanocarriers at room temperature (RT), which
avoids the formation of AuNPs before self-assembly. AuNP
formation is subsequently initiated by a temperature shi.
The applicability of the AuNHybs as bioimaging tool was
demonstrated in vitro using HepG2 human hepatocellular
carcinoma cells.
2. Experimental section
2.1 AuNP synthesis
AuNPs were synthesized following a modied Turkevich
method.7 Optimization of AuNP synthesis using a 23 full facto-
rial design of experiment (DoE) [Stavex 5.2, Aicos Technologies,
Basel, Switzerland] is described in detail in the ESI (Table S1†).
Briey, ddH2O with 1 mM tetrachloroaurate (Sigma-Aldrich,
Buchs, Switzerland) were heated to 70 !C for 20 min under
vigorous stirring. To start the formation of AuNPs, citrate
solution (170 mM; 50 mg mL"1) was added as a reducing and
capping reagent. The HAuCl4/citrate gold reaction mixture
(AuR-solution) was stirred at 70 !C for 10 min until the solution
had a deep-red color.
2.2 AuNHyb formation using lm rehydration
The lm rehydration method was used for lipids with a transi-
tion temperature (Tm) below RT with modications described
elsewhere.31 Liposomes were produced at a temperature which
inhibits the AuNP formation. In brief, 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (15 mmol) [POPC] (Avanti Polar-
Lipids, Alabaster, USA) and 1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-10-rac-glycerol (5 mmol) [POPG] (Avanti Polar-Lipids,
Alabaster, USA) were dissolved in chloroform/methanol (2 : 1,
v/v) and a homogenous dry lipid lm was prepared using a
Rotavapor A-134 (Bu¨chi, Flawil, Switzerland). The lipid lm was
rehydrated with a freshly prepared AuR-solution (HAuCl4 :
citrate ratio – 1 : 4) at RT and 120 rpm for 10 min with 3 g glass
beads (diameter 5 mm). Diﬀerent lipid (20 mM) to AuR-solution
ratios were tested starting from 1mMHAuCl4/4.1 mM citrate up
to 8 mM HAuCl4/32.8 mM citrate.
The resulting multilamellar vesicles were subjected to three
freeze–thaw cycles and extruded through polycarbonate
membranes with two diﬀerent pore sizes using a barrel extruder
(Lipex; Northern Lipids, Vancouver; Canada). Liposomes were
extruded at RT 3 times through a 200 nm polycarbonate
membrane and 11 times through a membrane with a pore size
of 100 nm (VWR International, Dietikon, Switzerland). AuNPs,
which were formed during the extrusion procedure, bind to the
lter membranes. Finally, the unilamellar liposomes were
heated to 70 !C for 10 min to start the formation of AuNPs. To
separate liposomes from free AuNPs, the sample was puried by
FPLC using a Superose 6 prep column (GE Healthcare,
Fig. 1 Diﬀerent methods for the preparation of gold nanohybrids. Schematic representation of the, (A) ﬁlm-rehydration–extrusion method for
lipids with Tm < room temperature (RT), (B) nanoprecipitation method for the di-block copolymer PEG–PCL, and (C) microﬂuidics platform for
lipids with Tm > RT. The formation of gold nanoparticles inside the nanocarriers was initiated by temperature increase after self-assembly. (C) The
microﬂuidics device had seven inlet channels converging to a single staggered herringbonemicromixer. (D) Microﬂuidic streams were visualized
using the ﬂuorescence dye ﬂuorescein. (E) Computational ﬂuid dynamics simulation of concentration gradients (in a.u.) in the microﬂuidics
device. Scale bars indicate 100 mm.
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Glattbrugg, Switzerland) eluting with 0.01 M phosphate buﬀ-
ered saline (PBS) containing 150 mM sodium chloride, pH 7.4
(Sigma-Aldrich, Buchs, Switzerland).
2.3 AuNHyb formation using nanoprecipitation
A nanoprecipitation method was used for the di-block copolymer
polyethyleneglycol–polycaprolactone [PEG–PCL] (Sigma-Aldrich,
Buchs, Switzerland). The polymer (5 mg) was dissolved in THF
(50 mL) [Sigma-Aldrich, Buchs, Switzerland] under constant stir-
ring with a magnetic bar (750 rpm). The AuR-solution (HAuCl4 :
citrate ratio – 1 : 4) was added dropwise (one drop per ve
seconds). The mixture was stirred for 10 min at 750 rpm followed
by 10 min on a thermomixer at 70 !C and 300 rpm. Diﬀerent
polymer to AuR-solution ratios were tested starting from 1 mM
HAuCl4/4.1 mM citrate up to 8 mM HAuCl4/32.8 mM citrate. To
separate the PEG–PCL–AuNHybs from free AuNPs, a FPLC puri-
cation step was used (see above).
2.4 Microuidics device design and fabrication
The microuidics device was fabricated with 0.05 mm thick
polystyrene foil (GoodFellow, Huntingdon, UK) and NOA 81
(Norland, Cranberry, USA) using standard so-lithography
techniques according to the procedure described previ-
ously.32,33 The microuidics device had seven inlet channels
converging to a single staggered herringbone micromixer. The
rectangular cross-section had dimensions of 468 mm length,
80 mm width, and 40 mm/200 mm height (Fig. 1C). Detailed
experimental procedures are given in the ESI.†
2.5 Flow visualization and computational uid dynamics
simulation
Detailed experimental procedures are given in the ESI.†
2.6 AuNHyb formation using microuidics
The microuidics method was used for lipids with a transition
temperature above RT (55 !C). Therefore, the AuNP formation
during the liposome production was hampered due to decreased
temperature. 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC)
[5.75 mmol] (Avanti Polar-Lipids, Alabaster, USA), cholesterol
[4 mmol] (Sigma-Aldrich, Buchs, Switzerland), and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-(methoxy(polyethylene glycol)-
2000) (DSPE-PEG2000) [0.25 mmol] (Avanti Polar-Lipids,
Alabaster, USA) were dissolved in ethanol. The microuidics
device was primed with water for the outer streams and with
ethanol for the central inlet (1 mL s"1) using syringe pumps.
Aerwards four diﬀerent syringes were connected: (I)
double-distilled water, (II) citrate solution (4.1 mM–32.8 mM),
and (III) tetrachloroaurate (HAuCl4) solution (1 mM–8 mM)
were connected to the outer streams (always with a HAuCl4 :
citrate ratio of 1 : 4) and (IV) lipids in ethanol (5 mM) were
connected to the central inlet. The speed was set to 4 mL s"1 for
syringe I, 2 mL s"1 for syringe II/III and 1 mL s"1 for syringe IV.
The sample was collected at the outlet. Finally, the liposomes
were heated to 70 !C for 10 min to start the formation of AuNPs.
To separate lipid-AuNHybs from free AuNPs, the sample was
puried by FPLC using a Superose 6 prep column eluting with
0.01 M PBS pH 7.4.
2.7 Size analysis using dynamic light scattering
Dynamic light scattering (DLS) measurements of AuNPs and all
lipid- and polymer-AuNHybs were conducted using a Delsa
Nano C Particle Analyzer (Beckman Coulter, Nyon, Switzerland).
The laser was adjusted to 658 nm and scattered light was
detected at a 165! angle. Data was converted using CONTIN
particle size distribution analysis. The AuNHyb size was
analyzed three times in PBS at RT.
2.8 UV-Vis and uorescence measurements
Ultraviolet-visible (UV-Vis) absorption from 260 nm to 750 nm
(step size one nm) of diﬀerent samples was measured using a
SpectraMax M2 (Molecular Devices, Sunnyvale, USA). Fluores-
cence of lipid-AuNHybs containing rhodamine labelled phos-
pholipids (Rho-PE) [Avanti Polar-Lipids, Alabaster, USA] was
analyzed by excitation at 560 nm and detection between 572 nm
to 750 nm.
2.9 Transmission electron microscopy of gold nanohybrids
Size and shape of the AuNPs and AuNHybs were analyzed by
transmission electron microscopy (TEM) using a CM-100 (Phi-
lips, Eindhoven, Netherlands) operating at 80 kV. Samples were
prepared by deposition onto a 400-mesh carbon-coated copper
grid (Polysciences Inc., Eppelheim, Germany). Prior to sample
deposition, the grid was exposed to plasma for 10 seconds to
increase sample binding. Grids were washed with double-
distilled water to prevent precipitation of uranyl salts by phos-
phate ions. Then the samples were negatively stained using a
2% uranylacetate solution (Sigma-Aldrich, Buchs, Switzerland),
the excess of uranylacetate was removed using lter paper, and
the samples were dried at RT overnight. Nanocarrier integrity
was preserved by this procedure as conrmed by Cryo-EM
analysis using sample vitrication (see below). To characterize
the size of AuNPs inside of AuNHybs, the diameter of at least
100 AuNPs was determined.
2.10 Cryo-TEM of gold nanohybrids
Aliquots (4 mL) of AuNHybs were adsorbed onto holey-carbon
supported grids (Quantifoil, Glossloebichau, Germany),
blotted with Whatman 1 lter papers, and vitried in liquid
nitrogen-cooled liquid ethane using a Vitrobot IV (FEI
Company, Eindhoven, Netherland). Cryo-electron imaging was
performed with a Philips CM200-FEG electron microscope
operated at an acceleration voltage of 200 kV. Micrographs were
recorded with a 4k # 4k TemCam-F416 CMOS camera (TVIPS,
Gauting, Germany).
2.11 Preparation of uorescent lipid based AuNHybs
Detailed experimental procedures are given in the ESI.†
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2.12 Passive uptake of AuNPs and AuNHybs in HepG2 cells
HepG2 cells were seeded on a 10 cm plate and cultured in 10mL
Dulbecco's modied Eagle's culture medium high glucose
supplemented with 10% fetal calf serum (FCS), 100 units mL!1
penicillin, and 100 mg mL!1 of streptomycin (DMEM comp). All
cell culture media components were purchased from Sigma-
Aldrich (Buchs, Switzerland). Cells were allowed to adhere for
24 h before the AuNPs or AuNHybs were added. Aer incubation
at 37 "C for 18 h, the tissue culture plate was washed three times
with DMEM comp (37 "C). Aerwards, the cells were xed with
DMEM containing 3% formaldehyde (Sigma-Aldrich, Buchs,
Switzerland) and 0.3% glutaraldehyde (Sigma-Aldrich, Buchs,
Switzerland) for two hours at RT and stored overnight at 4 "C.
The following day, cells were scraped, pelleted, and washed
three times with water, and then incubated with 2% uranyla-
cetate for two hours at 4 "C in the dark. The sample was washed,
dehydrated by series of methanol, and inltrated with LR-gold
resin (London Resin, London, UK) according to the manufac-
turer's instructions. Polymerization was performed at!10 "C by
UV light for one day. Sections of about 70 nm were collected on
carbon-coated Formvar-Ni-grids (EMS, Hateld, USA) and
stained for 15 min with 4% uranylacetate followed by two
minutes in Reynolds lead citrate solution. Sections were viewed
using a Phillips CM-100 electron microscope.
3. Results and discussion
3.1 Film rehydration (conventional liposomes)
For the preparation of AuNP loaded liposomes, the most direct
approach is the rehydration of a lipid lm with presynthesized
AuNPs. The well-characterized method developed by Turkevich
and Frens is ideal to synthesize AuNPs with diameters of
approximately 20 nm (see ESI† for experimental details).7,34,35
However, the AuNP encapsulation approach has several issues.
The AuNPs oen form aggregates up to several hundred nano-
meters (Fig. 2A), which results in low encapsulation eﬃciency
(Fig. 2D) and renders extrusion impossible due to blocked lter
membranes. Therefore, we developed an alternative strategy
and combined the lm-rehydration method with a ‘nanoreactor
approach’. We rehydrated the lipid lm with the Turkevich
reaction mixture consisting of tetrachloroaurate and citrate.
Then the formation of AuNPs was initiated inside the core of
preassembled liposomes by a shi in temperature [70 "C,
10 min] (Fig. 1A).
To prevent the formation of AuNPs during the preparation of
liposomes, we selected lipids that are characterized by a low
transition temperature (Tm). The lipid composition consisted of
POPC and POPG, which provides a Tm of !2 "C. The lipid lm
was rehydrated with a tetrachloroaurate and citrate reaction
solution in diﬀerent ratios and the liposomes were extruded at
RT before initiation of AuNP formation. The nal AuNHyb
sample exhibited the characteristic ruby-red color resulting
from the surface plasmon resonance of encapsulated AuNPs.36
To test if the temperature aﬀected the eﬃciency of the process,
the entire procedure was also carried out at 4 "C. However, there
was no diﬀerence between AuNHybs prepared at RT or at lower
temperatures. TEM showed that the AuNPs were encapsulated
inside the AuNHybs (Fig. 2B). Encapsulation eﬃciency (i.e. the
ratio between liposomes encapsulating AuNPs and liposomes
that were empty) was signicantly higher using the nanoreactor
approach compared with either extrusion at high temperature
(data not shown) or use of preformed AuNPs (Fig. 2D). The latter
condition lead to the formation of AuNP aggregates in the
medium surrounding the liposomes (Fig. 2D). In contrast, the
nanoreactor approach resulted in the encapsulation of a single
AuNP in the inner liposomal core.
POPC/POPG–AuNHybs were also analyzed by Cryo-TEM
(Fig. 2C). Under these conditions, the native, hydrated state of
the lipid formulation is presented.37 Cryo-TEM showed that
lipid-AuNHybs were spherical, mainly unilamellar, and eﬃ-
ciently loaded with AuNPs (Fig. 2C). AuNPs were located in the
hydrophilic core of the liposomes (Fig. 2C), consistent with TEM
analysis (Fig. 2B). Interestingly, some AuNPs were located in
close proximity to the lipid bilayer. This could be either an
artefact from the drying process during the TEM grid prepara-
tion or an interaction of the AuNPs with one of the phospho-
lipids. The number of AuNPs encapsulated was dependent on
the concentration of the AuR-solution. The highest AuNP
encapsulation eﬃciency was achieved with 4 mM tetra-
chloroaurate, 16.3 mM citrate, and 20 mM lipids. Higher AuR-
solution to lipid ratios resulted in the formation of AuNP
agglomerates outside of the liposomes. On the other hand,
lower AuR-solution to lipid ratios led to a signicant amount of
empty nanocarriers. Interestingly, TEM analysis revealed that
the AuNPs, which were synthesized inside liposomes were
signicantly smaller than AuNPs synthesized without lipids
(approximately 12.0 nm vs. 21.5 nm) (Fig. 2A vs. Fig. 2B). It is
tempting to speculate that the limited amount of tetra-
chloroaurate and citrate available inside the nanocarriers is
limiting the maximum size of the AuNPs. The POPC/POPG–
AuNHybs were analyzed by DLS. The size of POPC/POPG–AuN-
Hybs (104.7 nm # 5.2 nm) was similar to the size of empty
liposomes (Fig. 3A). Thus, AuNPs did not inuence the nano-
carrier diameter. In Fig. 4A, the absorption spectra of empty
POPC/POPG liposomes (negative control), AuNPs (positive
control), and POPC/POPG–AuNHybs are compared. As expected
no absorption maximum was observed for empty POPC/POPG
liposomes in the wavelength range from 500 nm to 600 nm.
In contrast, AuNPs and POPC/POPG–AuNHybs showed a
distinct surface plasmon absorbance peak at 525 nm. This
indicates the successful encapsulation of AuNPs inside POPC/
POPG liposomes.
3.2 Nanoprecipitation (di-block copolymer nanoparticles)
To demonstrate the broad applicability of our nanoreactor
approach, we investigated the formation of polymer-AuNHybs
using nanoprecipitation (Fig. 1B). For this method, the AuR-
solution was added dropwise to the di-block copolymer
PEG–PCL dissolved in THF (see ESI† for experimental details).
Similar to the lipid-AuNHybs, the addition of preformed
AuNPs to the polymer resulted in low encapsulation eﬃciency
(Fig. S1A†). In contrast, high encapsulation eﬃciency with one
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AuNP per polymeric nanocarrier was achieved using the nano-
reactor approach (Fig. 2E). Cryo-TEM analysis conrmed that
AuNPs with a size of 14.1 nm ! 3.1 nm were located inside the
polymer-AuNHybs (Fig. S1B†).
Polymer-AuNHybs consisting of PEG–PCL presented a
spherical morphology in which polymer chains self-assemble as
solid polymeric nanoparticles. Thus, the hydrophilic parts of
the di-block copolymer are exposed towards the outer buﬀer
environment (Fig. S1B†). Recently, this was also shown for other
polymeric nanoparticles.38 DLS analysis showed a mono-
disperse formulation of polymer-AuNHybs (polydispersity index
¼ 0.088) with a diameter of 77.5 nm ! 3.9 nm (Fig. 3B). Addi-
tionally, the polymer-AuNHybs showed a characteristic surface
plasmon band at 527 nm due to the unique optical properties of
AuNPs (Fig. 4B).
3.3 Microuidics (PEGylated liposomes)
Recently, it has been demonstrated that rapid microuidic
mixing oﬀers a controlled method to produce lipid nano-
carriers.39 Dened interfacial forces between the nanomaterial
components result in a controllable and highly reproducible
self-assembly process.40 To facilitate the production of AuNP
loaded PEGylated liposomes, we developed a microuidics
platform for the preparation of lipid-AuNHybs using lipids with
a transition temperature above RT. Briey, PEGylated lipid
based gold nanohybrids (PEG–Lipo–AuNHybs) were synthesized
by rapid mixing of an ethanolic lipid solution (5 mM, consisting
of DSPC, cholesterol, and DSPE-PEG2000) and the aqueous
Turkevich AuR-solution. In the last step of the process, the
PEGylated liposomes were heated to 70 #C to start the formation
of the AuNPs inside the liposomes.
In more detail, our microuidics device consisted of seven
inlet channels which converged into a single staggered-
herringbone micromixer (see ESI†). At the junction of the inlets,
the center stream was hydrodynamically focused to improve the
mixing. To illustrate the nanomanufacturing process, we simu-
lated the ow patterns and visualized themwith a uorescent dye
(Fig. 1D/E; ESI Fig. S2†). Liposomes are formed at the interface
between the hydrodynamically focused lipid stream and the AuR-
solution. The mechanism of controlled, focused, and rapid mix-
ing41 is visible both in the experimental setting (Fig. 1D) and the
computer simulation (Fig. 1E). The central inlet was used for the
model ethanolic lipid solution [5 mM] (Fig. S2B†). The other six,
outer inlets were used for tetrachloroaurate (Fig. S2C†), citrate
(Fig. S2D†), and water (two inlets for each solution). Syringe
pumps were usedwithow rates up to 4 mL s$1. The reagents were
supplied by separate inlets because the use of tetrachloroaurate
and citrate in the same inlet resulted in premature AuNP
formation in the herringbone micromixer (Fig. S3D†).40 In addi-
tion, the use of preformed AuNPs resulted in a low encapsulation
eﬃciency, as observed for the lm-rehydration and nano-
precipitation method with preformed AuNPs (Fig. S3E†). There-
fore, the best results were achieved using amicrouidics platform
with seven diﬀerent inlets (Fig. 1C–E).
Water (4 mL s$1) was used to improve the hydrodynamic ow
focusing of the lipid stream and to decrease the nal ethanol
concentration. Furthermore, we used a higher ow rate for the
outer inlets to increase the water to ethanol ratio. This is
important to prevent the destabilization of liposomes caused by
elevated ethanol concentrations.42 Microuidics parameters
were adjusted to optimize encapsulation eﬃciency and
size distribution. A continuous and eﬃcient production was
achieved with 2 mM tetrachloroaurate/8.2 mM citrate solution
Fig. 2 Characterization of gold nanoparticles (AuNPs) and gold nanohybrids (AuNHybs). Representative transmission electronmicroscopy (TEM)
(A/B, D–F) and Cryo-TEM (C) images are shown. (A) AuNPs were synthesized using a modiﬁed Turkevich method. (B) POPC/POPG–AuNHybs
were analyzed by TEM and (C) Cryo-TEM. (D) The ﬁlm-rehydration method for a lipid formulation with preformed AuNPs resulted in agglom-
erates. (E) PEG–PCL–AuNHybs prepared by nanoprecipitation and (F) PEG–liposome–AuNHybs after microﬂuidics platform preparation contain
a single AuNP. Scale bars indicate 100 nm.
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(for 5 mM lipids); and ow rates of 2 mL s!1 for the AuR-solutions,
and 1 mL s!1 for the lipid solution. The absolute production speed
was 420 mL min!1 (Fig. S2A†). Increasing the concentration of
the AuR-solution for the microuidics manufacturing resulted
in an increased number of encapsulated AuNPs per AuNHyb
(Fig. S3A–C†) until agglomerates were observed. AuNHybs with
several encapsulated AuNPs mostly resulted in Janus-like vesicle
structures (i.e. asymmetrical loading) as recently shown for
Janus magnetic liposomes.43 DLS and TEM showed that the size
of PEG–Lipo–AuNHybs was similar to that of empty PEGylated
liposomes (Fig. 2F and 3C). PEG–Lipo–AuNHybs with a mean
hydrodynamic diameter of 123 nm " 2.5 nm (Z-average) and a
monodisperse size distribution were obtained (Fig. 3C). Each
liposome incorporated one AuNP with a diameter of 6.8 nm " 1.5
nm as shown by TEM (Fig. 2F). A characteristic plasmon absorp-
tion at 525 nm was observed using UV-Vis spectroscopy (Fig. 4C).
3.4 Characterization of nanoreactor approach
We showed that our nanoreactor approach is applicable for a
wide range of nanomaterials, as well as diﬀerent preparation
methods. The lm rehydration method can be used for lipids
Fig. 3 Dynamic light scattering analysis of gold nanohybrids (AuNHybs). Intensity distribution of (A) POPC/POPG–AuNHyb, (B) PEG–PCL–
AuNHyb, and (C) PEGylated liposome–AuNHyb. Mean values of size and polydispersity index (PDI) are given " SD (n ¼ 5).
Fig. 4 UV spectra of empty nanocarriers, gold nanoparticles (AuNPs), and gold nanohybrids (AuNHybs). Relative UV-Vis absorption from 260 nm
to 750 nm (step size one nm) was measured for (A) POPC/POPG, (B) PEG–PCL, and (C) PEG–lipid based nanocarriers. Spectra were normalized
to an OD260 of 1.0. All AuNHybs showed a characteristic surface plasmon band at approximately 525 nm.
This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015, 5, 74320–74328 | 74325
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with a transition temperature below RT, whereas the nano-
precipitation method is suitable for several polymer nano-
materials.28,44 The microuidics method is especially designed
for lipids with a transition temperature above RT. However, this
technique is suitable for all nanomaterials, that need highly
controlled nanomanufacturing.40
The most important step of our nanoreactor approach is the
speed of the nanocarrier production. The nanocarrier formation
needs to be faster than AuNP aggregate formation. Therefore, the
AuNP formation inside the nanocarriers is initiated by a
temperature shi aer self-assembly. AuNP aggregates formed
outside of the self-assembled nanocarrier are removed by size
exclusion chromatography. During this step, the outer buﬀer can
be exchanged to a physiological compatible medium such as PBS.
Several publications have shown that a diﬀerence in tonicity
between the nanocarrier lumen and the outer buﬀer environment
is not aﬀecting the stability or morphology of nanocarriers.45–47
All tested combinations resulted in eﬃcient and reproduc-
ible formation of AuNHybs. Moreover, DLS, TEM, and Cryo-
TEM analysis showed that the nal AuNHybs preserved the
initial dimensions of the empty nanocarriers. Four distinct
observations indicate that the AuNPs were encapsulated inside
the nanocarriers. Firstly, the AuNHybs passed easily through
the size exclusion chromatography medium (Superose 6 prep)
whereas non-encapsulated AuNPs showed a high aﬃnity for the
chromatography medium, which was recently also shown for
quantum dots.48 Secondly, the AuNHybs exhibited an improved
stability in PBS and aggregation was prevented as compared to
free AuNPs. Thirdly, electron microscopy analysis showed a
single AuNP entrapped per nanocarrier and no clusters of
AuNPs were observed. Finally, the deep-red AuNHyb solutions
exhibited a specic surface plasmon absorption peak at 525 nm,
and a low 650 nm/530 nm ratio, which is characteristic for non-
agglomerated AuNPs.49
3.5 Cellular uptake experiments
To demonstrate the use of AuNHybs for bioimaging, we per-
formed uptake experiments with the AuNHybs in HepG2 cells
exploiting the unique optical properties of AuNPs. The electron-
density of AuNPs was used for further TEM analysis of cells
(Fig. 5) as shown recently for surface-modied AuNPs.50 Due to
the high quality and uniform size of AuNPs, TEM observations
were possible without silver enhancement. Using this approach,
fundamental insights about nanocarrier uptake and intracel-
lular fate can be obtained. For example, proteins covering the
surface of nanocarriers aer administration to biological
medium can inuence cellular uptake. However, formation of a
protein corona and opsonisation can be minimized using
PEGylated nanocarriers (i.e. PEG–PCL nanoparticles or PEGy-
lated liposomes).51,52 It remains to be elucidated to which degree
protein adsorption onto non-modied nanocarriers such as
conventional liposomes has to be taken into account for
biomedical applications.53,54
The interaction of free AuNPs with HepG2 cells is shown in
Fig. 5A and D. Free AuNPs formed aggregates which were located
on the cellular plasma membrane (Fig. 5A) or taken up into the
cell (Fig. 5D). These observations are in agreement with pub-
lished results.50,55 Fig. 5 shows the interaction with cells of lipid
(panel B/E) or polymer based AuNHybs (panel C/F). In contrast to
the uptake of free AuNPs, no AuNP aggregates were detected
using AuNHybs. Diﬀerent internalization steps were observed. An
early stage in the cellular uptake mechanism was indicated by
parts of the cellular plasma membrane around endosomes
located near the cellular membrane (Fig. 5B). Compartments
lled with more than one AuNP are most likely caused during
maturation of diﬀerent AuNHyb-lled vesicles (Fig. 5E/F).
AuNHybs could thus be used to examine nanoparticle–cell-
interactions and the intracellular fate of the nanocarriers
Fig. 5 Uptake experiments of gold nanoparticles (AuNPs) and gold nanohybrids (AuNHybs) in HepG2 cells. (A) AuNPs localized at the cell surface
or (D) inside the cell. Representative uptake images of (B/E) POPC/POPG–AuNHybs and (C/F) PEG–PCL–AuNHybs (arrows). ER¼ endoplasmatic
reticulum; LYS ¼ lysosome; M ¼ mitochondria; MVB ¼ multi vesicular body; PM ¼ plasma membrane. Scale bars indicate 200 nm.
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inside the cells using TEM, a technique which oﬀers greater
resolution compared to confocal microscopy. It should be noted
that liposomes encapsulating AuNPs can act simultaneously as
a carrier for uorescent dyes (see ESI† for experimental details).
For example rhodamine labelled phospholipids (Rho-PE) can be
used to uorescence label AuNHybs (Fig. S4b†). This oﬀers the
possibility to image uorescent AuNHybs by confocal uores-
cence microscopy or to quantify them with ow cytometry
analysis.
4. Conclusions
In conclusion, we have developed a novel strategy for the
preparation of lipid and polymer based AuNHybs. Aer encap-
sulation of the required reagents inside nanocarriers, formation
of AuNPs was triggered by a temperature shi. In future, a
similar approach could be used for the preparation of alterna-
tive metal nanohybrids such as silver nanoparticles. Diﬀerent
preparation techniques were used in combination with various
nanomaterials. To the best of our knowledge, this nanoreactor
approach is unique and was not used previously. The high
reproducibility and versatility of our nanoreactor approach is
unprecedented and makes this technology suitable for many
nanomaterials. Microuidics oﬀers the possibility for an eﬃ-
cient and large scale production.
The produced AuNHybs have a size of 70 nm to 130 nm,
which makes them ideal for bioimaging applications.56 In
addition, AuNHybs can be stored over a prolonged period of
time (i.e. >3 months/4 !C) maintaining their initial size and
monodispersity.
In order to target specic cells or tissues, AuNHybs can be
easily modied using surface-conjugated receptor ligands.57
Our nanoreactor approach will be instrumental to develop a
better understanding of cellular uptake and intracellular traf-
cking of targeted nanocarriers.
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1. Supplementary Information Experimental Section
1.1 Gold nanoparticle (AuNP) synthesis
The AuNP synthesis was optimized using a 23 full factorial design of experiment (DoE) [Stavex 5.2, Aicos Technologies, Basel, 
Switzerland]. Variables are listed in Table S1. All glass equipment was cleaned with aqua regia to prevent the formation of gold 
seeds. The best condition (smallest AuNPs and mild reaction condition) from our screening was used for further AuNHyb 
preparations (1.0 mM HAuCl4 / 4.1 mM citrate; 1:4 molar ratio). 
Table S1: AuNP synthesis screening using Turkevich method. Variations of 
citrate or tetrachloroaurate concentration, pH, and temperature. 
Sampl
e
c (HAuCl4) 
[mM] c (Citrate) [mM]
c (NaOH) 
[mM] T [°C] Size [nm]
Factorial Design
(Mild Conditions)     
A 0.5 2.0 - 70 20.2
B 1.0 2.0 - 70 24.3
C 0.5 4.1 - 70 43.1
D 1.0 4.1 - 70 16.6
E 0.5 2.0 - 85 20.8
F 1.0 2.0 - 85 19.8
G 0.5 4.1 - 85 17.0
H 1.0 4.1 - 85 17.8
Other Approaches 1–4
I 0.5 2.0 -
boilin
g 18.7
K 1.0 4.1 -
boilin
g 19.3
L 2.5 5.1 5.0 70 26.6
M 2.5 5.1 6.6 85 19.6
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Phone: +41 (0)61 267 15 13
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1.2 Microfluidics device design and fabrication
For the master fabrication, SU8 (Microchem, Newton, USA) spin coated silicon wafers (Si-Mat, Kaufering, Germany) were used. 
To produce a master with a staggered herringbone micromixer, multi-layer photolithography was carried out using appropriate 
photomasks (JD Pho-tools, Oldham, UK) and a MJB4 mask aligner (SUSS MicroTec AG, Garching, Germany). 
The first layer was made of SU8-3025 and the second one of SU8-3050 negative photoresists. PDMS and cross-linker (Sylgard 
184, Dow Corning GmbH, Wiesbaden, Germany) were mixed in the mass ratio of 10:1, degassed, and poured on the masters 
followed by overnight curing. Cured PDMS stamp was peeled off from the wafer.
To prepare a 3D channel device, two sides (bottom side and top side) of polystyrene foil/NOA 81 were prepared as follows. A 
drop of NOA 81 was pipetted onto the structure of the PDMS stamp. Then a piece of polystyrene foil was placed on the NOA 81 
and pressed down until the polystyrene foil touches elevated channel on the PDMS stamp that the channels were only laterally 
defined by NOA 81. NOA 81 was cured under UV-light for 3 min (366 nm, 2 x 8 W, Camag, Muttenz, Switzerland). The second side 
of the device was prepared the same way. Additionally, 0.75 mm holes were punched for tubing connection (Harris Unicore). 
Both polystyrene foil/NOA 81 sides were aligned, gently pressed, and cured under UV-light for 10 min. 
 
1.3 Flow visualization
Deionized water, ethanol, and a fluorescein solution were used to visualize the flow patterns of the microfluidics device (Figure 
1D). Images were taken using an Olympus IX81 inverted microscope (Olympus, Tokyo, Japan) equipped with fluorescence 
illumination (X-Cite Series 120 Q). 
1.4 Computational Fluid Dynamics Simulation
For the numerical computational fluid dynamics (CFD) simulations we used the CFD module of the software COMSOL 4.3a 
(COMSOL Inc, Burlington, USA). The microfluidics device was modeled in 3D using 792,779 finite elements solving the 
incompressible Navier-Stokes-equation and advection-diffusion equation. The stationary flow field was calculated and in a 
second step the material transport of the diluted species were calculated using the beforehand-obtained stationary flow fields. 
We assumed a Newtonian fluid having the properties of water at room temperature.5 Flow rates and inflow concentrations were 
specified at the seven inlets and the following diffusion coefficients were assumed: Dlipids = 5.10-11 m2 s-1, Dcitrate = 8.9.10-10 m2 s-1 
and DAuCL4 = 5.6.10-10 m2 s-1.
1.5 Preparation of fluorescent lipid based gold nanohybrids (AuNHybs)
To broaden the application spectrum of AuNHybs for bioimaging purposes, we introduced an additional fluorescence marker, 
namely Rho-PE (Avanti Polar-Lipids, Alabaster, USA), into lipid based nanocarriers. Rho-PE was post inserted into preformed 
75mol% POPC, 25mol% POPG liposomes as described elsewhere.6 The modified liposomes possessed specific absorption 
properties based on the encapsulated AuNPs and an additional fluorescence based on the post-insertion of Rho-PE. The non-
Rho-PE liposomes showed neither an absorption peak between 260 nm and 750 nm, nor a fluorescence after excitation at 
560 nm. In contrast, the Rho-PE containing liposomes possessed a strong fluorescence with a maximum at 596 nm after they 
were excited near their absorption maximum at 560 nm. Compared with lipid-AuNHybs, the Rho-PE containing AuNHybs showed 
an additional absorption peak and were fluorescent after they were excited at 560 nm. 
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2. Supplementary Information Figures
Figure S1. Electron microscopy analysis of PEG-PCL-gold nanohybrids (AuNHybs). Representative transmission electron 
microscopy (TEM) and Cryo-TEM images of solid polymeric nanoparticles are shown. (A) Preparation of PEG-PCL-AuNHybs using 
preformed AuNPs results in low encapsulation efficiency. (B) Cryo-TEM analysis of PEG-PCL-AuNHybs prepared via nanoreactor 
approach. Scale bars indicate 50 nm.
Figure S2. Computational fluid dynamics (CFD) simulations. (A) CFD simulation of the flow rate (m/s) of all seven inlet channels 
converging to a single micromixer is shown. Simulation of concentration gradients of (B) ethanol (in a.u.), (C) tetrachloroaurate 
(in mol/L), and (D) citrate (in mol/L) solution are presented.
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Figure S3. Preparation of gold nanohybrids (AuNHybs) using microfluidics. Representative transmission electron microscopy 
(TEM) images are shown. Increasing concentration of the reaction solutions (1x = 1 mM HAuCl4 / 4.1 mM citrate) for the 
nanoreactor approach resulted in an increased number of AuNPs per nanocarrier. (A) 2x, (B) 4x, and (C) 8x reaction solutions 
were used. (D) Preparation of AuNHybs with one combined reaction solution in the same inlet resulted in AuNP formation during 
microfluidics procedure. (E) Direct use of AuNPs resulted in agglomerates and low encapsulation efficiency. Scale bars indicate 
100 nm.
Figure S4. UV-Vis and fluorescence spectra of gold nanohybrids (AuNHybs) with and without fluorescent lipid (Rho-PE). (A) UV-
Vis absorption from 260 nm to 750 nm (step size one nm) was measured. Spectra were normalized to an OD260 of 1.0. 
Fluorescently labelled AuNHybs showed two absorbance maxima, i.e. characteristic surface plasmon band and absorbance 
maximum of Rho-PE. (B) Fluorescence spectra of AuNHybs between 572 nm to 750 nm after excitation at 560 nm. POPC/POPG-
RhoPE-AuNHybs showed strong fluorescence (RFU = relative fluorescence units), whereas POPC/POPG-AuNHybs were not 
fluorescent.
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Highlights: Active drug targeting strategies hold promising potential to specifically deliver drugs to 
their target cells. In this work, a drug delivery platform based on PEG-PCL micelles was evaluated to 
target human blood-brain barrier (BBB) endothelial cells. A monoclonal antibody directed towards the 
human insulin receptor (83-14 mAb) was therefore conjugated to PEG-PCL micelles. Functionalized 
micelles were characterized physico-chemically using state-of-the-art methods and their interaction 
with an in vitro model of the BBB was studied. The gold nanohybrid strategy described in Chapter III 
was further used to analyze the intracellular fate of targeted PEG-PCL micelles.  
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Nanoparticles are increasingly used to implement drug targeting strategies. In the present study, solid-sphere nanoparticles
(SNPs) made of poly(ethylene glycol)-b-poly(휀-caprolactone) (PEG-b-PCL) were covalently linked to a monoclonal antibody (83-
14mAb) targeted against the human insulin receptor that is highly expressed on human brain microvascular endothelial cells.
Resulting targeted SNPs were characterized using transmission electron microscopy (TEM), cryo-TEM, dynamic light scattering,
and )uorescence correlation spectroscopy.'e critical aggregation concentration was determined using a )uorescence approach.
Interaction with a well-characterized human in vitro model of the blood-brain barrier (hCMEC/D3) was analysed using an array
of methods ()ow cytometry, confocal laser scanning microscopy, and TEM). 'e toxicity on hCMEC/D3 cells and in addition
on the human liver cell line HepG2 was assessed using the MTT assay. SNPs with a diameter of 80 nm and a homogeneous size
distribution were obtained. Successful conjugation of 83-14mAb using a heterobifunctional linker resulted in 5-6 molecules of
)uorescently labeled 83-14mAb per SNP. Functionalized SNPs were taken up by hCMEC/D3 cells e+ciently without showing a
signi,cant toxic e-ect on cells of the blood-brain barrier and HepG2 cells. 'ese results indicate that functionalized PEG-b-PCL
SNPs are a promising candidate to deliver drugs to the CNS.
1. Introduction
Despite the presence of potent active pharmaceutical ingre-
dients (API), e+cient treatment of central nervous system-
(CNS-) related diseases remains a major challenge in phar-
macotherapy. 'e blood-brain barrier (BBB) that maintains
the homeostasis of the brain excludes many small and large
molecule drugs from the CNS [1, 2]. To reach therapeutic
concentrations of systemic administered drugs in the CNS,
high doses are o.en required.'is is linked with an increased
risk for toxic side e-ects. 'erefore, di-erent strategies for
e-ective drug transfer across the BBB are currently under
investigation [3]. Besides chemical optimization of the API
and invasive delivery techniques, targeting of transporters
and receptors expressed on BBB endothelial cells is a
promising way to speci,cally deliver drugs to the CNS [3].
Endogenous macromolecules can cross the BBB by receptor-
mediated transport and thus reach the brain despite their size
as shown for insulin [4, 5] and transferrin [6]. Antibodies can
mimic these endogenous ligands and transport bound drugs,
macromolecules, or nanoparticles across the BBB in vivo.
For example, the enzymeN-sulfoglucosamine sulfohydrolase
(SGSH) was conjugated to a monoclonal antibody (mAb)
directed against the human insulin receptor (HIR). Recom-
binant SGSH was not able to cross the BBB. However, it was
possible to reach therapeutic concentrations in the brain a.er
injection of the mAb fusion protein in Rhesus monkeys [7].
While antibody drug conjugates (ADCs) provide speci,c tar-
geting to a distinctive tissue or cell type, their drug carrying
capacity is very limited. Nanocarriers can exceed the drug
payload of ADCs by three to four orders of magnitude [8].
Within these nanocarriers, self-assembledmicelles consisting
of biodegradable diblock copolymers are extensively studied
as drug delivery systems (DDS) [9]. 'eir hydrophobic core
serves as a reservoir for poorly soluble drugs, sterically
stabilized by a hydrophilic corona [10]. Polymeric micelles
Hindawi Publishing Corporation
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can prevent premature drug degradation, reduce o"-target
e"ects, and increase bioavailability. In addition, these systems
can be directed towards speci#c organs, tissues, or cells
by coupling targeting moieties onto their surface [11]. In
recent years, various approaches were investigated to com-
bine NPs with BBB targeting mAbs. %e neuropeptide NK-
1900, for example, improved scopolamine-induced learning
impairments and memory de#cits in rats by i.v. adminis-
tration of NK-1900-loaded polymersomes conjugated to an
antitransferrin receptor mAb (OX-26) [12]. Previous stud-
ies by our group showed that polymersomes consisting of
poly(dimethylsiloxane)-b-poly(2-methyloxazoline) (PDMS-
b-PMOXA) modi#ed with 83-14mAb were taken up speci#-
cally by human brain capillary endothelial cells in vitro [13].
With 퐾퐷 of 0.45 ± 0.10 nM, 83-14mAb has a strong a,nity
to the 훼-subunit of the insulin receptor expressed on human
brain capillary endothelial cells (hBMEC). Its binding to the
HIR was shown to trigger receptor-mediated endocytosis in
vivo and 83-14mAb was shown to cross the primate BBB 10x
more e,ciently as compared to an antitransferrin receptor
mAb [14, 15].
With respect to polymer-based NPs, however, the ques-
tion arises if these particles can be safely degraded a.er deliv-
ering their drug payload, since accumulation and persistence
within the target tissue are of potential safety concern. For
example, PDMS-b-PMOXA vesicles used in our previous
studies are characterized by a high chemical and mechanical
stability [16]. Polyacrylamide-based nanocarriers used previ-
ously to implement drug targeting strategies could give rise to
potential toxicity due to degradation products [17]. Polylactic
acid-based NPs have been shown to be readily degradable
but lactic acid, a major degradation product, can lead to
acidi#cation of the metabolizing cell and organ [18–20].
To address these potential issues, this study aimed to
design and use PEG-b-PCL SNPs ([PP-SNP]) as a safe
alternative to existing technologies. %is polymer is already
approved by regulatory authorities such as the US Food
and Drug Administration (FDA) for tissue engineering and
drug delivery. PEG-b-PCL is known to be biocompatible and
biodegradable and was therefore used to implement an active
targeting strategy to the brain [21]. 83-14mAb was covalently
conjugated to the surface of [PP-SNP] by a PEG-spaced
heterobifunctional linker. Resulting [PP-SNP]-[mAb] was
then analysed using an array of analyticalmethods (i.e., TEM,
cryo-TEM, dynamic light scattering [DLS], pyrene encap-
sulation, and 0uorescence correlation spectroscopy [FCS]).
Interactions with eukaryotic cells and potential toxic e"ects
were studied in a well-characterized in vitro BBB model
(hCMEC/D3) and the human hepatocellular carcinoma cell
line HepG2 [13, 22].
2. Materials and Methods
2.1. Materials. PEG-b-PCL (PCL average푀푛 ≈ 13 000, PEG
average푀푛 ≈ 5000, stored at 4∘C under argon atmosphere,
batch number. MKBR7365V), pyrene (≥99%), anhydrous
tetrahydrofuran (THF; ≥99.9%), anhydrous dimethyl sulfox-
ide (DMSO;≥99.9%), 2-iminothiolane hydrochloride (Traut’s
reagent; ≥98%), 1,1耠-dioctadecyl-3,3,3耠,3耠-tetramethylindo-
carbocyanine perchlorate (DiI; ≥98%) gold(III) chloride
trihydrate, sodium citrate dihydrate (≥99%), and anti-
mouse IgG (whole molecule) gold antibody (5 nm colloidal
gold) were purchased from Sigma-Aldrich (Schnelldorf,
Germany). NH2-PEG-b-PCL (PCL average 푀푛 ≈ 15 500,
PEG average푀푛 ≈ 5000, batch number. P18343-NH2EGCL)
was purchased from Polymer Source (Montreal, Canada).
SM(PEG)24 and DyLight 488 NHS ester were purchased
from %ermo Fisher Scienti#c (Waltham, MA, USA).
%iazolyl Blue (MTT reagent; ≥98%) was purchased from
Carl Roth GmbH (Karlsruhe, Germany). Amicon Ultra-4
centrifugal #lter units (10 kDaNMWL, 30 kDaNMWL) were
purchased from Merck Millipore (Darmstadt, Germany).
%e hybridoma cell line producing 83-14mAb was kindly
provided by Professor Ken Siddle (Department of Clinical
Biochemistry, University of Cambridge, UK). Cell culture
reagents and chemicals are listed below.
2.2. Preparation of [PP-SNP]. [PP-SNP] composed of a mix-
ture of amphiphilic diblock copolymers (95%mol/mol PEG-
b-PCL and 5%mol/mol NH2-PEG-b-PCL) was prepared
using the cosolvent method, also called the solvent displace-
mentmethod [23]. In brief, the block copolymer (5.3mg) was
dissolved in THF (50휇L) and stirred at 700 rpm. Phosphate-
bu"ered saline (PBS; 157mM Na, 140mM Cl) EDTA 5mM,
pH 7.4 (1mL) was added dropwise under constant stirring.
%e mixture was stirred at room temperature (RT) overnight.
THF was removed by two consecutive steps: THF was
allowed to evaporate during overnight stirring [24]. Bu"er
was subsequently exchanged by gel #ltration chromatography
using Superose 6 Prep column eluting with PBS, pH 7.4
[25]. DiI-loaded [PP-SNP] ([PP-SNP-DiI]) was produced by
adding 1 휇g DiI per mg of PEG-b-PCL to THF and particles
were produced using the same protocol as described above.
2.3. Fluorescent Labeling of 83-14mAb. 83-14mAb (1mg/mL
in PBS, pH 8.0) was incubated with a 5x molar excess of NHS
ester functionalized DyLight 488 for 1 h at RT ([mAb-DL]).
%e sample was puri#ed using an AmiconUltra-4 centrifugal
#lter unit (MWCO 10 kDa).
2.4. Conjugation of 83-14mAb to SNPs. A heterobifunctional
linker (SM(PEG)24) was used to conjugate 83-14mAb or 83-
14mAbDL to [PP-SNP] giving rise to [PP-SNP]-[mAb], [PP-
SNP-DiI]-[mAb], [PP-SNP-Au]-[mAb], or [PP-SNP]-[mAb-
DL], respectively. SNPswere prepared as described above and
incubated with a 20x molar excess of linker for 1 h at RT in
PBS EDTA 5mM, pH 7.0. Unbound linkerwas removed using
an Amicon Ultra-4 centrifugal #lter unit (MWCO 30 kDa).
In parallel, a 2x molar excess of 0uorescently labeled 83-
14mAb in sodium borate 0.1M pH 8.5 was thiolated using
Traut’s reagent, that is, 100x molar excess of 2-iminothiolane.
A.er incubation for 1 h at RT, thiolated 83-14mAb was
puri#ed by using an Amicon Ultra-4 centrifugal #lter unit
(MWCO 10 kDa). SNPs and thiolated 83-14mAb DL were
mixed and incubated at RT overnight. Unbound 83-14mAb
was separated by gel #ltration chromatography (Superose 6
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Prep, PBS pH 7.4). For all experiments, modi$ed SNPs were
used immediately a%er preparation.
2.5. Gold-Nanohybrid SNP Formation. To visualize [PP-SNP]
in TEM, gold-nanohybrids [PP-SNP-Au] were prepared as
described recently [26]. In brief, 5.3mg of PEG-b-PCL was
dissolved in THF (50휇L) and stirred at 700 rpm. *e AuR-
solution (1mMHAuCl4, 4.1mM citrate) was added dropwise
under constant stirring. *e mixture was heated to 70∘C
under constant agitation at 300 rpm on the thermomixer
(*ermomixer Comfort; Eppendorf, Hamburg, Germany).
Free gold NPs were separated by gel $ltration chromatogra-
phy (Superose 6Prep) using PBS pH 7.4 as an eluent. Free gold
particles did not elute during gel $ltration chromatography.
*ey had a high a,nity for the stationary phase and were
retained in the chromatography column [26]. [PP-SNP-Au]
and [PP-SNP-Au]-[mAb] were collected a%er 8–12min using
a column volume of 30mL and a .ow rate of 1mL/min.
2.6. Characterization of [PP-SNP]. Morphology and size
distribution of [PP-SNP] were analysed using TEM, cryo-
TEM, andDLS. For TEM analysis, 5 휇L of nonconjugated and
conjugated SNPs was mounted on a carbon-coated copper
grid, negatively stained with 2% uranyl acetate solution, and
dried overnight. Samples were visualized using a Philips
Morgagni 268D transmission microscope. Mean SNP size
was determined based on 푛 = 50 particles. For cryo-
TEM analysis, 4휇L of the polymer suspension was adsorbed
onto glow-discharged holey carbon-coated grid (Quantifoil,
Großlo¨bichau, Germany), blotted withWhatman $lter paper,
and vitri$ed into liquid ethane at−178∘Cusing a vitrobot (FEI
Company, Eindhoven,Netherlands). Frozen gridswere trans-
ferred onto a Philips CM200-FEG electron microscope using
a Gatan 626 cryoholder. Electronmicrographs were recorded
at an accelerating voltage of 200 kV and a nominalmagni$ca-
tion of 50 000x, using a low-dose system (10 e−/A˚2) and keep-
ing the sample at −175∘C. Defocus values were −4 휇m.Micro-
graphs were recorded at 4K × 4K CMOS camera (TVIPS,
Gauting, Germany). DLS measurements were performed
using a Delsa Nano C Particle Sizer (Beckman Coulter, Brea,
CA, USA) operated in back scattering mode (165∘ angle).
2.7. Critical Aggregation Concentration (CAC). To assess the
stability of [PP-SNP] upon dilution, the CAC of PEG-b-PCL
was determined. Pyrene was used as a .uorescent probe as
described previously [27, 28]. Pyrene in acetone (0.5mL, 2.4× 10−6M) was mixed with 2mL of Milli-Q water and 0.05,
0.5, 5, 50, or 500휇g/mL of PEG-b-PCL. *e mixtures were
heated to 60∘C for 1 h and allowed to cool down to RT. A%er
degasing with N2, the .uorescence of pyrene was measured
(SpectramaxM2 plate reader, Molecular Devices, Sunnyvale,
CA, USA; excitation: 휆ex 332 nm; emission: 휆em1 373 nm,휆em2 384 nm).*e ratio of 휆em2/휆em1 was plotted against the
logarithm of the PEG-b-PCL concentration to determine the
CAC.
2.8. Density Measurements and Speci&c Volume Calculations.
Density of particle suspension was measured at 20∘C using
an Anton Paar Density Meter DMA 4500M (Anton Paar
GmbH, Graz, Austria). *e measured density (g/cm3) of a
suspension containing nanoparticles was used to calculate
the apparent speci$c volume (cm3/g) of the nanoparticles
(VPP-SNP) according to [29]
VPP-SNP = ( 1푐polymer)( 1휌suspension)− (1 − 푐polymer푐polymer )( 1휌blank) , (1)
where 휌suspension is the measured density of the suspension,휌blank is the measured density of the bu0er, and 푐polymer is the
weight fraction of the polymer.*e apparent volume (cm3) of
one polymer molecule in the assembled state was calculated
according to
Vpolymer ≈ 푀푤 × VPP-SNP푁퐴 , (2)
where 푀푤 is the molecular weight of the polymer and푁퐴 is
the Avogadro constant. *e aggregation number (푁agg) was
then calculated according to푁agg ≈ 푉PP-SNPVpolymer = (4/3) × 휋 × (퐷/2)3Vpolymer , (3)
where Vpolymer is the apparent volume of one polymer
molecule and 푉PP-SNP is the volume of one solid-sphere
nanoparticle ([PP-SNP]) and 퐷 is the nanoparticle diameter
as determined by DLS or TEMmeasurements.
2.9. Gold Labeling of 83-14mAb. To visualize conjugated 83-
14mAb, antibodies were stained using an anti-mouse IgG-
gold antibody. In brief, 0.25mg of [PP-SNP]-[mAb] was
incubatedwith 50휇Lof the anti-mouse IgG-gold antibody for
1 h at RT. Free anti-mouse IgG-gold antibodies were separated
by gel $ltration chromatography (Superose 6 prep) eluting
with PBS pH 7.4. Sampleswere negatively stained as described
above and were analysed by TEM. To exclude unspeci$c
binding of the anti-mouse IgG-gold antibody, [PP-SNP] was
stained using the same protocol.
2.10. Fluorescence Correlation Spectroscopy (FCS). Fluores-
cence correlation spectroscopy (FCS) was used to determine
the number of.uorescently labeled 83-14mAbper [PP-SNP]-
[mAb-DL]. Measurements were performed with an inverted
confocal .uorescence laser scanning microscope (Zeiss LSM
510-META/ConfoCor 2; Carl Zeiss AG, Oberkochen, Ger-
many) equippedwith an argon laser (488 nm) and a 40xwater
immersion objective lens (Zeiss C-Apochromat 40x, NA 1.2).
15 휇L of sample was measured on a cover glass (Huber &
Co AG, Reinach, Switzerland) at RT. Fluorescence intensity
.uctuations were analysed in terms of an autocorrelation
function. Autocorrelation curves were obtained by taking the
average of 10 measurements over 30 s. Di0usion times for
free DyLight 488 and DyLight 88-labeled antibodies were
independently measured and $xed in the $tting procedure
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in order to reduce the number of free "tting parameters.
Molecular brightness measurements were used to calculate
the number of #uorescently labeled antibodies per [PP-SNP]-
[mAb-DL].
2.11. Cell Culture. Immortalized human brain capillary
endothelial cells, hCMEC/D3 cells, were obtained under
license from the Institut National de la Sante´ et de la
Recherche Me´dicale, Paris, France. hCMEC/D3 cells were
grown in culture #asks coated with 0.1mg/mL rat tail
collagen type I (BD Bioscience, San Jose, CA, USA)
and cultured in endothelial cell basal medium (Provitro
GmbH, Berlin, Germany) supplemented with 5% fetal bovine
serum (FBS; Amimed BioConcept, Allschwil, Switzerland),
1 ng/mL basic "broblast growth factor (PeproTech, Hamburg,
Germany), 5휇g/mL ascorbic acid, 1.4 휇M hydrocortisone
(Sigma-Aldrich, Schnelldorf, Germany), 10 휇L/mL chemi-
cally de"ned lipid concentrate (Gibco Life Technologies,
Carlsbad, CA, US), 10mM HEPES (Sigma-Aldrich, Schnell-
dorf, Germany), 2mMGlutaMAX (Gibco Life Technologies,
Carlsbad, CA, US), 100U/mL penicillin, and 100mg/mL
streptomycin (Sigma-Aldrich, Schnelldorf, Germany). Only
passages 29 to 35 were used for experiments. Human liver
HepG2 cells were kindly provided by Professor Doctor
Dietrich von Schweinitz (University Hospital of Basel, Basel,
Switzerland). HepG2 cells were cultured in Dulbecco’s mod-
i"ed eagle medium (DMEM; Sigma-Aldrich, Schnelldorf,
Germany; glucose 4500 g/L) supplemented with 10% FBS,
100U/mL penicillin, and 100mg/mL streptomycin.
2.12. MTT Assay. Cell viability was determined using the
MTT assay as described previously [22]. Toxicity of [PP-
SNP] and [PP-SNP]-[mAb] was tested on the target cell
line (hCMEC/D3). In addition, the well-characterized and
frequently used human hepatocellular carcinoma cell line
HepG2 was used to con"rm cell viability results in another
cell line and to rule out cell line speci"c e*ects. In brief, cells
were seeded at a density of 2 × 104/well in a 96-well plate
(TPP, Trasadingen, Switzerland) coated with collagen type
I (10 휇g/cm2) or poly-D lysine (0.04mg/mL), respectively.
[PP-SNP] and [PP-SNP]-[mAb] were diluted with complete
or serum-free culture medium to a "nal concentration of
0.01–1mg/mL. PBS concentration was kept constant for all
[PP-SNP] concentrations. Cells were washed twice with Dul-
becco’s phosphate-bu*ered saline (DPBS) and incubatedwith
particle dilutions for 24 h in triplicate. Terfenadine (20휇M)
was taken as positive controls. Cells were washed three times
with DPBS and MTT working solution (100 휇L, ,iazolyl
Blue 5mg/mL) was added. A-er 1.5–3 h, MTT working solu-
tion was aspirated and resulting formazan crystals were dis-
solved with DMSO (100 휇L) protected from light for 15min
on an orbital shaker at RT. Absorption of dissolved formazan
was measured at 570 nm and unspeci"c signals measured
at 670 nm were subtracted (Spectramax M2 plate reader,
Molecular Devices, Sunnyvale, CA, USA). Cell viability was
expressed as percentage, whereas cell viability of untreated
cells was de"ned as 100%. MTT assays were performed in
triplicate and repeated three times. To determine statistical
signi"cance, one-way analysis of variance (ANOVA) fol-
lowed by Tukey’s post hoc test using OriginPro (Version
9.1.0, OriginLab Corporation, Northampton, MA, USA) was
performed.
2.13. Flow Cytometry. To analyse uptake of [PP-SNP]-[mAb-
DL] and [PP-SNP-DiI]-[mAb], #ow cytometry was used.
hCMEC/D3 cells were seeded at a density of 5 × 104
cells/cm2 in a 12-well plate (TPP, Trasadingen, Switzerland).
SNP formulations were diluted with culture medium to a
"nal concentration of 0.1mg/mL. Cells (80% con#uency)
were washed with DPBS and incubated with SNPs for
0.25, 0.5, 1, and 2 h. For competitive inhibition, cells were
preincubated with a 100x excess of 83-14mAb for 30min at
37∘C and washed twice with DPBS before incubating with
SNPs.Washed cells were detachedwith 0.25%Trypsin-EDTA
(Gibco Life Technologies, Carlsbad, CA, USA) for 3min
at 37∘C and Trypsin-reaction was stopped by adding 1mL
of ice-cold DMEM supplemented with 10% FBS. ,e cell
suspension of each well was collected, centrifuged at 200 g
for 5min (4∘C), and washed three times with ice-cold DPBS.
,e pellets were resuspended in 500 휇L of staining bu*er
(DPBS, 0.05% NaN3, 1% FBS, EDTA 2.5mM) and analysed
by #ow cytometry using a FACS Canto II #ow cytometer
(BD Bioscience, San Jose, CA, USA). Excitation wavelength
was 488 nm and 561 nm. Cell doublets were excluded from
analysis.,e green #uorescence of DyLight 488 was detected
using a 530/30 bandpass "lter; the red #uorescence of DiI
was detected using a 586/15 bandpass "lter. Signals from
10 000–20 000 cells were normalised to max and analysed
using FlowJo analysis so-ware version V9/X (Tree-Star,
Ashland, OR, USA). One-way analysis of variance (ANOVA)
followed by Tukey’s post hoc test using OriginPro (Version
9.1.0, OriginLab Corporation, Northampton, MA, USA) was
performed to determine statistical signi"cance.
2.14. Confocal Laser Scanning Microscopy (CLSM). Glass
coverslips were placed in a 12-well plate and were coated
with collagen (10 휇g/cm2). hCMEC/D3 cells were seeded at a
density of 2.5× 104 cells/cm2 and allowed to adhere overnight.
Level of con#uency was 70–80%. Cells were washed with
DPBS twice and incubated with [PP-SNP]-[mAb-DL], [PP-
SNP-DiI], or [PP-SNP-DiI]-[mAb] (0.1mg/mL) for 30 and
60min at 37∘C. Cell nuclei were stained by adding Hoechst
33342 dye (Eugene, OR, USA; 0.2 휇g/mL) for 10min. Cells
were washed three times with ice-cold DPBS and "xed
with freshly prepared paraformaldehyde (4%) for 15min at
4∘C. Paraformaldehyde was removed by washing three times
with ice-cold DPBS; then cells were mounted with Prolong-
Gold (,ermo Fisher Scienti"c, Waltham, MA, USA). Cells
were analysed using an Olympus FV 1000 inverted laser
scanning microscope and 40x (NA 1.30) and 60x (NA 1.40)
oil immersion objectives (Olympus, Tokyo, Japan).
2.15. Transmission Electron Microscopy (TEM). Transwell
polycarbonate membrane inserts (Corning, Baar, Switzer-
land; 0.4휇m pore size, 12mm insert diameter) were coated
with collagen type I (10 휇g/cm2) for 1 h at 37∘C. Filters
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Figure 1: Transmission electron microscope (TEM) images of PEG-b-PCL nanoparticles ([PP-SNP]). (a) TEM images [PP-SNP]. Size bar:
200 nm. (b) TEM image of gold-nanohybrid [PP-SNP] ([PP-SNP-Au]). Size bar: 200 nm. (c) Cryo-TEM images of [PP-SNP]. Size bar: 100 nm.
were washed twice with DPBS and hCMECM/D3 cells were
seeded at a density of 5 × 104 cells/cm2. Cells were grown to
con+uency for 8 days; medium was exchanged at days 4 and
7. At day 8, hCMEC/D3 cells were incubated with colloidal
gold-loaded [PP-SNP-Au]-[mAb] at a /nal concentration of
0.1mg/mL on the apical side for 0.25, 0.5, 1, 2, and 4 h.
Cells were incubated with /xing medium (3% formaldehyde,
0.3% glutaraldehyde) at 4∘C overnight. Cells were carefully
rinsed three times with Hepes bu0er (0.5M, pH 7.0) and
dehydrated usingmethanol. hCMEC/D3 cells were in/ltrated
with LR-Gold (PolyScience,Warrington, PA, USA) according
to the manufacturer’s instructions. 1e /lter membrane was
removed from the transwell insert using a scalpel. Membrane
cuts were placed on a polymerized drop of resin in a
plastic +at embedding mold and covered with a fresh resin.
Polymerization was induced by UV-light at −10∘C for 24 h.
Sections of 70 nm were cut and collected on a carbon-coated
Ni-grids and stained with uranyl acetate (2%) for 15min and
with lead citrate (Reynold’s solution) for 2min. Sections were
analysed using a Philips CM 100 TEM.
3. Results
3.1. Characterization. TEMmicrographs of [PP-SNP] showed
spherical particles with a homogenous size distribution (Fig-
ure 1(a)). Mean diameter of 푛 = 50 particles determined by
TEM was 67 ± 15 nm. Size and size distribution of [PP-SNP]
Table 1: Comparison of nonconjugated PEG-b-PCL SNPs ([PP-
SNP]) and targeted [PP-SNP]-[mAb]. [PP-SNP] and [PP-SNP]-
[mAb] were analysed and the hydrodynamic diameter, polydis-
persity index (PDI), zeta potential, morphology, and the number
of antibodies per NP (mAb/NP ratio) were compared (푛 = 3
experiments; values are means ± S.E.M).
[PP-SNP] [PP-SNP]-[mAb]
Hydrodynamic diameter (nm) 78.2 ± 1.7 79.9 ± 2.4
PDI 0.069 ± 0.021 0.079 ± 0.021
Zeta potential (mV) −4.13 ± 0.24 2.43 ± 0.16
Morphology Spherical Spherical
mAb/NP ratio — 5
were con/rmed by DLS. A mean hydrodynamic diameter of78.2 ± 1.7 nm and a narrow size distribution (0.069 ± 0.021)
were determined (Table 1).1e zeta potential was−4.13±0.24
(Table 1). In bu0er (PBS, pH 7.4, room temperature), [PP-
SNP] was stable for at least 2months as shown by a constant
particle size and a PDI below 0.2. To characterize the core
structure of the NPs, cryo-TEM was performed. In cryo-
TEM, awell-de/nedmembrane can be observed for polymer-
somes, while no such structure is visible inmicelles and solid-
sphere NPs [30]. Nomembrane was observed inmicrographs
of [PP-SNP] as shown in Figure 1(c), indicating the solid-
sphere structure of [PP-SNP].1erefore, these particles were
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Figure 2: Determination of the mAb/NP ratio by transmission electron microsopy and (uorescence correlation spectroscopy. ((a) and (b))
Visualization of 83-14mAb using a 5 nm colloidal gold-labeled anti-mouse IgG monoclonal antibody (white arrows). (a) PEG-b-PCL solid-
sphere nanoparticles [PP-SNP] covalently conjugated to 83-14mAb ([PP-SNP]-[mAb]). (b) Nonmodi.ed [PP-SNP] a/er control incubation
with gold-labeled anti-mouse IgGmAb (secondary mAb only). Size bar: 100 nm; insert: 2x magni.cation of a single NP and a noninteracting
gold-labeled secondary antibody before puri.cation. (c) FCS analysis of PEG-b-PCL SNPs conjugated to DyLight 488-labeled 83-14mAb
([PP-SNP]-[mAb-DL]). Dotted line: free DyLight 488; dot-dashed line: DyLight 488-labeled 83-14mAb; dashed line: [PP-SNP]-[mAb-DL];
solid lines: normalized autocorrelation curves. (d) Schematic drawing of [PP-SNP]-[mAb] incubated with colloidal gold-labeled anti-mouse
IgG mAb.
classi.ed as solid-sphere nanoparticles (SNPs).1e CAC was
determined using a hydrophobic (uorescent probe [27, 28].
By this technique, changes in (uorescence characteristics of
(uorescent dyes, induced by their environment, are analysed.
1us, lipophilic dyes will be redistributed to the hydrophobic
PCL-core of [PP-SNP] at concentrations above the CAC.1e
CAC of PEG-b-PCL determined by pyrene encapsulation
during this study was 5 휇g/mL (2.8 × 10−7M). In this study,
in vitro cell uptake experiments were always performed at
0.1mg/mL, a concentration that is about 20 times higher than
the determined CAC.1e speci.c volume VPP-SNP of the [PP-
SNP] suspension was determined to be 0.87 ± 0.01 cm3/g.
3.2. Functionalization. To covalently conjugate 83-14mAb
to [PP-SNP], a PEG-spaced heterobifunctional linker was
used. 1e linker was reactive towards primary amines
(i.e., NH2-PEG-b-PCL as a constituent of [PP-SNP]) and
sul3ydryl groups (i.e., thiolated 83-14mAb). FCS was used
to quantify the number of (uorescently labeled antibodies
per [PP-SNP]-[mAb-DL]. Figure 2(c) shows the normalized
autocorrelation curves of free DyLight 488 dye, DyLight 488-
labeled 83-14mAb ([mAb-DL]), and [PP-SNP] conjugated
to DyLight-labeled mAbs ([PP-SNP]-[mAb-DL]). Di4usion
times for [mAb-DL] and [PP-SNP]-[mAb-DL] were 282 휇s
and 2594 휇s. 1e increase in the di4usion times observed
indicated the immobilization of [mAb-DL] on [PP-SNP]-
[mAb-DL].1emAb/NP ratio was determined by comparing
the mean molecular brightness (CPM) of [PP-SNP]-[mAb-
DL] (CPM = 85 kHz) to [mAb-DL] (CPM = 17 kHz). 1e
CPM of [PP-SNP]-[mAb-DL] was 5x higher than the CPM
of [mAb-DL]. 1erefore, on average, 5 antibodies were con-
jugated to one [PP-SNP]-[mAb-DL]. Covalently attached 83-
14mAb to the surface of SNPs was furthermore visualised by
TEM. Schematic drawing is shown in Figure 2(d). [PP-SNP]-
[mAb] was incubated with a gold-labeled secondary mAb
directed towards murine IgGs to visualize 83-14mAb (Fig-
ure 2(a)). Gold particles were located in close proximity to
the [PP-SNP]-[mAb] surface con.rming 83-14mAbpresence
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and accessibility. When nonfunctionalized [PP-SNP] was
stained according to the same protocol, gold particles were
not immobilized on SNP surface before (Figure 2(b) insert)
and a#er puri$cation using gel $ltration chromatography
(Figure 2(b)). %is result indicates speci$c binding of the
secondary mAb.
3.3. Toxicity. SNPs composed of the FDA-approved, biode-
gradable PEG-b-PCL show high biocompatibility [21, 31].
%is is particularly important with respect to brain delivery of
SNPs since accumulation of polymeric material could lead to
toxic side e(ects within the CNS. To con$rm these $ndings,
hCMEC/D3 cells and a human hepatocellular carcinoma
cell line (HepG2) were incubated with [PP-SNP] and [PP-
SNP]-[mAb] (0.01–1mg/mL) to analyse cell viability using
the MTT assay. Even high polymer concentrations of up to
1mg/mL caused only a slight decrease in cell viability. Uptake
experiments were performed with 0.1mg/mL PEG-b-PCL.
%is concentration does not show any signi$cant cytotoxic
e(ects on HepG2 and hCMEC/D3 cells.
3.4. Uptake. To study cellular uptake, hCMEC/D3 cells were
incubated with [PP-SNP-DiI]-[mAb] or [PP-SNP-DiI] for
30 and 60min and analysed using +ow cytometry. Mean
+uorescence intensity (MFI) increased in a time dependent
manner (Figure 4). A representative +ow cytometry graph is
shown in Figure 5(b). For cells incubated with nonmodi$ed
[PP-SNP-DiI], increase in MFI of 7.7 ± 1.6 and 21.2 ±4.3 was observed a#er 30min and 1 h of incubation as
compared to blank control cells. When cells were incubated
with [PP-SNP-DiI]-[mAb], a signi$cant increase in MFI
was observed. A 2x increase in MFI was observed a#er
30min (MFI = 16.3 ± 1.6) and 1 h (MFI = 38.9 ± 6.7)
as compared to cells incubated with their nonmodi$ed
counterparts (Figure 4). [PP-SNP-DiI]-[mAb]-uptake could
be inhibited competitively by preincubating the cells with
an excess of free, unlabeled 83-14mAb (MFI = 26.3 ± 4.8)
as shown in Figures 4 and 5(b). To con$rm these $ndings,
the experiments were repeated using an alternative labeling
method for the NPs. 83-14mAb covalently labeled with
DyLight 488 was conjugated to [PP-SNP] ([PP-SNP]-[mAb-
DL]). Again, MFI decreased and was close to untreated
control cells when cellular uptakewas competitively inhibited
(Figure 5(a)). In addition, SNP uptake by hCMEC/D3 cells
was analysed using CLSM (Figure 5(c)). hCMEC/D3 cells
were incubatedwith 0.1mg/mL of [PP-SNP-DiI] or [PP-SNP-
DiI]-[mAb] for 30min. Distinct +uorescence signals (red
dots)were observed close to the cell nuclei in theDiI-channel.
Competitive inhibition reduced the [PP-SNP-DiI]-[mAb]
signal. To study the intracellular localization of SNPs, gold-
nanohybrids functionalized with 83-14mAb ([PP-SNP-Au]-
[mAb]) were prepared. Using such gold-nanohybrids, intra-
cellular tra/cking could be visualised by electronmicroscopy
as a result of the high electron density of the Au-core whereas
morphology, size, and PDI of [PP-SNP-Au] are similar to [PP-
NP] (Figures 1(b) and 6(d)). Encapsulated gold NPs have a
diameter of 14.1 ± 3.1 nm as shown previously [26]. Intra-
cellular vesicles with [PP-SNP-Au]-[mAb] were observed
a#er 15min (Figures 6(a)–6(c)). A#er 60min of incubation,
[PP-SNP-Au]-[mAb] was detected in multivesicular bodies
(MVBs; Figure 7).
4. Discussion
In this study, PEG-b-PCL diblock copolymer was used
to produce a nanosized drug delivery system. SNPs were
prepared using the cosolvent method at a $nal concentration
of 5.3mg/mL polymer. Particles assembled immediately a#er
stirring at 700 rpm and adding PBS dropwise. %is method
is easy to handle, fast, and highly reproducible and uses no
expensive or complex equipment. A fast preparation protocol
is of huge advantage for di(erent applications, for example,
for scale-up or when radiolabeled NPs are prepared for phar-
macokinetics studies. To target the NPs towards a speci$c
tissue or cell type, ligands have to be attached to the NP
surface. Di(erent strategies can be used for such modi$ca-
tions. Since di(erent classes of targetingmoieties (e.g., mAbs,
peptides, or small molecules) may require di(erent conju-
gation strategies, a universal coupling tool is advantageous.
%erefore, 5%mol/mol of amine-terminated PEG-b-PCL
(NH2-PEG-b-PCL) was used to covalently couple targeting
moieties to [PP-SNP] by using the heterobifunctional linker
SM(PEG)푛. SM(PEG)푛 contains an amine-reactive NHS ester
functionality and maleimide that reacts to a metabolically
stable thioether in the presence of sul0ydryl groups. A
PEG-spacer of variable length links the two reactive groups.
While a very low degree of functionalization was observed
using SM(PEG)2 with a spacer length of 17.6 A˚, conjuga-
tion with 24 PEG-subunit long SM(PEG)24 (spacer length:
95.2 A˚) resulted in an increased mAb/NP ratio per [PP-
SNP]-[mAb] using the same reaction conditions. Further-
more, PEG-spacers also can prevent the covalently attached
mAb from being covered by particle-adsorbed biomolecules
[32]. FCS was used to determine the mAb/NP ratio. On
average, 5 molecules of +uorescently labeled 83-14mAb
were conjugated to the surface of one [PP-SNP]-[mAb-DL]
(Figure 2(c)). FCS was used similarly in previous studies
to determine the amount of +uorescently labeled molecules
on SNPs [13, 33]. Radiolabeling, as typically used for the
quanti$cation of antibodies per NP, can be avoided by using
FCS [34].%e number of targetingmoieties on theNP surface
in+uences the interactionwith the target cell and can promote
cellular uptake but may lead to increased clearance from the
blood circulation [35]. In addition, a de$ned and narrow size
distribution and the surface charge are important determi-
nants for the fate of nanoparticles upon systemic exposure.
NPs with a size below 6 nm can easily be excreted by renal
$ltration, while NPs with >300 nm in diameter or with a high
surface charge will be recognized and removed by the retic-
uloendothelial system [36, 37]. Noncharged, pegylated NPs
with a diameter below 200 nm show reduced protein opson-
isation and remain in the systemic circulation for hours [38].
In cryo-TEM micrographs, no membrane was observed
for [PP-SNP] indicating a solid-sphere structure of [PP-
SNP] (Figure 1(c)). In comparison to low-molecular weight
surfactants, SNPs show a low CAC, which is important for
stability and drug retention. A high CAC can lead to amicelle
collapse and subsequent burst release of the incorporated
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Figure 3: Cell viability of hCMEC/D3 and HepG2. hCMEC/D3 and HepG2 cells were incubated with 0.01–1.0mg/mL PEG-b-PCL solid-
sphere nanoparticles ([PP-SNP]) and 83-14mAb modi,ed [PP-SNP] ([PP-SNP]-[mAb]). Cell viability was analysed using the MTT assay
24 h a-er incubation. Cell viability is expressed as % viable cells compared to untreated control cells. Terfenadine (Terf) was used as positive
control. White bars: [PP-SNP]-[mAb]; grey bars: [PP-SNP]. ANOVA and Tukey’s post hoc means comparison was used to test for statistical
signi,cance (푛 = 3 experiments; ∗∗푝 < 0.05; ∗푝 < 0.1; S.E.M. is shown with error bars).
drug upon dilution in the blood compartment [10, 39].
Whereas typical low-molecular weight surfactants have CAC
values in the range of 10−3–10−4M,CACs of diblock polymers
can typically be found in range 10−6–10−7M.Additionally, the
kinetic stability of the core structure of SNPs is high and thus
the disassembly of SNPs a-er dilution below the CAC occurs
slowly allowing an e/cient retention of their drug payload
[40].0e CAC of [PP-SNP] was determined using a 1uores-
cent probe-based approach as described previously [28].0e
CAC of PEG-b-PCL is 5 휇g/mL (2.8 × 10−7M), comparable
to previously published data characterizing similar polymers
[27].
0e apparent speci,c volume VPP-SNP of the [PP-SNP]
suspension was calculated from the measured density as
described by Sommer et al. [29]. VPP-SNP was 0.87±0.01 cm3/g,
which is close to the speci,c volume determined for micelles
formed by the PEG-derived nonionic surfactant “Brij” [29].
Using this result, one can calculate the apparent volume of a
single PEG-b-PCL polymer molecule (Vpolymer) according to
(2). In our experiment, Vpolymer was 51 nm3. 0e aggregation
number (푁agg) of [PP-SNP] can then be estimated according
to (3). A similar approach using apparent volumes to calculate
aggregation numbers was proposed previously to determine푁agg of NPs consisting of a cell-penetrating peptide [41].
Since this calculation depends on the diameter of the particle,푁agg covers a range of ∼2200 to ∼10 000 for [PP-SNP] with
diameters of 60 to 100 nm, respectively. 0ese numbers are
higher than results obtained by, for example, static light
scattering (SLS) or 1uorescent techniques where typical푁agg
for diblock copolymer micelles are lower than 1000 [42, 43].
Among the broad range of polymer-based DDS, NPs
composed of the FDA-approved, biodegradable PEG-b-PCL
show high biocompatibility [21, 31, 44]. 0is is an important
advantage regarding organ delivery of NPs since accumula-
tion of polymeric material might lead to toxic side e5ects, for
example, in the CNS. Because toxic e5ects of polymeric NPs
on cells are driven not only by the polymericmaterial but also
by many other characteristics including particle size, charge,
or impurities, each NP formulation needs to be tested [45].
Toxicity of [PP-SNP] and [PP-SNP]-[mAb] on hCMEC/D3
cells was tested using the MTT assay. [PP-SNP] induced
only a slight decrease in cell viability on hCMEC/D3 cells
if incubated in concentrations up to 0.2mg/mL (Figure 3).
Cells incubated with [PP-SNP]-[mAb] showed as well a high
cell viability. Even at high concentrations of 1mg/mL, more
than 60% of the incubated cells were viable. For cellular
uptake experiments performed in this work, a concentration
of 0.1mg/mL was used. At this concentration the decrease
in cell viability was negligible. 0e MTT assay was repeated
with a second cell line to con,rm the biocompatibility of
the nanoparticles and to rule out cell line speci,c e5ects.
0e human hepatocellular carcinoma derived cell lineHepG2
was used. Again, only a slight decrease in cell viability was
observed (Figure 3). We conclude from these experiments
that PEG-b-PCL SNPs are well tolerated within a typical dose
range used in nanomedicine [22].
[PP-SNP-DiI]-[mAb] was taken up by hCMEC/D3 cells.
0ese cells express similar HIR protein levels as freshly
isolated hBMECs (1 fmol HIR/휇g protein) and were therefore
successfully used as an in vitro targeting model in previ-
ous studies [13, 46–48]. A time dependent increase in the
1uorescence signal was observed (Figure 4). Conjugation
with 83-14mAb leads to an increase in MFI. Furthermore,
uptake was speci,c and mediated by the 83-14mAb since
competition for the target receptor (HIR) with free mAb
leads to a decrease of intracellular 1uorescence (Figures 4
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Figure 4: Uptake of PEG-b-PCL nanoparticles ([PP-SNP]) by hCMEC/D3 cells. Uptake ofDiI-loaded PEG-b-PCL solid-sphere nanoparticles
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Figure 5: Cellular uptake of PEG-b-PCL nanoparticles ([PP-SNP]) analysed by -ow cytometry and confocal laser scanning microscopy
(CLSM). (a) Flow cytometry analysis of uptake of [PP-SNP] conjugated to DyLight 488-labeled 83-14mAb ([PP-SNP]-[mAb-DL]) by
hCMEC/D3 cells. Dark grey shaded: untreated cells; light grey shaded: cells incubated with [PP-SNP]-[mAb-DL] for 1 h; dashed line: cells
incubated with [PP-SNP]-[mAb-DL] in the presence of a 100x excess of unlabeled 83-14mAb. (b) Flow cytometry analysis of cellular uptake
(hCMEC/D3) of DiI-loaded [PP-SNP] ([PP-SNP-DiI]) and 83-14mAbmodi+ed [PP-SNP-DiI] ([PP-SNP-DiI]-[mAb]) a/er 1 h of incubation.
Solid line: [PP-SNP-DiI]; dashed line: cells incubated with [PP-SNP-DiI]-[mAb] in the presence of a 100x excess of unlabeled 83-14mAb;
light grey shaded: [PP-SNP-DiI]-[mAb]. (c) Cellular uptake of [PP-SNP-DiI] and [PP-SNP-DiI]-[mAb] analysed by confocal laser scanning
microscopy. Blue: nuclei stained with Hoechst 33342; red: [PP-SNP-DiI]-[mAb]. Size bar: 40휇m. Single-cell inserts: 2x magni+cation.
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Figure 6: Uptake of gold-nanohybrid PEG-b-PCL nanoparticles conjugated to 83-14mAb ([PP-SNP-Au]-[mAb]). ((a)–(c)) hCMEC/D3 cells
were incubatedwith [PP-SNP-Au]-[mAb] for 15min. Black arrows: gold particles; PM: plasmamembrane;M:mitochondria. Size bar: 500 nm.
(d) TEM image and schematic drawing of [PP-SNP-Au]-[mAb].
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Figure 7: Intracellular localization of gold-nanohybrid PEG-b-PCL SNPs conjugated to 83-14mAb ([PP-SNP-Au]-[mAb]). hCMEC/D3 cells
were incubated with [PP-SNP-Au]-[mAb] for 60min. (a) Cross section of a cell grown on a transwell insert. Size bar: 250 nm. Black arrows:
gold particles. (b) [PP-SNP-Au]-[mAb] localized within a multivesicular body (MVB). Black arrows: gold particles; AP: apical compartment;
PM: plasma membrane; TF: transwell /lter membrane; M: mitochondria; ER: endoplasmic reticulum; MVB: multivesicular body. Size bar:
500 nm.
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and 5). Immunoelectron transmission microscopy was used
to study the subcellular localization of [PP-SNP-Au]-[mAb].
SNPs were visualized by a preembedding staining technique.
To this end, a protocol to prepare gold-nanohybrids ([PP-
SNP-Au]) was developed by our group [26]. %is opens
attractive possibilities to monitor intracellular tra&cking of
SNPs. hCMEC/D3 cells were grown on transwell inserts for
8 days as it was reported that hCMEC/D3 cells grown under
these conditions show BBB characteristics and develop cell
polarity [49]. %is was furthermore demonstrated by their
use for quantitative drug transport studies and qualitative
analysis of albumin-gold-conjugates by TEM [50, 51]. [PP-
SNP-Au]-[mAb] targeting the HIR was found in intracellular
vesicles a,er 15min of incubation at 37∘C (Figure 6(c)).
Accumulation in multivesicular bodies (MVBs) was detected
a,er 60min of incubation (Figure 7). Cellular uptake of
gold-labeled insulin was studied previously using retinal
vascular endothelial cells. It was shown that insulin was
taken up fast and e&ciently and accumulated in MVBs a,er
30min of incubation [52]. However, cellular uptake of insulin
seems to be faster and more e&cient as compared to [PP-
SNP-Au]-[mAb]. Similarly, previous studies using OX-26-
immunoliposomes targeting the transferrin receptor showed
that size is a crucial factor with respect to cellular uptake
kinetics and e&ciency.%e permeability surface area product,
a factor describing the BBB permeability, of the free OX-
26mAbwas signi.cantly higher as compared to the immuno-
liposomes in vivo [53]. In the present study, single colloidal
gold particles were detected at all time-points, indicating
that gold particles were taken up while incorporated into
[PP-SNP-Au]-[mAb]. Free colloidal gold particles prepared
without PEG-b-PCL agglomerated very fast and were found
as clusters of particles when analysed by TEM [26]. To the
best of our knowledge, this is the .rst study using gold-loaded
targeted polymeric SNPs to visualize their uptake in a cell-
based model. Further experiments such as quantitative in
vitro transport studies and colocalization studies by /uores-
cent imaging, as performed previously, could help to identify
the uptake mechanism of 83-14modi.ed SNPs [13, 54–56].
5. Conclusion
SNPs of the biodegradable diblock copolymer PEG-b-PCL
were prepared and characterized in vitro. Our SNPs are char-
acterized by a hydrodynamic diameter of 79.6 nm, a homoge-
neous size distribution, a slightly negative zeta potential, and
a low CAC in the submicromolar range. In second step, [PP-
SNP]was conjugated to anti-HIRmAb to enhance the cellular
uptake by hCMEC/D3 cells. %is resulted in targeted [PP-
SNP]-[mAb] decorated with 5 molecules of mAb per SNP.
[PP-SNP]-[mAb] was taken up by human BBB endothelial
cells in vitro as shown by confocal microscopy and /ow
cytometry. Furthermore, the intracellular localization of
gold-nanohybrids [PP-SNP-Au]-[mAb] in hCMEC/D3 cells
grown on transwell inserts was analysed by TEM. Accumu-
lation in multivesicular bodies of target cells was observed
a,er 60min of incubation. A similar behaviourwas described
for gold-labeled insulin [52]. Our in vitro data suggest that
SNPs consisting of PEG-b-PCL are well tolerated. %ey are
promising candidates for the implementation of a targeted
drug delivery strategy. Further experiments will be needed to
explore their potential in experimental animals.
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Abstract 
Hepatocellular carcinoma (HCC) is still lacking of adequate therapeutic options 
resulting in poor prognosis. Thus, novel treatment strategies are urgently needed. 
Here, we report a novel therapeutic approach using a virus-derived anticancer gene 
(large-non structural protein 1, NS1) delivered using lipoplex nanoparticles (LNPs). 
We used a set of established HCC-derived cell lines to study cellular LNP 
internalization, subsequent gene expression, and to analyze oncotoxic effects 
mediated by our anticancer protein. We achieved high gene delivery efficiencies in 
vitro in liver cancer-derived cell lines and were able to induce multimodal cell death. 
Expression of NS1 resulted in superoxide induction, reduced intracellular ATP levels, 
promoted morphological alterations, and subsequently induced apoptosis and 
necrosis. Notably, we show that healthy primary human hepatocytes are not affected 
by NS1 gene delivery. Furthermore, we validated a prognostic marker for the 
sensitivity to NS1-mediated therapy and we were able to render non-susceptible cells 
sensitive by expression of a constitutive active isoform of phosphoinositide-
dependent kinase 1 (PDK1). Our therapeutic approach was well tolerated in vivo 
after multiple dosing indicated by a constant weight and a good overall health 
condition of treated mice. Our data suggest that NS1 can be efficiently delivered 
using LNPs and that this anticancer gene is a promising therapeutic option for HCC.  
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Introduction 
Recently, anticancer genes and their proteins that selectively induce cell death in 
cancer cells have gained much attention [1]. This class of drugs allows efficient killing 
of cancer cells whereas healthy tissue stays unaffected. Apoptin, for example, a 
14 kDa protein from the Chicken anemia virus (CAV), was tested on various human 
tumor cell lines and efficiently induced apoptosis [2,3]. In contrast, no or only minor 
effects were observed in healthy cells such as primary hepatocytes [4]. Another 
candidate is derived from the rat parvovirus (H-1PV). This virus showed promising 
results in the treatment of various tumors in a preclinical setting and was recently 
tested in a clinical Phase-I/IIa trial in patients suffering from glioma [5]. The major 
effector protein of H-1PV is NS1 consisting of 672 amino acids (i.e. 83 kDa) [6]. NS1 
is essential for viral replication [7] and interestingly, the expression of NS1 without 
other viral components is sufficient to kill cancer cells [8,9]. NS1 can induce 
multimodal cell death via apoptosis, necrosis, lysosomal-like programmed cell death, 
and cytolysis exclusively in neoplastically transformed (i.e. tumor) cells [6,10,11]. 
These oncotoxic effects result from physical interaction with cellular proteins rather 
than own enzymatic functions of NS1 [12,13]. For example, NS1 recruits components 
of cellular DNA replication and repair machineries for viral DNA transcription and 
replication [14–18] and can interact with other cellular proteins such as the catalytic 
subunit of casein kinase II (CKIIα) [12]. Pivotal for NS1 functions is the regulation of 
NS1 by cellular kinases: Activation of the PDK1/PKC/PKB signaling pathway was 
shown to be a prerequisite for H-1PV-mediated oncotoxicity and oncotropism (i.e. 
specificity) [19].  
For the first time, we report the use of plasmid DNA (pDNA)-loaded lipoplex 
nanoparticles (LNPs) encoding the sequence of the oncotoxic protein NS1 for the 
treatment of HCC (Fig. 1A). We observed selectively induced cell death in HCC cells 
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in vitro without toxic effects on healthy liver cells. Detailed analysis of cell death 
mechanisms revealed contribution of apoptotic and necrotic pathways. We were able 
to render non-permissive cells susceptible for NS1-mediated cell death by activating 
PDK1 and therefore propose PDK1 activity as prognostic marker for the sensitivity to 
NS1 in HCC therapy. In vivo, NS1-LNP constructs were well tolerated after single or 
multiple administrations.  
 
Results 
Development of LNPs for efficient pDNA delivery to human liver cancer cells 
To analyze expression of NS1, we generated plasmid DNA (pDNA) constructs coding 
for NS1 under control of the cytomegalovirus (CMV) promoter (Fig. 1A). This 
promoter can be used in a broad range of cell types with a very high activity and is 
therefore frequently used in mammalian expression plasmids [20]. To analyze the 
expression of NS1 in liver cancer-derived cell lines, we additionally generated an 
NS1-green fluorescence protein (GFP) fusion protein (NS1-GFP). NS1-GFP had the 
correct size (see below) and GFP did not alter the subcellular distribution (see below) 
or intrinsic toxicity of NS1 (data not shown). We therefore used NS1 or NS1-GFP (i.e. 
fluorescent marker) for further experiments. For gene delivery assays, pDNA was 
rapidly mixed with lipid nanoparticles to induce spontaneous LNP formation. We 
characterized LNPs by Nanoparticle Tracking Analysis (NTA), electrophoretic light 
scattering, and transmission electron microscopy (TEM). LNPs had an average size 
of 101.0 ± 2.6 nm (Fig. 1B) and were characterized by a positive zeta potential 
(11.6 ± 1.0 mV) that is typical for lipoplexes [21]. To obtain additional information 
about LNP morphology, we analyzed electron micrographs of LNPs and found 
spherical particles with an average diameter of 81.8 ± 27.0 nm (n = 100) and a 
monodisperse size distribution (Fig. 1C) corresponding to a polydispersity index 
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(PDI) of 0.109. Size, shape, and zeta potential did not change significantly for LNPs 
containing pDNA coding for GFP, NS1, NS1-GFP, or empty vector control (data not 
shown).  
In a first step, we analyzed the interaction of LNPs with a set of 9 established 
immortalized HCC cell lines. To assess the cellular uptake of LNPs, we fluorescently 
labeled pDNA using a carbocyanine dye and analyzed intracellular fluorescence after 
LNP incubation by confocal microscopy (CLSM). A time-dependent increase of 
intracellular fluorescence was observed in all cell lines already after 60 min (Fig. 1D 
and Supplementary Fig. 1A). In sharp contrast, we observed significantly lower 
fluorescence signals when cells were incubated with naked pDNA. In a next step, we 
analyzed NS1-GFP gene delivery efficiency qualitatively and quantitatively by CLSM 
and flow cytometry respectively. We used a final pDNA concentration of 0.1 ng per 
cell and used complete culture medium containing fetal calf serum (FCS). All cell 
lines tested showed a high NS1-GFP expression after 24 h of incubation with 
expression levels up to 85% NS1-positive cells (Fig. 1E/F). LNPs were therefore 
deemed as suitable non-viral vectors for NS1 gene delivery for further experiments. 
The NS1 expression level in NS1 positive cells was strongly depending on the cell 
line: A high variability in NS1-GFP expression (88-fold to 2994-fold increase in mean 
fluorescence intensity, MFI) was observed (Fig. 1F). Subsequently, expression of 
NS1 was analyzed by western blotting. We observed a typical NS1 signal (i.e. double 
band) at 80 kDa (Fig. 1G). Similar results were observed in cells infected with H-1PV 
previously [19]. We furthermore quantified expression levels of NS1 and normalized 
the results to the expression of β-actin. We again found pronounced differences in 
NS1 levels between different cell lines (Supplementary Fig. 1B). NS1-GFP showed 
an increase in the apparent molecular weight and was detected above 100 kDa 
confirming the presence of a GFP (27 kDa) fusion protein (Supplementary Fig. 1C). A 
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fluorescence signal that overlapped with NS1-GFP western blot bands was detected 
when acrylamide gels loaded with non-denaturized proteins were illuminated at 
488 nm (data not shown).  
Recently, it was reported that during viral infection, a distinct intracellular distribution 
pattern of NS1 can be observed with a preferential localization in the cell nucleus [22]. 
However, the contribution of other viral proteins to the redistribution of NS1 is not 
completely revealed yet. Therefore, we were interested, if this phenomenon can be 
observed without other viral components present. We analyzed NS1-GFP expression 
over time by CLSM and compared the distribution of the fluorescence signal to the 
expression of GFP. Indeed, we found nuclear accumulation of NS1-GFP already 
after 4 h of LNP uptake (Fig. 1H) whereas GFP was evenly distributed inside the cell 
(Fig. 1E). Since it was reported that GFP may have an inherent nuclear accumulation 
[23], we repeated the experiment using immunohistochemistry (IHC) in cells 
expressing NS1. Confirming our results using the NS1-GFP fusion protein, we found 
a nuclear accumulation of NS1 (Supplementary Fig. 1E). 
 
Effect of NS1 expression on human liver cancer-derived cell lines 
Recent work has revealed that parvovirus infection induces apoptosis, necrosis, and 
lysosomal-like programmed cell death in cancer cells [9,24,25]. As major effector for 
these oncotoxic effects NS1 was identified [6,8,9] (Fig. 1A). However, little is known 
about the therapeutic use of NS1 uncoupled from H-1PV infection.  
To address this question, we analyzed NS1-induced changes in cell viability in 9 
HCC cell lines 72 h after LNP uptake. We normalized results to cells incubated with 
LNPs containing empty plasmid vector (Fig. 2A) or pDNA coding for GFP. Not all of 
the 9 HCC cell lines tested were susceptible for NS1-mediated toxicity. Whereas in 
some cell lines a significant decrease in cell viability of more than 60% was observed 
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(e.g. Hep3B), others did not show a significant response (less than 10%) to NS1 (e.g. 
HepT1). Thus, we categorized the HCC cells into strong, medium, weak, and non-
responders (Fig. 2A). A huge advantage of parvovirus therapy is the oncotropism of 
this virus that renders the treatment selective for transformed cells whereas their 
healthy counterparts stay unaffected [10,11]. To show that our therapeutic approach 
using LNP-mediated NS1 gene delivery is still selective to tumor cells (i.e. 
oncotropism), we transfected freshly isolated primary human hepatocytes (PHH) and 
HepaRG cells. It should be noted that HepaRG cells share features with PHH and 
are used as an alternative to ex vivo cultured hepatocytes [26]. Importantly, PHH and 
HepaRG cells were not affected by the expression of NS1 and did not show a 
decrease in cell viability as compared to vector-treated control cells (Fig. 2A). For all 
further experiments, we selected a weak (HepG2), a medium (HuH7), and a strong 
responding cell line (Hep3B). First, we analyzed NS1 expression over time and 
analyzed effects on cell morphology. GFP and NS1-GFP fluorescence was detected 
already starting 4 h post LNP uptake. The gene expression increased over time with 
a maximum after 24 h (Fig. 2B). As described above, NS1 preferentially accumulated 
in cell nuclei. Interestingly, NS1 induced morphological alterations: Cells shrinked in 
size and nuclei became fragmented whereas GFP expressing cells rendered their 
morphology up to 72 h after gene delivery (Fig. 2B). We were further interested in the 
dynamics of NS1-induced cell death. Cell viability, induction of apoptosis, and 
necrosis were analyzed using fluorescence and luminescence-based assays [27]. 
Cell viability of HuH7 and Hep3B cells decreased over time with a maximal decrease 
72 h after LNP uptake (Fig. 2C). We observed no change in cell viability for HepG2 
cells (Fig. 2C). Consequently, we found a strong induction of apoptosis in strong 
responding Hep3B cells with a maximum after 72 h (5.40 ± 1.51-fold increase) with 
only minor effects on HepG2 (1.15 ± 0.38) and HuH7 (0.99 ± 0.03) cells (Fig. 2D). A 
 102 
  
! 8!
similar behavior was observed for the induction of necrosis (Fig. 2E). We further used 
propium iodide (PI) to stain dead cells and to quantify cytotoxic effects of NS1-GFP 
(Fig. 2F). A significant increase in PI positive cells was observed in all cell lines 
ranging from an 1.75 ± 0.46-fold increase (p < 0.05) for weak responding HepG2 
cells up to a 2.91 ± 0.56-fold increase (p < 0.01) for strong responding Hep3B cells. 
In summary, the kinetic experiments confirmed the findings of the initial cell viability 
screening using a HCC cell panel as described above (Fig. 2A).  
 
In vivo safety evaluation 
NS1 did not induced any toxic effects in PHH and HepaRG cells as shown above. 
Furthermore, we were interested if our therapeutic approach is well tolerated in vivo 
after single or multiple dosing. For multiple dosing, we weekly injected LNPs 
containing pDNA coding for NS1 or empty vector control i.p. for 4 weeks (i.e. 4 
injections). Weight of mice was monitored and compared to the initial body weight at 
day zero (start of the experiment). At day 31, mice were sacrificed and spleens were 
resected, weighted, and compared to vector treated control mice.  
Body weight decreased the day after the treatment. However, animals recovered two 
days post injection and body weight did not alter significantly as compared to non-
treated mice (Fig. 3A) or vector-treated control mice (Fig. 3B). We additionally found 
no increase in spleen weight after NS1 therapy as compared to vector-treated control 
animals (Fig. 3C). Thus, our non-viral gene delivery approach of NS1 well tolerated 
after single or multiple dosing.  
 
Mechanisms of NS1-induced cell death 
Whereas some anticancer genes selectively induce apoptosis [28], H-1PV infection 
was reported to induce various cytotoxic effects [6]. Therefore, we were again 
 103 
  
! 9!
interested whether the expression of NS1 independent from H-1PV infection is 
sufficient for multimodal killing of HCC cells.  
To identify the contribution of apoptotic and necrotic cell death upon NS1 expression, 
we used Annexin V/PI staining and subsequent analysis by flow cytometry. Results 
were normalized to control cells incubated with medium. Representative flow 
cytometry contour plots for Hep3B cells are shown in Figure 4B. Measurements 
revealed a significant increase (p < 0.05) in apoptosis in Hep3B (29.58 ± 1.75% of 
total cells) and HuH7 (12.19 ± 2.99% of total cells) cells expressing NS1, whereas 
the fraction of apoptotic cells was comparable to vector treatment in weak responding 
HepG2 cells (Fig. 4A). We observed similar trends for the analysis of necrosis 
(Fig. 4A). Since apoptosis seems to play a major role in NS1-induced cell death, we 
took a closer look to the induction of apoptosis. Thus, we were interested in cleavage 
of pro-apoptotic caspases 9 and 3 as well as cleavage of poly(ADP-
ribose) polymerase (PARP). For this we used western blot analysis to detect cleaved 
and non-cleaved protein species in cells after NS1 treatment. We found a strong 
increase in cleaved caspases 9/3 and PARP in Hep3B and HuH7 cells indicating an 
apoptotic cell death induction 48 h (Supplementary Fig. 2A/B) and 72 h after LNP 
uptake (Fig. 4C). Conforming our results that HepG2 cells are less susceptible for 
NS1 treatment, no increase in cleaved caspase 9/3 and PARP was observed as 
compared to vector-treated control cells (Fig. 4C). A representative western blot of 
Hep3B cells 72 h after LNP uptake is shown in Figure 4D. We further analyzed 
activity of caspases 3 and 7 using a luminescence-based assay. Notably, NS1 
expression increased caspase 3 and 7 activity in strong-responding Hep3B and 
medium-responding HuH7 cells in a time dependent manner. Caspase activity rapidly 
increased within 24 h after gene delivery and reached a maximum after 48 h 
(Fig. 4E). In HepG2 cells, the caspase activity was close to vector-treated control 
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cells (Fig. 4E). Intracellular ATP levels were reported to serve as a switch between 
apoptosis and necrosis [29] and may be used as marker for disruption of 
mitochondrial function [30]. We therefore used a luminescence-based assay to 
determine NS1-induced decrease of intracellular ATP levels compared to vector-
treated control cells. All three cell lines analyzed showed significantly (p < 0.05) 
reduced ATP levels (Fig. 4F). Recently, it was shown that induction of reactive 
oxygen species (ROS)-accumulation is a major mechanism for NS1-mediated 
apoptosis [31]. To address this question, we analyzed NS1-induced increase in 
intracellular superoxide levels using flow cytometry. Indeed, expression of NS1 was 
sufficient to elevate intracellular superoxide levels in responding cells. An increase in 
superoxide levels by a factor of 2.12 ± 0.32 and 1.63 ± 0.34 was observed in Hep3B 
and HuH7 cells, respectively, as compared to vector treated control cells (Fig. 4G). 
HepG2 cells showed only a minor increase (1.43 ± 0.58-fold) in superoxide levels 
(Fig. 4G). Importantly, gating of Hep3B cells revealed that only NS1-expressing cells 
showed an increase in superoxide levels, whereas GFP-expressing or non-
transfected cells did not show an induced superoxide production (Fig. 4H). We made 
similar findings when we subsequently visualized stained cells by CLSM. A strong 
increase in superoxide was observed in NS1-GFP expressing Hep3B cells whereas 
cells treated with empty vector of GFP showed only minor increase (Fig. 4I).  
 
Regulation of NS1 toxicity and prognostic biomarker 
As described previously, our non-viral gene delivery of NS1 was not efficient to treat 
all HCC cell lines. Notably, there was no overall correlation between these findings 
and transfection efficiencies. Thus, we evaluated the biomarkers that allow 
identification of susceptible cells reported previously for parvovirus treatment. 
Activation of the PDK1/PKC/PKB signaling pathway was revealed as prognostic 
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marker for H-1PV toxicity in previous studies: Constitutive activation of PDK1 was 
sufficient to render non-susceptible cells responsive for H-1PV-induced cell death 
[19].  
PDK1 was expressed in all HCC-derived cell lines tested (data not shown). However, 
PDK1 activity rather than overall PDK1 expression will lead to activation of NS1. We 
therefore expressed a PDK1 isoform (PDK1:S138E) that is constitutively active [19] 
in HCC cells using recombinant adeno-assicoated viruses (rAAV). Subsequently, we 
incubated transduced cells with LNPs for gene delivery of GFP or NS1-GFP and 
stained dead cells using PI. In weak-responding HepG2 cells, activation of the PDK1 
signaling pathway resulted in a significant increase (p < 0.05) in dead cells (Fig. 5A) 
when NS1-GFP was expressed (1.39 ± 0.05-fold). In contrast, no additional 
therapeutic benefit was observed (Fig. 5A) in strong-responding Hep3B cells 
(1.00 ± 0.04-fold). No difference in the percentage of PI-positive cells was observed 
when only GFP was expressed (Fig. 5A). We performed a similar experiment using a 
dominant negative variant of PDK1. PDK1 is a master kinase with essential functions 
for proliferation and survival, thus inactivation of PDK1 induces severe side-effects 
[32]. Expression of a dominant negative PDK1 (i.e. functional knock-out, 
PDK1:K204M) was toxic for all three HCC cells analyzed (data not shown) and thus, 
we were not able to correlate changes in PI-positive cells with NS1-GFP expression. 
It was shown that NS1 is phosphorylated by PKC isoforms (e.g. PKCη) rather than 
direct regulation by PDK1 [33,34]. PKCη was detected in all HCC cell lines tested 
(data not shown). Due to the interaction of PKCη and NS1, nuclear translocation of 
PKCη during parvovirus infection was observed [35]. To see if this redistribution of 
PKCη can be triggered by non-viral gene delivery of NS1, we performed an 
immunofluorescence staining of NS1 and PKCη 24 h after LNP internalization. 
Whereas PKCη showed a diffuse distribution pattern in vector control treated cells, 
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we observed a pronounced accumulation of PKCη in the cell nucleus when NS1-GFP 
was expressed (Fig. 5B and Supplementary Figure 1E).  
 
Discussion 
Oncotoxic viruses such as the rodent parvovirus H-1PV are promising candidates for 
the treatment of cancer. This therapeutic strategy has several advantages over 
conventional cancer chemotherapies: (i) rodent parvoviruses selectively induce cell 
death in cancer cells [6,10,11] and (ii) a low resistance to H-1PV treatment is 
expected due to multimodal killing [6]. However, there are several issues including 
concerns about the safety of viral therapies [36–38] and a restriction to specific 
cancer types for some onctoxic viruses.  
In this study, we therefore wanted to develop a therapeutic approach that is distinct 
from previous studies and virus-based strategies. For the first time, we uncoupled 
NS1 for therapy of HCC from the virus: We generated pDNA vectors coding for the 
virus-derived anticancer gene (NS1) and prepared LNPs for non-viral gene delivery. 
We achieved high transfection efficiencies (Fig. 1E/F) in a set of 9 established HCC 
cell lines and confirmed expression of NS1 by western blot analysis (Fig. 1G). NS1 is 
a multifunctional protein that is endowed with various functional domains [39] 
including a nuclear localization signal [40] (NLS): After H-1PV infection, a nuclear 
accumulation of NS1 was reported. Moreover, a distinct distribution pattern in cell 
nuclei was described. Both, an accumulation in nuclear bodies, so-called H-1PV-
associated replication bodies (PAR), and a diffuse distribution in the nucleoplasm 
were observed [22]. However, NS1 was absent in nucleoli of infected cells [22]. We 
made similar findings when we used our non-viral gene delivery approach in HCC 
cells (Fig. 1I and Fig. 2B). NS1-GFP accumulated in the cell nucleus already 4 h after 
LNP uptake: Fluorescence signals were found in distinct nuclear foci and distributed 
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in the nucleoplasm, whereas no signal was detected in nucleoli (Supplementary 
Fig. 1D). Recently, a similar approach using a fluorescent canine parvovirus (CPV) 
NS1 fusion protein (NS1-EYFP) revealed comparable results [41]. Over time, we 
observed strong morphological alterations due to NS1-GFP expression whereas GFP 
expression induced no changes in cell morphology (Fig. 2B). Morphological 
alterations (i.e. cytopathic effects) of host cells during H-1PV life cycle were 
described previously and were attributed to rearrangement and degradation of micro- 
and intermediate filaments of the cytoskeleton [24]. We observed increased cytotoxic 
effects over time starting 24 h after LNP uptake with a maximal therapeutic effect 
after 72 h (Fig. 2C-E). We found an early onset of necrotic cell death starting 24 h 
after gene delivery (Fig. 2C) followed by the induction of apoptosis after 48 h in highly 
susceptible Hep3B cells (Fig. 2D). Interestingly, we observed increased activity of 
caspases 3/7 within 24 h after LNP uptake (Fig. 4E) and found cleaved caspases 9/3 
and PARP after 48 h and 72 h (Fig. 4C/D). Intracellular ATP levels were already 
decreased 24 h after gene delivery (Fig. 4F). Importantly, we found no complete 
intracellular ATP depletion that would prevent cells to enter apoptotic pathways [29]. 
Thus, the multimodal killing described for H-1PV can be achieved via non-viral gene 
delivery of NS1 as shown in this study. Conventional chemotherapies are often 
directed towards single cellular targets and mutation of these can result in rapid 
development of acquired therapy resistances [42,43]. In contrast, NS1 targets 
multiple cellular pathways and can therefore bypass such acquired mutations and 
minimize the risk for therapy resistances. Furthermore, NS1 is able to kill cells that 
are resistant to apoptosis-inducers (e.g. cisplatin) and may therefore serve as an 
important therapeutic alternative for pre-treated patients [25]. Besides direct killing of 
tumor cells (i.e. oncolytic effect), a major contribution of the immune system is 
attributed to the overall oncotoxic effect of H-1PV. H-1PV infection stimulates natural 
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killer (NK) [44] and dendritic cells [45]. Release of viral and cellular immunogenic 
signals (e.g. heat shock protein HSP72) during cell lysis was observed [46]. 
Furthermore, vesicular egress of virus progenitors can increase the exposure of 
tumor-associated and viral antigens [13,47]. Notably, NS1 activity is required for 
vesicular viral egress [47]. We found accumulation of NS1 in cellular structures close 
to nuclei (Fig. 1H) that could be structures of the endoplasmic reticulum (ER). 
Therefore, the question whether NS1 is transported to the cell surface and may 
initiate an anti-tumor immune response should be addressed in future experiments. It 
should be noted that not all HCC cells tested in this study were susceptible for NS1 
gene therapy. We therefore asked the question whether decrease in cell viability 
correlates with transfection efficiency or protein expression levels. However, we did 
not find an overall correlation between efficiency of gene delivery (i.e. transfection 
efficiency, MFI, and protein expression levels) and cytotoxic effects. It was shown 
previously, that expression of oncogenes and cell transformation render resistant 
cells sensitive for parvovirus-induced cell death [10,11]. Therefore, we focused on 
the intracellular activation pathway of NS1. NS1 is a “prodrug” that needs intracellular 
activation prior to its pharmacological function. Mutation at distinctive PKC 
phosphorylation sites interfered with NS1 function and resulted in reduced toxic 
effects upon parvovirus infection [48]. PKC isoforms were shown to phosphorylate 
NS1 in vivo and co-localize with NS1 in cell nuclei [35,49]. We observed similar 
results when NS1 was expressed using our non-viral gene delivery approach 
(Fig. 5B). We were therefore interested if PKCη can be used to modify NS1 toxicity. 
However, expression of PKCη using rAAV transduction was not sufficient to increase 
NS1-mediated toxicity (data not shown) as it was described previously for H-1PV 
therapy [50]. Activation of PKCη by e.g. the master kinase PDK1 [51,52] seems thus 
to be a prerequisite for NS1 phosphorylation. Indeed, expression of a constitutive 
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active PDK1 isoform (PDK1:S138E) [19] was sufficient to render NS1 resistant HCC  
cells susceptible for NS1 therapy (Fig. 4B). However, besides the constitutive active 
PDK1 isoform that was proposed as marker in glioma therapy [19], alternative PDK1 
activation mechanisms have to be considered for HCC treatment [53,54]. 
Conclusively, PDK1 activity seems to be a valid prognostic marker. It is tempting to 
speculate that this marker can further be used to stratify patient subpopulations for 
personalized HCC therapy. In addition, activation of NS1 by cellular proteins that are 
preferentially overexpressed in transformed cells is an important key factor for H-1PV 
selectivity to cancer cells (i.e. oncotropism). We were interested, if our therapeutic 
approach renders this tumor specificity and we therefore tested the effect of NS1 
expression in PHH and the model cell line for ex vivo cultured hepatocytes HepaRG. 
We observed no toxic effects and PHH as well as HepaRG cells were unaffected by 
NS1 (Fig. 2A). Furthermore, we analyzed the toxicity of our non-viral gene delivery 
approach of NS1 in vivo after single or multiple i.p. injection. Notably, single or 
weekly-administered non-viral gene delivery of NS1 was well tolerated by female 
SCID mice (Fig. 3A/B).  
In summary, our work demonstrates the potential of non-viral gene delivery of NS1 in 
tumor therapy. We provide a detailed insight into NS1 expression, intracellular 
distribution, and NS1-mediated cytotoxicity. Moreover, we show that our therapeutic 
approach is selective for tumor cells without affecting healthy cells in vitro and in vivo 
and we propose a biomarker that can be used to stratify HCC patient populations and 
thus for personalized HCC treatment.  
 
Outlook  
Further experiments will help to understand the oncotoxicity and the oncotropism of 
NS1 in more detail. First, a targeted RNA sequencing in NS1-treated and vector-
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treated control cells is ongoing. Using this approach, we hope to identify further 
cellular pathways that are involved in NS1-mediated cell death in susceptible cells 
over time. Second, an in vivo proof-of-concept study in mice (Hep3B xenograft) is 
ongoing. Mice are treated weekly for 4 weeks (i.e. 4 injections): This scheme was 
already tested in our safety study and was well tolerated (Fig. 5A/B). The therapeutic 
effect of NS1 and the expression pattern of NS1 in tumor and healthy tissue will be 
analyzed and compared to vector-treated control animals. Third, a tissue microarray 
in human HCC tissue samples is ongoing. As shown previously [19] and as further 
confirmed in this study, PDK1 activity is a potent biomarker for susceptibility of NS1 
(and H-1PV) treatment. We therefore aim to characterize total PDK1 levels, PDK1 
activation (staining of PDK1phosphoS241), and the constitutive active PDK1 isoform 
(PDK1phosphoS135) that was described in human glioma patients. With these 
results, we will be able to identify patient subpopulations that are susceptible for 
NS1-mediated therapy: PDK1 activity could potentially be tested prior to therapy to 
allow patient stratification and personalized treatment of HCC patients. In addition, 
these results could help to understand HCC development and progression. For 
example, total PDK1 expression levels correlate with prognosis of HCC patients [55].  
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Figure 1 Characterization of lipoplex nanoparticles (LNPs), cellular LNP internalization, and 
expression of the large non-structural protein 1 (NS1) in hepatocellular carcinoma (HCC) cells. HCC 
cells were incubated with LNPs containing plasmid DNA (pDNA) coding for an NS1-green 
fluorescence protein (GFP) fusion protein (NS1-GFP) at a final pDNA concentration of 0.1 ng/cell. (A) 
Schematic overview of the therapeutic approach developed in this study. The sequence of H-1 
parvoviral NS1 was cloned on a pDNA vector and delivered via LNPs to healthy cells and HCC cells. 
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(B) Characterization of LNPs by Nanoparticle Tracking Analysis (NTA). The average mode size 
distribution is plotted against the LNP concentration (black line) ± S.D. of n = 4 measurements. Insert: 
representative video frame obtained by NTA. (C) Transmission electron micrograph (TEM image) of 
spherical LNPs after uranyl-acetate negative staining. Scale bar: 200 nm. (D) Uptake of fluorescently 
labeled LNPs by HuH7 cells after 0, 15, and 60 min of incubation analyzed by confocal microscopy. 
Blue: cell nuclei (Hoechst 33342); red: plasma membrane (Cell Mask); green: pDNA (DiYO-1). Scale 
bar: 20 µm. (E) Expression of NS1-GFP in a set of 9 HCC cell lines 24 h after LNP uptake analyzed by 
confocal microscopy with corresponding bright field image (insert). Green: NS1-GFP. Scale bar: 
150 µm. (F) Analysis of NS1-GFP expression in 9 HCC cell lines by flow cytometry 24 h after LNP 
uptake. A representative flow cytometry dot blot for each cell line is shown. Black: vector-treated 
control cells, green: NS1-GFP. Quantification of NS1-GFP positive cells, expressed as percentage of 
total cells (bar) and shift in relative mean fluorescence intensity (cross). Results represent 
means ± S.D. of n = 3 experiments. (G) Western blot analysis of NS1 expression 24 h after LNP 
uptake. NS1 (+) was visualized using a polyclonal anti-NS1 antibody[19], empty vector (-) was used as 
control.  β-actin was used as protein loading control. (H) Expression and nuclear localization of 
NS1-GFP and GFP in HuH7 cells 24 h after LNP uptake analyzed by confocal microscopy. Blue: cell 
nuclei (Hoechst 33324); white: plasma membrane (Cell Mask); green: GFP or NS1-GFP. Scale bar: 
10 µm. 
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Figure 2 Pharmacological effects of NS1 expression in HCC cells. HCC cells were incubated with 
LNPs containing pDNA (0.1 ng/cell) coding for an NS1-green fluorescence protein (GFP) fusion 
protein (NS1-GFP), GFP, or empty vector control. (A) Analysis of cell viability 72 h after LNP uptake 
using the MTT assay. Results are expressed as relative cell viability normalized to vector-treated 
control cells. Results represent mean ± S.D. of n = 4 experiments. (B) Analysis of NS1-GFP and GFP 
expression over time by confocal microscopy. Green: GFP or NS1-GFP. Scale bar: 20 µm. (C) 
Change in cell viability over time analyzed 24, 48, and 72 h after LNP uptake. Relative cell viability 
normalized to vector-treated control cells is expressed as fold change. Values represent mean ± S.D 
of n = 3 experiments. (D, E) Induction of apoptosis and necrosis over time after NS1 gene delivery 
analyzed by fluorescence and luminescence-based kinetic assays. Results were normalized to vector-
treated control cells and represent mean ± S.D. of n = 3 experiments. (F) Staining of dead cells using 
propium iodide (PI) 24 h after LNP uptake. Red: dead cells (PI), green: GFP (insert) or NS1-GFP. 
Scale bar: 200 µm. Fluorescence was quantified and normalized to GFP control cells (insert) and is 
presented as mean ± S.D. of n = 4 experiments.  
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Figure 3 Toxicity of non-viral gene delivery of NS1 in vivo. LNPs containing pDNA coding for NS1 or 
empty vector control were administered i.p. in mice as (A) single dose or (B) weekly over a period of 4 
weeks. Body weight was measured and normalized to day zero (start of the experiment). Treatment 
days are indicated with black arrows. (C) Spleens were resected after 4 weeks of weekly 
administration of LNPs, were weighted, and mean weight normalized to vector-treated control mice. 
Results are shown as mean ± S.D. of n = 4 experiments. Grey: vector-treated control mice, red: NS1-
treated mice.   
 115 
  
! 21!
 
Figure 4 Induction of apoptosis and necrosis after NS1 expression. Cells were incubated with LNPs 
containing pDNA (0.1 ng/cell) coding for NS1-GFP, GFP, or empty vector control. (A) Percentage of 
cells in apoptosis and necrosis determined by Annexin V/PI staining analyzed by flow cytometry 72 h 
after LNP uptake: medium control (left panel, light color), vector control (middle panel, medium color), 
and NS1-GFP (right panel, dark color). Results normalized to medium control are expressed as 
mean ± S.D. of n = 3 experiments (p < 0.05). (B) Representative density plot of Annexin V/PI stained 
Hep3B cells. (C) Analysis of native and cleaved caspases 9/3 and PARP by western blot 72 h after 
LNP uptake. Ratios of cleaved vs. non-cleaved caspases 9/3 and PARP normalized to vector-treated 
control cells are shown as mean ± S.D. of n = 3 experiments. GADPH was used as protein loading 
control. (D) Representative western blot of apoptotic proteins form (C) of Hep3B cells. (E) Analysis of 
caspase 3/7 activity over time after LNP uptake using a luminescence-based assay. Normalized 
results (vector control) are shown as mean ± S.D. of n = 3 experiments. Red: Hep3B; green: HuH7; 
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blue: HepG2. (F) Intracellular ATP content 24 h after LNP uptake. Results normalized to vector-treated 
control cells represent mean ± S.D. of n = 3 experiments (p < 0.01). (G) Induction of superoxide 
accumulation 24 h after LNP uptake analyzed by flow cytometry. Results normalized to vector-treated 
control cells represent mean ± S.D. of n = 3 experiments (p < 0.05). (H) Representative confocal 
microscopy image of Hep3B cells. Blue: nucleus (Hoechst 33342), red: superoxide (Superoxide 
detection reagent). 
 
 
 
 
 
 
Figure 5 Biomarker for NS1 therapy. (A) Influence of constitutive active PDK1 (PDK1:S138E) on NS1 
toxicity after non-viral gene delivery. PDK1:S138E was expressed using recombinant adeno-
associated viruses (rAAVs) and GFP or NS1-GFP was subsequently delivered using LNPs (0.1 ng 
pDNA/cell). Propium iodide staining was used 72 h post LNP uptake to visualize dead cells. Red: dead 
cells (PI), green: GFP or NS1-GFP. Quantified PI signal was normalized to non-transduced cells. 
Values represent mean ± S.D. of n = 4 experiments (p < 0.05). Scale bar: 150 µm. (B) Intracellular 
localization of PKCη. HuH7 cells analyzed 24 h after LNP uptake. Blue: cell nuclei (Hoechst 33342), 
green: NS1-GFP, red: PKCη (sc-136036). Scale bar: 20 µm.  
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Supplementary Figure S1 (A) Uptake of LNPs by the three selected cell lines after 0, 1, 5, 15, 30, 
and 60 min of incubation analyzed by confocal microscopy. Blue: cell nuclei (Hoechst 33342); Red: 
plasma membrane (Cell Mask); Green: pDNA (DiYO-1). (B) Quantification of NS1 expression by 
western blotting 24 h after LNP uptake. (C) Western blot analysis of NS1 and the NS1-GFP fusion 
protein 24 h after LNP uptake. (D) Nuclear localization of NS1-GFP in HuH7 cells 4 h after LNP uptake 
analyzed by confocal microscopy. Cell morphology is outlined (dashed line), nucleoli are indicated by 
white arrows. Scale bar: 10 µm. (E) Nuclear localization of NS1 after non-viral gene delivery analyzed 
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by confocal microscopy 24 h after LNP uptake. Blue: cell nuclei (Hoechst 33342); green: NS1 
(polyclonal anti-NS1 antibody). Scale bar: 10 µm. 
 
 
 
 
 
 
 
Supplementary Figure S2 (A) Analysis of native and cleaved caspases 9/3 and PARP by western 
blot 48 and 72 h after LNP uptake. Representative western blots of non-cleaved and cleaved 
caspases 9/3 and PARP. GADPH was used as protein loading control. (B) Quantification of (A) 48 h 
after LNP uptake. The ratio of cleaved versus non-cleaved (native) caspases 9/3 and PARP 
normalized to vector-treated control cells represented as mean ± S.D. of n = 3 experiments.  
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Experimental section 
Lipoplex preparation and characterization 
DNA-Lipoplex Preparation. pDNA lipid nanoparticles (LNPs) were produced according to the 
manufacturers recommendation. In brief, pDNA was diluted in OptiMEM, mixed thoroughly, and p3000 
reagent was added. Lipofectamine was diluted with OptiMEM, mixed with the pDNA mixture, and 
vortexed. After 5 min of incubation at room temperature, LNP were used for further experiments. For 
in vivo experiments, OptiMEM transfection medium was replaced by sterile glucose solution (5% w/v).  
Nanoparticle Tracking Analysis. LNP size and size distribution was determined by 
Nanoparticle Tracking Analysis (NTA) using a Nanosight NS200, LM20 (Malvern Instruments Ltd., 
Malvern, United Kingdom) equipped with a 405 nm laser as described previously[56]. In brief, the 
chamber was cleaned before measurements using 0.02 µm filtered (Anotop 25, Whatman, Glattbrugg, 
Switzerland) water and absence of particles was confirmed. LNPs were prepared as described above 
and were injected using a 1 mL sterile syringe (Norm-Ject, HSW, Tuttlingen, Germany). Four videos of 
90 s were recorded using replenished sample for each measurement. Settings for video recording 
were set to obtain clear and sharp images. NTA 2.2 software was used for capturing and analysis of 
average particle size and size distribution. In order to obtain statistically reliance, a minimum of 300 
completed tracks was required. Results are expressed as mean ± S.D. of n = 4 experiments.  
Zeta Potential Measurement. The zeta potential of LNPs was determined using the Delsa 
Nano C Particle Analyser (Beckman Coulter, Nyon, Switzerland). Samples were analyzed using a 
laser wavelength of 685 nm operated in an angle of 15° and converted according to the Smoluchowski 
equation.  
Transmission Electron Microscopy. LNPs were visualized by transmission electron microscopy 
(TEM) after negative staining. In brief, 5 µL of the LNP suspensions were mounted on a carbon-coated 
copper grid, negatively stained with uranyl acetate (2%), and dried overnight. Samples were then 
analyzed using a CM-100 transmission microscope (Philips, Eindhoven, Netherlands) at an 
accelerating voltage of 80 kV. Size was determined by measuring n = 100 particles and results are 
depicted as mean ± S.D.  
 
Cloning of plasmids 
Cloning of plasmids. pcDNA3.1+ was obtained from Invitrogen (Zug, Switzerland) and 
pTagGFP-N was purchased from Evrogen (Moscow, Russia). pdB-H-1PVwt (German Cancer 
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Research Center DKFZ, Heidelberg, Germany) was used as template for NS1 and extracted by 
polymerase chain reaction (PCR) using primers 1 and 2 (pcDNA3.1-NS1) and primers 1 and 3 
(pTag-NS1-GFP) [Supplementary experimental section]. Phusion® High-Fidelity DNA Polymerase 
(New England Biolabs, Ipswich, MA, USA) was used according to the manufacturers recommendation. 
DNA was initially denaturated at 98 °C for 30 sec followed by 35 cycles of denaturating (98 °C, 10 sec), 
annealing (67 °C, and elongation (72 °C, 45 sec). DNA was extended finally at 72 °C for 10 min. 
Subsequently, the PCR product was digested and ligated into the expression plasmids pcDNA3.1+ 
(pcDNA3.1-NS1 using BamHI and NotI sites) or pTagGFP-N (pTag-NS1-GFP using BamHi sites). The 
resulting plasmids were sequenced to confirm NS1 sequence and correct reading frame. Plasmids 
were then purified using the Plasmid Mini Kit (Qiagen, Hombrechtikon, Switzerland) in accordance 
with the manufacturers recommendations. 
 
Cell culture 
Cell culture. Human hepatoma cell lines (HepG2, Hep3B, HuH7, HuH6, SNU449, PLC/PRF-5, 
HepT1, HLE, SkHep1) were cultured in Dulbecco’s modified Eagle’s culture medium high glucose 
(DMEM) supplemented with 10% FCS, penicillin 100 U/mL, and streptomycin 100 µg/mL at 37 °C and 
5% CO2 and saturated humidity. Primary human hepatocytes (donor: BHum 16043) were obtained 
from QPS Hepatic Biosciences (Barcelona, Spain). Cells were maintained in 
Fresh Maintenance Medium (FMM, QPS Hepatic Biosciences, Barcelona, Spain) supplemented with 
dexamethasone according to the manufacturers recommendation at 37 °C and 5% CO2 and saturated 
humidity. HepaRG cells were cultured as described previously [57,58].  
Transfection of adherent cells. A standard transfection protocol was developed. Cells were 
seeded in complete culture medium at a density of 2.5 x 104 cells/cm2 in poly-D-lysine coated 
(0.4 mg/mL) wells or slides and allowed to adhere over night. Plasmid DNA (pDNA) was added at a 
concentration 0.1 ng pDNA per cell (1 µg/mL) using freshly prepared LNP formulation (see above).  
 
NS1-GFP expression analysis.  
Confocal microscopy. Cells were seeded in a 24-well plate (TPP, Transadigen, Switzerland) and were 
transfected with GFP or NS1-GFP as described above. Expression of GFP and NS1-GFP 
fluorescence was analyzed using a FV1000 confocal microscope (Olympus, Tokyo, Japan) equipped 
with a 10x water immersion objective (NA 0.4; Olympus, Tokyo, Japan). Excitation and emission 
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wavelength were 488 nm and 516 nm, respectively. For live cell imaging, cells were seeded on glass 
bottom culture slides (µ-slide, Ibidi, Martiensried, Germany) and cultured in complete culture medium 
using phenol red-free DMEM. 
 Flow cytometry. To quantify the percentage of NS1-GFP expressing cells and the average 
expression level, transfected cells were analyzed by flow cytometry. Cells were detached at inidcated 
time points, washed once with D-PBS, centrifuged (400 x g, 5 min, 4 °C) and resuspended in FACS 
staining buffer (D-PBS supplemented with 0.05% NaN3 and 1% FCS). Cells were then analyzed by 
flow cytometry using a FACS Canto II flow cytometer (Becton Dickinson, San Jose, CA, USA) exciting 
at 488 nm. Doublets were excluded and fluorescence signals were collected using FL1 (505LP-
530/30). Results were analyzed using Flow Jo VX (TreeStar, Ashland, OR, USA) and percentage of 
NS1-GFP-positive cells was evaluated. Mean fluorescence intensities (MFI) were normalized to 
vector-treated control cells. Results are shown as mean ± S.D. of n = 3 experiments. 
 
NS1 expression analysis. 
NS1 staining and confocal microscopy. For analysis of NS1 expression in adherent cells, cells 
were seeded on a 254 mm2 cover slip (Menzel Gläser, Braunschweig, Germany) coated with poly-D-
lysine (0.4 mg/mL). At indicated time points post transfection, cells were washed three times with D-
PBS (0.5 mM Ca2+, 1 mM Mg2+) and fixed using 4% PFA (30 min, RT). Cells were then incubated with 
D-PBS (50 mM NH4Cl) for 6 min at RT and treated with Triton-X100 0.1% for 10 min at RT. Cells were 
then washed three times with D-PBS (0.5 mM Ca2+, 1 mM Mg2+) and incubated with FCS 10% for 
30 min. After blocking, cells were incubated with primary antibody (Dr. Jürg Nüesch, DKFZ, 
Heidelberg) in FACS staining buffer for 2 h at RT. Cells were washed three times with D-PBS (0.5 mM 
Ca2+, 1 mM Mg2+) and incubated with secondary antibody (DILUTION) in FACS staining buffer for 
60 min at RT under light protection. Hoechst 33342 was added at a final concentration of 0.1 µg/mL 
10 min prior to the end of the staining procedure. Expression of GFP and NS1-GFP fluorescence was 
analyzed using a FV1000 confocal microscope (Olympus, Tokyo, Japan) using a 60x oil immersion 
objective (NA 1.4; Olympus, Tokyo, Japan). Excitation and emission wavelength were 488 nm and 
516 nm, respectively. Emission wavelengths were 405 nm and 488 nm, fluorescence was collected at 
425-575 nm and 500-545 nm, respectively.  
 
 
 122 
  
! 28!
Western blot analysis.  
Extraction of proteins. Expression of NS1 and intracellular kinases was analyzed by western 
blotting. Collection of cellular proteins was performed on ice. At indicated time points, culture medium 
was collected and cells were detached in ice cold D-PBS using a pre-cooled cell scraper. Supernatant 
and cell suspension were centrifuged (590 x g, 5 min, 4 °C) and resuspended in 60 µL of IP-buffer 
(20 mM Hepes pH 7.5, 5 mM MgCl, 300 mM NaCl, 0.1% NP40) containing 1x protease and 
phosphatase inhibitor cocktail (Roche diagnostics, Indianapolis, USA). Cells were incubated on ice for 
30 min and vortexed every 10 min. Cell extracts were used immediately after preparation or snap 
frozen in liquid nitrogen and stored at -80 °C. Total protein concentration was determined using the 
Pierce BCA Protein Assay Kit (Thermo Scientific, Zug, Switzerland) according to the manufacturers 
recommendation. For further analysis, samples were mixed with 4x sample buffer (140 mM SDS, 20% 
glycerol, 25% β-mercaptoethanol, bromphenol blue) and incubated at 96 °C for 5 min.  
 
SDS Page. 7.5% acrylamide gels were casted manually according to the manufacturers 
recommendation. After completion of polymerization, slots were washed with water and gels were 
mounted in the gel running chamber. Running buffer (25 mM Tris, 0.19 mM glycine, 3.5 mM SDS) was 
added. Samples and protein standard (NAME) were loaded into the slots and proteins were separated 
at 120 V.  
Western blotting. Proteins were blotted on cellulose or PVDF (Immobilon-P®) membranes 
using a semi-dry approach. In brief, 6 filter papers soaked in blotting buffer (48 mM Tris pH 9.2, 
39 mM glycine, 1.3 mM SDS, 20% MeOH) were placed on the anode of the blotting chamber 
(XX,XX,XX). Pre-wetted membranes were placed on top and covered by SDS page gels. 6 pre-
soaked filter papers were placed on top and proteins were blotted at 0.7 mA/cm2 of membrane for 
1.5 h.  
Immuno-staining of proteins. Blotted membranes were blocked by 3% BSA, 10% skim milk, or 
2% casein in TBS-T (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween 20) for 60 min at RT. 
Membranes were incubated with appropriate primary antibodies over night at 4 °C in TBS-T, washed 
three times with TBS-T, and incubated with horseradish-peroxidase-conjuagted secondary antibodies 
for 60 min at RT. After repetition of the washing procedure, Western ECL Blotting Substrates (Bio-Rad, 
Hercules, CA, USA) were added to produce luminescence. ANALYSIS 
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Subcellular localization of NS1 
Live cell imaging of NS1-GFP. To analyze expression and subcellular localization of NS1-GFP, 
cells were seeded in poly-D-lysine coated glass bottom culture slides (µ-slide, Ibidi, Martiensried, 
Germany) and transfected as described above. At indicated time-points, images were captured by 
confocal laser scanning microscopy using a FV1000 microscope (Olympus, Tokyo, Japan) equipped 
with a 60x oil immersion objective (NA 1.4; Olympus, Tokyo, Japan). Samples were excited at 488 nm 
and fluorescence was collected at 500-545 nm. Due to changes in NS1-GFP expression, laser 
intensity was adjusted at each time point. In additional samples, cell nuclei and plasma membrane 
were stained 24 h post transfection using Hoechst 33342 and Cell Mask (manufacturer), respectively. 
Cells were incubated with Hoechst 33342 at a final concentration of 0.1 µg/mL for 10 min at 37 °C and 
washed three times with D-PBS. Then, 200 µL of Cell Mask staining solution (0.2 µL Cell Mask/400 µL 
culture medium) was added. Images were captured using a FV1000 microscope (Olympus, Tokyo, 
Japan) equipped with a 60x objective (NA 1.4; Olympus, Tokyo, Japan). Emission wavelengths were 
405 nm, 488 nm, and 635 nm. Fluorescence was collected at 425-575 nm, 500-545 nm, and 655-
755 nm, respectively.  
 
Analysis of the pharmacological effect in vitro 
Cell viability assay. In vitro cell viability was determined using the MTT assay. Cells were 
seeded in 250 µL of complete culture medium in poly-D-lysine coated 96-well plates (TPP, 
Transadigen, Switzerland). Terfenadine (20 µM) was used as positive control. After indicated time 
points, 100 µL of the culture medium was removed carefully and 100 µL of MTT working solution 
(Thiazolyl blue, 5 mg/mL) were added. Cells were incubated for 2-4 h at 37 °C. Then, medium was 
removed and formazan crystals were dissolved with acidified isopropyl alcohol (100 µL) and SDS (3%, 
20 µL). Absorption was measured at 570 nm and unspecific signals measured at 670 nm were 
substracted (Spectramax M2 plate reader, Molecular Devices, Sunnyvale, CA, USA). Cell viability was 
expressed as percentage, whereas cells treated with empty vector (?) were defined as 100%. MTT 
assays were performed in triplicates and repeated three times and results are expressed as 
mean ± S.D.  
Intracellular ATP content. Intracellular ATP content was analyzed using the CellTiter Glo 
Luminescent cell viability assay (Promega, Wallisellen, Switzerland) in accordance with the 
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manufacturers recommendation as described previously [30]. In brief, 100 µL of assay buffer were 
added to each 96-well containing 100 µL of complete culture medium. Samples were incubated for 
12 min at RT under light protection and luminescence was measured using a XXX reader. Intracellular 
ATP content is normalized to vector-treated control cells. 0.1% Triton-X100 was used as positive 
control. Results are shown as mean ± S.D. of n = 3 experiments.  
Kinetic cell viability assay. Cell viability over time was determined using the RealTime-GloTM 
MT Cell Viability Assay (Promega, Madison, WI, USA) with modifications. In brief, cells were seeded in 
96-well plates (TPP, Transadigen, Switzerland) and transfected as described above. 100 µL of culture 
medium were removed 8 h post transfection and MT Cell Viability Substrate and NanoLuc® Enzyme 
were added at a concentration of 1x at a total volume of 200 µL per well. At indicated time points, 
luminescence was collected with an integration time of 1000 ms using an Infinite 200Pro plate reader 
(Tecan, Männedorf, Switzerland) and cell viability was calculated. Values were normalized to vector-
treated control cells. Experiments were performed in quadruplicates and results are expressed as 
mean ± S.D.  
Kinetic apoptosis assay. Apoptosis induction over time was analyzed by using the prototype 
RealTime-GloTM Annexin V Apoptosis Assay (Promega, Madison, WI, USA) with midifications. In brief, 
cells were seeded in 96-well plates (TPP, Transadigen, Switzerland) and transfected as described 
above. After 8 h of incubation with LNPs, 100 µL of culture medium were removed. Necrosis Detection 
Reagent, CaCl2, Annexin V-SmBiT, Annexin V-LgBiT, and RT substrate were added at a 
concentration of 1x at a total volume of 200 µL. At indicated time points, luminescence (integration 
time: 1000 ms) and fluorescence (excitation at 488 nm, emission at 525 nm) were measured using a 
Infinite 200Pro plate reader (Tecan, Männedorf, Switzerland) and increase in apoptosis compared to 
vector-treated control cells was calculated. Experiments were performed in quadruplicates and results 
are expressed as mean ± S.D. 
Kinetic cytotoxicity assay. Cytotoxicity over time was determined using the CellToxTM Green 
Cytotoxicity Assay (Promega, Madison, WI, USA) with modifications. Briefly, cells were seeded in 96-
well plates (TPP, Transadigen, Switzerland) and transfected as described above. 100 µL of culture 
medium were removed 8 h post transfection and CellToxTM Green Dye was added at a final 
concentration of 1x at a total volume of 160 µL. At indicated time points, fluorescence was measured 
using a Infinite 200Pro (Tecan, Männedorf, Switzerland). Excitation wavelength was 513 nm, 
fluorescence was collected at an emission wavelength of 532 nm. Fold change in cytotoxicity as 
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compared to vector-treated control cells was calculated. Experiments were performed in 
quadruplicates and results are presented as mean ± S.D.   
Propium iodide (PI) staining. Cells were seeded in a 96-well plate (TPP, Transadigen, 
Switzerland) and were transfected with GFP or NS1-GFP as described above. After 72 h, PI was 
added at a final concentration of 500 nM for 5 min and cells were washed carefully with D-PBS. 
Fluorescence was analyzed using a FV1000 confocal microscope (Olympus, Tokyo, Japan) using a 
10x water immersion objective (NA 0.4; Olympus, Tokyo, Japan). Excitation wavelengths were 488 nm 
and 559 nm. Fluorescence was detected at 520 nm and 619 nm respectively. Fluorescence was 
quantified using ImageJ 1.46 software (National Institutes of Health). Lower particle threshold was set 
to 20 pixels. Percentage of PI positive cells was calculated by dividing counted particles in PI channel 
by the sum of particles counted in GFP and PI channel. Results are displayed as mean ± S.D of n = 4 
experiments.  
 
Apoptosis/Necrosis 
Annexin V/PI staining. Apoptotic and necrotic cells were stained using the Dead Cell 
Apoptosis Kit (Thermo Scientific, Zug, Switzerland) with modifications. At indicated time points, cells 
were detached using 0.25% trypsin-EDTA, washed once, and centrifuged (400 x g, 5 min, 4 °C). Cell 
pellets were resuspended in 100 µL Annexin V staining buffer (5 µL Alexa Fluor® 488 Annexin V and 
95 µL of 1x Annexin-binding buffer) and incubated for 15 min. Then, propium iodide was added to a 
final concentration of 0.7 µg/mL and cells were incubated for additional 15 min at RT. Fluorescence 
was then analyzed by flow cytometry using a FACS Canto II flow cytometer (Becton Dickinson, San 
Jose, CA, USA) exciting at 488 nm and 561 nm. Fluorescence was collected using FL1 (505LP – 
530/30) and FL5 (586/15). To evaluate the percentage of apoptotic and necrotic cells, Flow Jo VX 
software (TreeStar, Ashland, OR, USA) was used. Results are expressed as mean ± S.D. of n = 3 
experiments.  
Caspase 3- and 7 activation assay. Caspase 3 and 7 activation was analyzed using Caspase-
Glo 3/7 Assay (Promega, Wallisellen, Switzerland)in accordance with the manufacturers 
recommendation. Briefly, at indicated time points, 67 µL of freshly prepared Caspase-Glo 3/7 Reagent 
was added to each 96-well to a total volume of 135 µL. Plates were shaken carefully for 30 sec using 
a plate mixer and incubated for 60 min at RT. Luminescence was measured using an Infinite 200Pro 
plate reader (Tecan, Männedorf, Switzerland) with an integration time of 1000 ms. Results were 
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normalized to vector-treated control cells and are expressed as mean fold caspase activation ± S.D. of 
n = 3 experiments.  
Detection of apoptosis in western blot. Cells were seeded in 6-well plates (TPP, Transadigen, 
Switzerland) and transfected as described above. A slightly modified protocol to the one described 
above was used. In brief, cells were washed with ice-cold D-PBS at indicated time points. Cells were 
lysed with RIPA buffer (50 nM Tris-HCL pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% sodium dodecylsulfate, and 1 mM EDTA) containing 1x protease inhibitor cocktail 
(Roche diagnostics, Indianapolis, USA) for 15 min under constant agitation. Proteins were collected by 
centrifugation (15700 x g, 10 min, 4 °C) and protein concentrations were determined by Pierce BCA 
Protein Assay Kit (Thermo Scientific, Zug, Switzerland) according to the manufacturers 
recommendation. 15 µg protein for 48 h-samples and 12.5 µg protein for 72 h-samples were 
separated on 4-12% bis-tris gradient gels using MOPS SDS running buffer (Invitrogen, Carlsbad, CA, 
U.S.A). After separation, proteins were transferred to nitrocellulose membranes using the Trans-Blot 
Turbo Transfer System from Bio-Rad (Hercules, CA, U.S.A). After transfer, the membranes were 
washed once with PBS-T for 5 min at 70 rpm on an orbital shaker and subsequently blocked with 5% 
skim milk for 1 h at 70 rpm. They then were washed 3 times for 5 min at 70 rpm with PBS Tween and 
incubated overnight with the indicated primary antibody in the cold room at 4 °C. Membranes were 
washed three times with PBS-T and were incubated with a HRP conjugated secondary antibody at 
room temperature for 1 h. Then, membranes were again washed three times with PBS-T before 
detection. Luminescence was produced using Western ECL Blotting Substrates (Bio-Rad, Hercules, 
CA, USA) and analyzed! using the Fusion Pulse TS device from Vilber Lourmat (Oberschwaben, 
Germany). In order to incubate the membranes with another antibody, they were stripped for 15 min at 
70 rpm with Restore™ PLUS Western Blot Stripping Buffer (Thermo Scientific, Waltham, MA, USA), 
washed three times with PBS-T, blocked for 1 h with 5% skim milk and washed again three times. 
Detection of GADPH was used to confirm uniform loading and for normalization. 
 
Detection of superoxide 
Analysis of intracellular superoxide. Real-time analysis of reactive oxygen species (ROS) and 
superoxide induction was performed using the total ROS/Superoxide detection kit (Enzo Life Sciences, 
Lausen, Switzerland) with modifications. Cells were seeded in 6-well plates (TPP, Transadigen, 
Switzerland) and transfected as described above. At indicated time points, cells were washed once 
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with D-PBS and were detached (0.25% trypsin/EDTA). Cells were resuspended in 1 mL of complete 
culture medium, centrifuged (400 x g, 5 min, RT), and washed once with 1x wash buffer. Cell 
suspensions were incubated with either 500 µL of oxidative stress detection reagent or superoxide 
detection reagent at a final concentration of 2 µM for 30 min at 37 °C under light protection. Cells were 
then analyzed by flow cytometry using a FACS Canto II flow cytometer (Becton Dickinson, San Jose, 
CA, USA) exciting at 488 nm and 561 nm. Fluorescence signals were collected using FL1 (505LP-
530/30) and FL6 (600LP-610/10). Results were analyzed using Flow Jo VX (TreeStar, Ashland, OR, 
USA). Cells were subsequently analyzed using confocal microscopy. To stain cell nuclei, Hoechst 
33342 at a final concentration of 0.1 µg/mL was added for 10 min at RT. Cells were then washed once 
with D-PBS, centrifuged (400 x g, 5 min, RT), and the pellet was resuspended in 20 µL of D-PBS. Cell 
suspensions were mounted on cover slips using ProLong Gold according to the manufacturers 
recommendation. Cells were analyzed using a FV1000 confocal laser scanning microscope (Olympus, 
Tokyo, Japan) equipped with a 60x oil immersion objective (NA 1.40). Emission wavelengths were 
405 nm, 488 nm, and 559 nm, fluorescence was collected at 425-475 nm, 500-545 nm, and 575-
620 nm, respectively. Results were normalized to vector-treated control cells. Results are expressed 
as mean ± S.D of n = 3 experiments.  
 
Transduction of PDK1 and PKCη using recombinant adeno-associated viruses 
Influence of PDK1 on NS1 toxicity. To study the influence of PDK1 activation on NS1 toxicity, 
cells were transduced with PDK1:S138E, dominant negative PDK1 (PDK1:K204M), PKCη, or 
dominant negative PKCη using recombinant adeno-asociated viruses (rAAV)[19]. It should be noted 
that PDK1:S138E mimics constitutive active PDK1phosphoS135 [19]. In brief, cells were seeded in 
96-well plates as described above and transfected with rAAVs (104 genomes/cell). If indicated, cells 
were incubated 24 h post-transduction with LNPs for 72 h. PI at a final concentration of 500 nM was 
added for 5 min and cells were washed carefully with D-PBS. Fluorescence was analyzed using a 
FV1000 confocal microscope (Olympus, Tokyo, Japan). LASER. Fluorescence was quantified using 
ImageJ 1.46 software (National Institutes of Health). Lower particle threshold was set to 20 pixels. 
Percentage of PI positive cells was calculated by dividing counted particles in PI channel by the sum 
of particles counted in GFP and PI channel. Results are expressed as mean ± S.D of n = 4 
experiments.  
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In vivo toxicity 
 In vivo toxicity assessment. Animal experiments were authorized by the Ethics committee of 
the Medical University of Vienna and were performed according to the guidelines of the Federation of 
Laboratory Animal Science Association (FELASA) as well as the Arrive guidelines. To analyze toxicity 
of NS1 and empty vector gene delivery, 12 8-week-old female CB-17 scid/scid (SCID) mice were 
obtained from Harlan Laboratories (San Pietro al Natisone, Italy). Mice were divided into 4 groups. 4 
animals received LNPs containing pDNA coding for empty vector or NS1 by weekly i.p. administration 
at a dose of 200 µg pDNA per injection. For single dose treatment, two animals received either NS1 or 
vector treatment administered as described above. Body weight was monitored constantly for 31 days. 
At day 31, mice were sacrificed and spleens were resected and weighted.  
 
Statistical analysis 
Statistical analysis.  Statistical analysis was performed by one-way analysis of variance 
(ANOVA) followed by Tukey’s posthoc test using OriginPro (Version 9.1.0, OriginLab Corporation, 
Northampton, MA, USA). Number of experiments (n) and level of significance are indicated at the 
respective experiments.  
 
Supplementary experimental 
Primers. The following primers were used for cloning of NS1 and NS1-GFP: 
Primer 1: 5’-attggatccgcgatggctggaaacgcttactcc-3’ 
Primer 2: 5’-tattaatgcggccgcttagtccaaggtcagctcctcg-3’ 
Primer 3: 5’-aatggatccgcgtccaaggtcagctcctcg-3’ 
Antibodies. Monoclonal and polyclonal anti-NS1 antibodies were kindly provided by Dr. Jürg 
Nüesch (German Cancer Research Center DKFZ, Heidelberg, Germany). Anti-PDK1 antibody (mouse 
monoclonal, CP10363) was purchased from Cell Applications Inc. (San Diego, CA, USA). Anti-PKCη 
(rabbit polyclonal, sc-136036) and anti-GADPH (mouse monoclonal, sc-365062) antibodies were 
purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Antibodies for detection of caspase 3 
(rabbit polyclonal, ♯96655), caspase 9 (mouse monoclonal, ♯95085), and PARP (rabbit monoclonal, 
♯95325) were purchased from Cell Signalling Technologies (Danvers, MA, USA). 
!
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DISCUSSION 
During the last decades, great progress in the field of nanomedicine was made. Various drug 
formulations were developed and tested in a preclinical and clinical setting. This PhD project focused 
on the development of nanoparticulate drug delivery systems for the treatment of cancer. In a first 
part (Chapter II-IV), a versatile drug delivery system for small molecular anticancer compounds was 
developed. In a second part (Chapter V), a novel gene therapy approach for the treatment of liver 
cancer was implemented. Nanomedicines for cancer therapy need to overcome several hurdles to 
reach their site of action: NPs need to show a long blood circulation time, extravasate to the 
tumor microvascular environment (TME), penetrate the tumor, be internalized by (preferentially) 
cancer cells, and release the drug at the site of action [153]. Many of these aspects were analyzed 
during this PhD project and are summarized in the following section.  
 
 
Figure 5 Physico-chemical characteristics of nanoparticles and hurdles in tumor targeting [154]. 
 
1 PHYSICO-CHEMICAL CHARACTERIZATION 
PEG-PCL was chosen as biocompatible and biodegradable di-block copolymer. General aspects and 
advantages of this polymer are reviewed in Chapter I. In a first step, a preparation protocol for 
PEG-PCL micelles was developed. Resulting PEG-PCL micelles had a spherical shape, were 
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characterized by a solid-sphere (i.e. micelle-like) structure, and were below 100 nm in diameter 
(Table 1). In addition parameters such as the critical aggregation concentration (CAC) and the 
aggregation number (i.e. number of polymer unimers per micelle, Nagg) were determined.  
 
Table 1 Summary of physico-chemical properties of PEG-PCL micelles and expert opinion on their impact for tumor targeting.  
 
 
Extensive characterization of nanocarriers is of big importance regarding their further use. Physico-
chemical properties of NPs determine their in vivo behavior such as PK properties and cellular 
Characteristics Method Result Impact 
Critical aggregation 
concentration (CAC) 
Pyrene 
encapsulation 
2.8 x 10-7 M [155] (+) Stability upon dilution (e.g. 
injection),  
(+) Prevention of burst relesae Langmuir 
 
2.8 x 10-7 M [Fig. S3] 
Aggregation number 
Specific volume 2200-10 000 [155] 
 Nanoparticle 
tracking analysis 
(NTA) 
 
139 ± 17 [Fig. S1] 
Shape 
Transmission 
electron 
microscopy (TEM) 
Spherical [155,156] 
(+) Efficient cellular uptake 
(+) Long blood-circulation time 
 
(-) High aspect ratio favorable 
for deep tumor penetration 
Core morphology 
Cryo-EM Solid-spheres [155] (+) Ideal for hydrophobic drugs 
 
(-) Delivery of hydrophilic 
drugs 
Static light 
scattering (SLS) 
 
Solid-spheres 
Size (Diameter) 
Dynamic light 
scattering (DLS) 
78.2 ± 1.7 nm [155] 
(+) Favorable PK properties 
(+) Passive tumor 
accumulation 
(+) Efficient cellular uptake  
(+) Size-dependent tumor 
penetration 
NTA  83.2 ± 19 nm [Fig. S1] 
TEM 67 ± 15 nm [155] 
Ultra small angle X-
ray spectroscopy 
(U-SAXS) 
109.4 [Fig. S2] 
Size distribution DLS PDI: 0.08 ± 0.03 [155] (+) Monodisperse micelles 
Zeta potential 
Electrophoretic light 
scattering 
-4.13 ± 0.24 mV [155] 
(+) Decreased uptake by MPS 
(+) Reduced protein 
opsonation 
(+) Reduced unspecific uptake 
(+) Favorable PK properties 
NP concentration NTA 
2.44 ± 0.28 x 1014 NPs x g-1 PEG-PCL 
[Fig. S3] 
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internalization (Figure 5) [154]. A summary of the physico-chemical characteristics of PEG-PCL 
micelles used in this PhD project is provided in Table 1 including an expert opinion commenting their 
importance for the implementation of nanoparticulate drug delivery systems for cancer therapy.  
 
Table 2 Hurdles for nanomedicines in cancer therapy. Adapted from references [154,157–159]. PEG-PCL micelle 
characteristics were obtained in Chapters II-IV. 
 
A set of “ideal properties” was defined, which is a prerequisite for NPs to be effective in vivo (Table 2) 
[153,157,158,160]. In addition, Table 2 provides information about PEG-PCL micelles used in the 
present study.  
 
2 DRUG LOADING, PHARMACOKINETICS, AND TISSUE DISTRIBUTION 
In a second step, the model drug doxorubicin was encapsulated in PEG-PCL micelles. The 
anticancer drug doxorubicin was chosen due to several reasons. First, free doxorubicin is 
Factor Ideal properties Design consideration PEG-PCL micelles 
Pharmacokinetics  
- Low interaction with 
serum proteins 
(opsonins) 
- Stable in circulation 
- High t1/2 
- Coating with hydrophilic 
polymers 
- Neutral or slightly negative 
zeta potential 
- NP size within 10-500 nm 
(+) Ideal physico-chemical characteristics 
(+) Similar PK profile as gold-standard 
(PEG-liposomes) 
 
(?) Interaction with serum proteins  
(?) PK after multiple dosing 
Biodistribution, 
extravasation and 
tumor accumulation 
- Minimal peripheral 
(tissue) volume 
- Extravasation of 
leaky blood vessels 
- Low lymphatic 
clearance 
- NP size < 200 nm 
- High NP concentration in 
plasma 
(+) Low volume of distribution 
 
(?) Tumor extravasation  
Tumor penetration 
- Efficient and deep 
penetration of tumor 
- Small size (< 200 nm) 
(+) NP size 
 
(?) Test in a suitable tumor animal model or 
3D cell culture model 
 
(?) Impact of aspect ratio (elongated NPs vs. 
spherical NPs) 
Tumor cell uptake 
and intracellular 
trafficking 
- Efficient uptake 
- Specific uptake 
- Active targeting: 
  Target/ligand 
  Surface density  
(+) Active drug targeting implemented 
 
(?) Choice of suitable target/ligand  
Drug release 
- High dose per NP 
- Efficient release at 
the site of action 
- Active drug loading 
- Active drug release  
(+) No burst release observed 
 
(?) Potent hydrophobic drug  
(?) In vivo drug release  
(?) Active drug release 
 
(-) Low encapsulation efficiency for 
doxorubicin 
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characterized by unfavorable PK properties. After systemic administration, the drug is removed 
efficiently from the central plasma compartment [61,76]. Therefore, this drug may profit from 
advanced drug delivery systems. Consequently, the first nanoparticulate drug delivery system to 
reach market approval was a lipid-based nanocarrier of doxorubicin (Doxil®) [10]. Second, 
doxorubicin is characterized by an inherent fluorescence that can be used for imaging. Methods such 
as confocal laser scanning microscopy or flow cytometry offer the possibility to analyze the 
interaction of doxorubicin-loaded NPs and cancer cells without further labeling. Third, doxorubicin is 
a cytotoxic drug. Thus, its pharmacological effect can be studied using established cell viability or 
cytotoxicity assays. Fourth, tritium-labeled doxorubicin ([3H]-doxorubicin) is commercially available. 
Liquid scintillation counting (LSC) can be used to determine [3H]-doxorubicin concentrations: Having 
a sensitive analytical method is a prerequisite for in vivo experiments such as determination of PK 
parameters and tissue distribution. In addition to the methods described in Chapter II, 
[3H]-doxorubicin was used to study the PK profile of liposomes consisting of lipids with different 
transition temperatures [161]. Fifth, various studies using doxorubicin in the field of oncology are 
available allowing direct comparison of different formulations: Therefore, the gold standard for long 
circulating NPs (PEG-liposomes) was used in this study.  
Drug loading into PEG-PCL micelles was less efficient than drug loading into PEG-liposomes since 
an active encapsulation strategy was applied for PEG-liposomes using a pH gradient. The use of 
active (remote) loading strategies can dramatically increase the encapsulation efficiency [162]. 
Optimization of a protocol using transmembrane phosphate gradients for the encapsulation of 
doxorubicin in liposomes, for example, resulted in a 75-fold increase of the loading efficiency as 
compared to passive loading [163]. However, most active drug loading protocols using ion-gradients 
cannot be applied to micelles. Therefore, passive loading was used for PEG-PCL micelles resulting in 
a lower encapsulation efficiency as compared to PEG-liposomes. With respect to passive drug 
loading, PEG-PCL micelles may however be superior to liposomes for the delivery of highly lipophilic 
compounds such as paclitaxel, cyclosporine A, or the tyrosine-kinase inhibitor nintedanib. Whereas 
the loading capacity of the liposomal lipid bilayer is limited, the hydrophobic core of polymeric 
micelles serves as reservoir for such substances. It was, for example, shown the hydrophobic drug 
β-carotene (XLogP3: 13.5) was encapsulated efficiently in PEG-PCL micelles whereas a lower 
encapsulation efficiency and drug loading content was obtained with doxorubicin [164]. The core of 
polymeric micelles is in general characterized by a remarkable stability [165]. Consequently, 
doxorubicin was stably encapsulated in PEG-PCL micelles and a slow drug release was observed: 
Less than 20% of the initial drug content was released after 3 days. 
In a next step, the pharmacological effect of doxorubicin was analyzed. Doxorubicin showed similar 
effects on cell viability and subcellular distribution when applied as free drug, encapsulated in 
PEG-liposomes, or PEG-PCL micelles. Thus, no benefit on the in vitro pharmacological effect of 
doxorubicin was obtained. Nevertheless, the use of PEG-PCL micelles for the delivery of doxorubicin 
may be beneficial regarding its in vivo performance: A major advantage of nanoparticulate drug 
delivery systems is the ability to change PK properties of drugs. As mentioned above, free 
doxorubicin is characterized by poor blood circulation properties and its use is therefore limited. In 
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addition, accumulation in off-target tissues such as the heart can be dose limiting. Cardiotoxicity is a 
serious issue related with doxorubicin therapy and is significantly reduced when long-circulating drug 
carriers are used as compared to administration of the free drug [166,167]. Although previous 
research was analyzing the PK profile of PEG-PCL NPs (summarized in Chapter I), variable particle 
characteristics such as size and size distribution, surface charge, and drug payload influence the PK 
profile. Therefore, new NP formulations need to be tested individually. In addition, the experimental 
procedure (e.g. route of injection, animal species, and anesthesia) and the analytics can strongly 
influence the experimental outcome of PK studies. To obtain valid results, an established protocol 
[61,76] using cannulated rats was chosen  and the PK profile of PEG-PCL micelles was compared to 
free doxorubicin and the gold standard for long-circulating drug carriers (PEG-liposomes) in the same 
experimental setting. Encapsulation of doxorubicin in PEG-PCL micelles dramatically influenced its 
circulation half-life, plasma clearance, and tissue distribution. A similar behavior was observed for 
doxorubicin-loaded PEG-liposomes. Thus, the question arises, why alternatives to PEG-liposomes 
are of big interest? As mentioned above, PEG-PCL micelles show advantages regarding the loading 
efficiency of hardly soluble drugs. In addition, enhanced clearance of PEG-liposomes upon repeated 
administration was reported. This phenomenon is called accelerated blood-clearance (ABC) effect 
and is attributed to an immune response (e.g. anti-PEG-liposome IgM) [168]. The extent of this 
clearance depends on factors such as architecture and orientation of the PEG coating, type of 
nanocarrier, encapsulated drug, dose, and dose regimen [169,170]. Thus, chemically versatile 
PEG-PCL NPs depict an alternative if an immune response and subsequent ABC is observed in 
patients treated with PEG-liposomes. Importantly, previous studies in pretreated ABC animals 
showed that PEGylated micelles have a lower cross reactivity in vivo as compared to other 
PEGylated nanocarriers [171].  
 
3 EXTRAVASATION, TUMOR ACCUMULATION, AND TISSUE PENETRATION 
Long circulating drug delivery systems such as PEG-PCL micelles that remain in the blood 
compartment for hours can be used for passive targeting of solid tumors (EPR effect). As outlined in 
the Introduction, such tumors are often characterized by leaky vasculature and show reduced and 
inefficient lymphatic drainage [63–65,172,173]. As a result, NPs can extravasate from the blood 
circulation and accumulate at the tumor due to reduced and inefficient removal from the interstitial 
space. The extravasation to tumors strongly depends on physico-chemical properties of the 
nanomedicine, the tumor blood flow, the extend and size of the endothelial fenestration (i.e. 
leakiness), and the TME [174,175]. It has to be considered that tumor-related factors vary significantly 
within a tumor and between patient subpopulations. This heterogeneity and inadequate patient 
selection criteria in clinical trials is believed to be one of the main reasons for the poor translation of 
promising preclinical results into the clinical application [68]. Therefore, the use of diagnostic 
companion NPs or theranostics is an important consideration for future application of nanomedicines 
in cancer therapy [153]. In Chapter III, a protocol for the preparation of gold-nanohybrid NPs was 
developed. Encapsulation of gold NPs did not change the physico-chemical properties of the drug 
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carrier. The nanoreactor protocol was applicable to different types of nanomaterials (i.e. lipid- and 
polymer-based) and may therefore serve as a valuable strategy for the preparation of diagnostic or 
theranostic NPs. The protocol could further be adapted for the synthesis of iron oxide-nanohybrids 
that serve as contrast agents for MRI and PET [87,176,177]. PEG-PCL gold- and iron oxide-
nanohybrids, for example, were used for imaging in vivo using MRI [176]. The use of PEG-PCL 
nanohybrids can thus help to identify patients that benefit from nanoparticulate drug delivery and 
drive the development of personalized treatment approaches. The extent of passive tumor 
accumulation of PEG-PCL micelles developed in this PhD project needs however to be tested in 
further experiments (see Outlook).  
After extravasation and accumulation in the tumor, NPs need to reach the tumor cells. Notably, many 
solid tumors are characterized by necrotic areas that show a low blood supply and are therefore not 
accessible via the vascular route. Deep tumor penetration is therefore an important factor for 
successful treatment of solid tumors using NPs [153]. Several strategies such as modification of the 
TME or NP decoration with cell penetrating peptides were discussed to enhance the depth and 
uniformity of tumor penetration. It was shown that the size and shape of NPs strongly influence the 
extent of tumor penetration: Small NPs and NPs with an elongated shape (i.e. high aspect ratio) 
penetrate tumor tissue more efficiently and deeply as their spherical counterparts [178]. An 
adaptation of the preparation protocol for PEG-PCL micelles conducted in our group resulted in the 
formation of filomicelles (Supplementary Fig. S4) with a high aspect ratio of ≈ 5.2 ± 1.9 [179]. These 
elongated PEG-PCL micelles could therefore be used for the treatment of tumors that have large 
necrotic areas and are accessible via deep tumor penetration only.  
 
4 ACTIVE DRUG TARGETING AND CELLULAR INTERNALIZATION 
Many drugs that show efficiency in large tumors do not reach metastatic sites. In contrast to solid 
tumors that may show EPR and allow passive accumulation of long circulating nanomedicines, small 
tumors and metastases are often characterized by poor vascularization and are less susceptible for 
passive targeting [56,68,180]. Keeping in mind that the high mortality rate of cancer diseases is often 
correlated with secondary cancer (i.e. metastases) rather than primary solid tumors, the 
implementation of active drug targeting strategies that enable specific delivery of drugs to small 
tumors or metastases is needed. The use of novel high-throughput “-omics” technologies (e.g. 
proteomics) lead to the detection of surface antigens and receptors that are preferentially expressed 
on malignant cells. By using targeting moieties such as antibodies to decorate nanoparticulate drug 
delivery systems, enhanced cellular uptake can be achieved [181]. In Chapter IV, targeted PEG-PCL 
micelles were developed. As a model antibody which might have advantages for glioma therapy as 
described in the following section, 83-14 mAb was conjugated to PEG-PCL micelles. This antibody is 
directed against the human insulin receptor (HIR), a receptor that is highly expressed on endothelial 
cells of the blood-brain barrier (BBB) [182]. The BBB prevents transport of many drugs to the brain 
and is a major obstacle in the treatment of central nervous system (CNS)-related diseases [183]. 
Several strategies to overcome this barrier were therefore developed. A promising approach is the 
 140 
use of so-called Trojan horses, i.e. the use of ligands or antibodies that bind specific receptors on the 
BBB and promote transport (i.e. transcytosis) of their cargo to the brain [184]. This strategy was used 
to ferry enzyme-antibody fusion proteins across the BBB with promising results in the treatment of 
e.g. lysosomal storage diseases [185–187]. The BBB also plays an important role in cancer 
progression and therapy. The BBB is, for example, a key factor for migration of cancer cells in the 
development of brain metastases [188]. Since CNS metastases often result in poor prognosis, 
targeting the BBB and inhibiting cancer cell migration into the brain may depict a promising 
therapeutic approach. In primary brain tumors, the BBB function is impaired in hypoxic areas of the 
tumor and can be considered to be leaky: Therefore, the term blood-brain tumor barrier (BBTB) was 
introduced [189]. This phenomenon can lead to the development of peritumoral edema and tumor-
derived seizures [189]. However, in less aggressive and diffuse parts of brain tumors, the BBTB 
remains its protecting function and shows a high similarity with the intact BBB [190]. The transport of 
anticancer drugs to these parts of the tumor is therefore limited. Improving the delivery of small 
molecular drugs and biologics to CNS tumors is thus a prerequisite for efficient treatment of brain 
tumors and needs to be improved in future therapeutic approaches [191]. Whereas the drug carrying 
capacity for ADCs and antibody-fusion proteins is limited, NPs can transport a substantial number of 
drug molecules that exceed ADCs by three to four orders of magnitude [3]. Targeted PEG-PCL 
micelles developed in this work showed an increased cellular uptake by human brain microvascular 
endothelial cells. The gold-nanohybrid strategy described in Chapter III was used to analyze the 
intracellular fate of PEG-PCL micelles. An accumulation in multi-vesicular bodies (MVBs) after 60 min 
of incubation was observed. MVBs are intracellular sorting organs that contain intraluminal vesicles 
[192]. Interestingly, the endogenous substrate of the HIR, insulin, was found to accumulate in MVBs 
in a similar manner [193]. However, it needs to be elucidated if PEG-PCL-mediated transport can be 
translated into the in vivo situation. Whereas 83-14 mAb was shown to be transported across the 
BBB more efficiently than other ligands such as anti-transferrin receptor (TFR) antibodies [194], this 
promising targeting ligand shows some drawbacks with respect to preclinical testing: Only few 
species (i.e. primates) may be used for testing 83-14 mAb constructs in vivo [195]. Therefore, 
alternative anti-rodent insulin receptor antibodies such as the 29B4 antibody are of big interest to 
enable preclinical testing [196]. Alternatively, such targeting strategies may be adapted to other 
epitopes and receptors such as the TFR, the low-density lipoprotein receptor (LDLR), or the low-
density lipoprotein receptor-related protein 1 (LRP1) [197–199].  
 
5 NS1-THERAPY FOR HEPATOCELLULAR CARCINOMA 
The use of anticancer genes and their proteins is a promising therapeutic concept [200,201]. In 
Chapter V, a novel therapeutic strategy to treat liver cancer was established using the H-1PV-
derived anticancer gene coding for NS1. NS1 is a multifunctional protein that interacts with various 
cellular proteins and interferes with several cellular pathways resulting in a multimodal killing of 
cancer cells: NS1 (H-1PV infection) can promote apoptosis, necrosis, and lysosomal-like 
programmed cell death [138]. As outlined in the Introduction, most tumors do not depend on single 
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dysregulations and thus the paradigm to target various signaling pathways in cancer treatment was 
introduced [127,130,131]. The fast development of acquired therapy resistances due to mutation of 
single cellular targets can dramatically reduce the therapeutic success of anticancer drugs targeting 
single pathways [129,202]. In contrast, multimodal killing induced by NS1 has a lower risk of acquired 
resistances since mutation of a single cellular target will be bypassed by complementing toxic effects. 
In addition, NS1 can be used to treat pre-treated patients that already acquired resistances to 
chemotherapeutics and apoptosis-inducers such as cisplatin [203]. Furthermore, NS1 is a prodrug 
that needs to be activated prior to its pharmacological effect. Activation of the PDK1/PKC/PKB 
signaling pathway is pivotal for NS1 toxicity. As a consequence, NS1-mediated therapy is 
preferentially toxic for malignantly transformed cells since this signaling cascade frequently shows 
increased activity in cancer cells. Thus, this strategy has the potential to increase the therapeutic 
efficiency, to increase tumor specificity, minimizes the risk for development of resistances, and to 
serve as alternative therapeutic approach for patients suffering from resistances (i.e. bypass 
resistances) [128,129]. The anticancer gene NS1 and its protein product is therefore an ideal drug for 
the treatment of cancer. However, most approaches using NS1 in cancer therapy were limited to 
infection with H-1PV. The rat parvovirus H-1PV was well characterized in preclinical studies and 
successfully entered a Phase-I/IIa clinical trial for the treatment of patients suffering from recurrent 
glioblastoma multiforma [138,150,204]. As mentioned above, viral therapeutics may suffer form 
several drawbacks. Therefore, this project aimed to use non-viral gene delivery methods for the 
expression of NS1 and to further increase the therapeutic potential of this promising anticancer gene. 
Established lipoplex NPs (LNPs) were chosen to study non-viral NS1-based therapeutic approaches. 
LNPs were characterized by a size around 100 nm and a slightly positive zeta potential. LNPs were 
efficiently internalized by HCC cells in vitro and a high transfection efficiency with up to 85% of 
NS1-GFP positive cells was achieved. The use of positively charged drug delivery vehicles is 
however limited: After systemic administration, these drug carriers show a fast removal from the 
central blood compartment and accumulate in off-target tissue such as the lungs [205]. An ideal 
carrier for NS1 would show long circulating properties and allow targeted delivery to tumor cells while 
remaining the high transfection efficiency obtained in this study. A strategy to improve this drawback 
is outline in the Outlook of this thesis.  
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OUTLOOK AND FUTURE PERSPECTIVES 
This PhD project aimed to implement nanoparticulate drug delivery systems and novel therapeutic 
strategies for the treatment of cancer. Several ongoing and future research projects and 
collaborations were initiated and will further contribute to the development of PEG-PCL micelles for 
cancer therapy.  
 
1 SCALE-UP AND STORAGE STABILITY 
Scale-up of nanoparticulate drug delivery systems remains difficult. Thus, innovative approaches for 
the formulation of such systems are of big need. Microfluidics (Chapter III) is a promising method 
that shows several advantages over bulk production. This method allows systematic optimization of 
NP formulations, especially when combined with design of experiments (DoE). In addition, 
microfluidics-assisted formulation of NPs is a promising tool for transfer of small research-scale 
batches to large-scale production in clinical research [206]. In a next step, a preparation protocol for 
PEG-PCL micelles using microfluidics will be established. In preliminary experiments, PEG-PCL 
micelles with a diameter below 100 nm were obtained using acetone as a solvent. This protocol can 
further be adapted for drug loading and/or labeling of PEG-PCL micelles.  
Although PEG-PCL micelles prepared in this thesis were stable over month when stored in adequate 
buffer and at reduced temperatures, storage stability of NPs is an important issue. During a master 
thesis project, a DoE was therefore used for the optimization of freeze-drying of doxorubicin-loaded 
PEG-PCL micelles (Supplementary Fig. S5) [207]. Lyophilization dramatically improves the storage 
stability of NPs and allows production of large batches, a major advantage regarding the scale-up of 
NP formulations [208]. The influence of additives such as bulking agents and cryo-protectants on the 
parameters size, size distribution, and drug release after NP reconstitution was analyzed [207]. The 
optimized formulation contained a mix of trehalose and poloxamer 188. After reconstitution, Dox-
PEG-PCL micelles showed less than 15% change in mean particle diameter and had a monodisperse 
size distribution (PDI below 0.2) [207]. 
 
2 PEG-PCL MICELLES FOR DELIVERY OF SMALL MOLECULAR DRUGS 
Doxorubicin-loaded PEG-PCL micelles will be analyzed in a xenograft model for their capacity to 
passively accumulate at the tumor site. In a first step, biodistribution of PEG-PCL micelles can be 
followed by using near infrared dyes such as DiR that allow real-time in vivo imaging of small 
experimental animals. Labeling of PEG-PCL micelles using hydrophobic carbocyanine dyes (DiI) was 
already performed (Chapter IV) and was shown to be feasible. In a next step, concentrations of 
tritium-labeled doxorubicin in target (tumor) and off-target tissue can be analyzed ex vivo as shown in 
Chapter II. In a last step, therapeutic effects induced by doxorubicin encapsulated in PEG-PCL 
micelles will be analyzed by tracking of tumor volume and overall health status of tumor-bearing 
animals. In addition, staining of proliferating (Ki67) and apoptotic (TUNEL) tumor cells can be used. A 
similar approach was used in the preliminary in vivo proof-of-concept study of NS1 (Chapter V).  
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Since loading of doxorubicin was suffering from a low encapsulation efficiency and drug loading 
content, a more hydrophobic drug could be combined with PEG-PCL micelles in a next step. 
Inhibitors of fibroblast growth factor receptor 4 (FGFR4) are promising candidates for the treatment of 
liver cancer [209–211]. A couple of candidates are in ongoing clinical trials (e.g. the Novartis 
compound FGF401 in a Phase I/II clinical trial). The FDA approved FGRF4 (multi-tyrosine kinase) 
inhibitors nintedanib (BIBF 1120) and ponatinib were successfully used for the treatment of HCC. 
They showed similar or superior effects as compared to sunatinib, the gold-standard in HCC 
chemotherapy [209,212]. However, these compounds are characterized by severe side effects (e.g. 
liver toxicity) and suffer form low water solubility. Therefore, advanced delivery strategies are needed. 
In collaboration with the research group of Prof. Dr. Walter Berger (Cancer Research Center, Medical 
University of Vienna, Austria), delivery of FGFR4 inhibitors encapsulated in PEG-PCL micelles will be 
analyzed. This group has a great expertise in this class of therapeutics and the understanding of 
acquired resistances during cancer therapy.  
 
3 PEG-PCL MICELLES FOR TARGETED DRUG DELIVERY IN VIVO 
The strategy to develop targeted PEG-PCL micelles shown in Chapter IV can be further improved. In 
a next step, a targeting ligand that can be used for preclinical testing in experimental animals such as 
mice or rats will be used. For example, conjugation of antibodies directed against LRP1 is a 
promising approach. Such antibodies were developed by the group of Prof. Dr. Claus Pietrzik 
(Johannes zu Gutenburg-University, Mainz, Germany) to analyze the influence of LRP1 in BBB 
transport of Aβ peptides in Alzheimer’s disease [213,214]. In addition, this group has developed 
powerful assays to analyze LRP1-mediated transport in vitro and has established an inducible knock-
out mouse that is deficient of LRP1 in brain capillary endothelial cells [214]. These tools will allow 
testing targeted PEG-PCL micelles in vitro and in vivo for their use as drug delivery vehicles. In 
preliminary experiments, successful conjugation of these antibodies to PEG-PCL micelles and PEG-
liposomes was achieved. These targeted PEG-PCL micelles will now be analyzed for their ability to 
enhance drug delivery to the brain. Fluorescence correlation spectroscopy (FCS) will further be used 
to determine and optimize the number of antibodies per PEG-PCL micelle. In addition, the use of 
gold-nanohybrids (Chapter III) will further help to understand the mechanisms of cell interaction and 
to track targeted micelles after cellular uptake. Besides the potential for treatment of Alzheimer’s 
disease, LRP1 was successfully used for the treatment of brain tumors recently. Angiopep-2, a 
peptide ligand of LRP1 [215], was conjugated to paclitaxel (ANG1005) [216] or paclitaxel-loaded 
PEG-PCL NPs [217,218]. These constructs showed superior efficiency in treatment of CNS tumors as 
compared to free paclitaxel.  
 
4 NS1-THERAPY FOR HEPATOCELLULAR CARCINOMA 
H-1PV-derived NS1 was analyzed as therapeutic intervention for HCC (Chapter V). Expression of this 
oncotoxic protein resulted in specific induction of multimodal cell death in cancer cells whereas 
healthy primary human hepatocytes were unaffected. Activation of NS1 by cellular kinases 
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(PDK1/PKC/PKB pathway) that are dysregulated in cancer was found to be major reason for this 
oncotropism that was previously described for H-1PV in glioma therapy [149]. The analysis of PDK1 
status in more than 400 HCC patients (i.e. tissue microarray) is ongoing and results are expected 
soon. This will give insight in HCC cancer progression and sensitivity of this cancer type to NS1-
mediated therapy. In the future, this biomarker can be used for patient stratification and thus to allow 
personalized medicine. In addition, a targeted RNA sequencing is ongoing to reveal a more detailed 
mechanistic insight into NS1-induced cell death in liver cancer cells. Finally, a proof-of-concept study 
in HCC-bearing mice (Hep3B xenograft model) is ongoing to show the potential of NS1 in vivo.  
The use of positively charged LNPs restricts the use of this therapeutic approach to tumors that are 
accessible via local delivery [205]. Whereas this may be feasible for cancers such as HCC (e.g. via 
catheter for chemo-embolization) or melanoma, therapy of delocalized tumors and metastases is not 
possible. Consequently, future experiments will focus on the development of delivery and targeting 
strategies. Chemically modified PEG-PCL will be used to prepare PEG-PCL pDNA micelles and to 
specifically deliver NS1 to cancer cells. As summarized in Chapter I, synthesis of PEG-PCL-PEI tri-
block copolymers for the formulation of micelles is a promising strategy for systemic nucleic acid 
delivery. Whereas these polymeric micelles are able to efficiently complex pDNA, their PEG corona 
renders them long circulating and enables systemic delivery.  
To further improve the therapeutic effect of NS1, several combination therapies with small molecules 
and other biologics were proposed. The simultaneous therapy with H-1PV and sub-toxic doses of 
valproic acid, for example, increased the therapeutic potential of H-1PV [219]. In another trial, the 
combination of oncolytic measles vaccine virus and another histone deacetylase (HDAC) inhibitor 
(resmonistat) with FDA Orphan Drug status for liver cancer showed promising results in the treatment 
of HCC [220]. However, as summarized in Chapter I, translating synergistic therapy regimens from 
the preclinical setup to the patient situation remains difficult. The use of a multi-component 
nanoparticulate drug carrier for the synchronized delivery of NS1 and a small molecular HDAC 
inhibitor such as resmonistat could improve the in vivo performance of this therapeutic approach. For 
example, a multi-component PEG-PCL-PEI micelle was used for the simultaneous delivery of siRNA 
to knock-down the expression of p-glycoprotein (P-gp) and doxorubicin [221]. Additionally, 
combination of NS1 with other viral proteins such as apoptin or the H-1PV structural (capsid) protein 
VP1 could further potentiate the toxic effects of NS1. It was shown that NS1 and apoptin can be 
combined to further enhance the therapeutic effect of NS1 [212]. Similar results were obtained when 
NS1 was combined with VP1: Combination of these two parvoviral proteins resulted in increased 
cytotoxicity and several strategies such as the parallel expression or the formation of a NS1 VP1 
fusion protein were proposed [213]. 
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CONCLUSION 
The use of targeted nanomedicines for the delivery of small molecular drugs and nucleic acids is a 
promising alternative to conventional chemotherapies. By enhancing the ratio of toxicity in tumor 
versus non-target cells, these drug carriers can improve the therapeutic index of cancer therapy. 
Especially in small or delocalized (e.g. metastatic) tumors where radiotherapy and surgical removal 
are not applicable, there is an urgent need for the development of adequate chemotherapeutics and 
advanced drug delivery systems. Characterized by biodegradability and biocompatibility, PEG-PCL 
depicts a promising polymer for the development of such delivery systems. PEG-PCL micelles are 
long circulating, can be chemically modified to target specific cell types, PEG-PCL gold-nanohybrids 
can be used for imaging and diagnostics, and PEG-PCL variants are suitable for gene delivery. The 
proposed drug delivery and drug targeting strategies will be instrumental to implement PEG-PCL 
micelles for cancer therapy.  
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ABBREVIATIONS 
 
AAV  Adeno-Associated Virus 
ABC  Accelerated Blood-Clearance 
ADC  Antibody Drug Conjugate 
AUC Area Under the Plasma Concentration 
Curve 
 
BBB  Blood-Brain Barrier 
BBTB  Blood-Brain Tumor Barrier 
 
CAC Critical Association Concentration 
Cas9  CRISPR Associated Protein 9 
CL  Plasma Clearance 
CNS  Central Nervous System 
CRISPR Clustered Regularly Interspaced Short 
Palindromic Repeats 
CT  Computer Tomography 
 
DiI 1,1’-Dioctadecyl-3,3,3’,3’-
Tetramethylindocarbocyanine 
Perchlorate 
DiR 1,1’-Dioctadecyl-3,3,3’,3’-
Tetramethylindotricarbocyanine Iodide 
DLS  Dynamic Light Scattering 
DMPK Drug Metabolism and 
Pharmacokinetics 
DNA  Deoxyribonucleic Acid 
DoE  Design of Experiments 
 
EGFR Endothelial Growth Factor Receptor 
ENM  Engineered Nanomaterials 
EPR Enhanced Permeability and Retention 
Effect 
 
Fab’  Monoclonal Antibody Fragment 
FDA U S Food and Drug Administration  
FGFR4 Fibroblast Growth Factor Receptor 4 
 
GBM  Glioblastoma Multiforme 
GFP  Green fluorescence protein 
GM-CSF Granulocyte-Monocyte Colony-
Stimulating Factor 
GNP  Gold Nanoparticle 
 
H-1PV  H-1 Parvovirus 
HCC  Hepatocellular Carcinoma 
HDAC  Histone Deacetylase 
HIR  Human Insulin Receptor 
 
IFN  Interferon 
IL-2  Interleukin-2 
LDLR Low-Density Lipoprotein Receptor 
LNP  Lipoplex Nanoparticle 
LRP1  Low-Density Lipoprotein  
  Receptor-Related Protein 1 
 
mRNA  Messenger RNA 
miRNA  Micro RNA  
MMP  Matrixmetalloprotease 
MPS  Mononuclear Phagocyte System 
MRI  Magnet Resonance Imaging 
MVB  Multi-Vesicular Body 
MVM  Minute Virus of Mice 
 
Nagg  Aggregation Number 
NIR  Near Infrared 
NP  Nanoparticle 
NS1  Large Non-Structural Protein 1 
NTA  Nanoparticle Tracking Analysis 
 
PC  Phosphatidylcholine 
PCL  Poly(ε-caprolactone) 
PDK1 Phosphoinositide-Dependent Kinase-
1 
pDNA  Plasmid DNA 
PEG  Poly(ethylene glycol) 
PEI  Poly(ethyleneimine) 
PET Positron Emission Tomography 
PGA  Poly(glycolic acid) 
P-gp  P-Glycoprotein 
PK  Pharmacokinetics 
PKB  Protein Kinase B 
PKC  Protein Kinase C 
PLA  Poly(lactic acid) 
PLGA  Poly(lactide-co-glycolide) 
PTEN Phosphatase and Tensin Homolog 
Deleted on Chromosome 10 
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PV  Parvovirus 
 
RNA  Ribonucleic Acid 
siRNA  Small Interfering RNA 
SLS  Static Light Scattering 
ssDNA  Single Strand DNA 
 
t1/2  Plasma half-life 
TEM Transmission Electron Microscopy 
TFR  Transferrin Receptor 
TGF-β  Tumor Growth Factor β 
TME Tumor Microvascular Environment 
 
TUNEL TdT-Mediated dUTP-Biotin Nick End 
Labeling 
 
U-SAXS Ultra Small X-Ray Spectroscopy 
 
VD Systemic Volume of Distribution 
VEGFR-2 Vascular Endothelial Growth Factor 
Receptor 2 
VP1 H-1 parvovirus structural protein 1 
 
WHO  World Health Organization 
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SUPPLEMENTARY INFORMATION 
S1. Nanoparticle Tracking Analysis 
 
Figure S1 Nanoparticle Tracking Analysis of of PEG-PCL micelles. Size distribution represents mean ± S.D. of n = 5 
measurements. Insert: representative video frame. 
 
Table S1 Nanoparticle Tracking Analysis of PEG-PCL micelles. Values represent means ± S.D. of n = 5 experiments.  
 PEG-PCL-NPs 
Mean [nm] ± SE 83.2 ± 0.9 
Mode [nm] ± SE 78.8 ± 1.5 
D10 [nm] ± SE 67.1 ± 0.8 
D90 [nm] ± SE 95.9 ± 1.1 
Conc [NPs/mL] ± SE 1.22 x 109 ± 1.44 x108 
 
Experimental section. 
NTA analysis of NP size and size distribution was performed using the Nanosight NS300 equipped 
with a 405 nm laser (Malvern Instruments Ltd, Instrumat AG, Switzerland). In brief, the chamber was 
cleaned with fresh PBS (Sigma-Aldrich, PBS, D8537) and analyzed to confirm the absence of any 
particles. The PEG-PCL micelle suspensions were diluted 1:1000 in PBS and injected using 1 mL 
sterile syringes. For the video recording the syringe pump speed was set to 50. The temperature was 
kept between 25.7°C ± 0.1, the camera level was set to 11 and detection threshold was set to 2. A 
total number of 1498 frames were recorded using a sCMOS camera and analyzed using the NTA 3.1 
Build 3.1.54 software. Five video recordings of each sample were performed. Aggregation number 
(Nagg) of PEG-PCL micelles was calculated using the particle concentration obtained in NTA analysis. 
The number of PEG-PCL unimers per mL was therefore divided by the particle concentration that 
was measured by NTA.  
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S2. Ultra-small angle X-ray scattering analysis 
 
Figure S2 Ultra-small angle X-ray scattering analysis of PEG-PCL micelles.  
 
Table S2 Ultra-small angle X-ray scattering analysis of PEG-PCL micelles.  
  PEG-PCL-NPs 
Distribution 1 Mean [nm] 109.4 
 Max. probability [nm] 100 
 Volume [%] 49.47 
Distribution 2 Mean [nm] 497.1 
 Max. probability [nm] 381.6 
 Volume [%] 50.53 
Average (1+2) Mean [nm] 305.3 
 R-factor 0.0373 
 
 
Experimental section. 
Ultra small-angle X-ray scattering (U-SAXS) measurements were performed on Rigaku SmartLab 
diffractometer equipped with 9kW rotating anode generator, 2-bounce Ge (220) monochromator and 
high resolution U-SAXS 2-bounce channel crystal analyser (Rigaku Corporation, Tokyo, Japan). The 
samples (~50 mg/mL in miliQ water) were filled in glass capillaries (0.9 mm diameter, 0.01 mm wall 
thickness, Hilgenberg, Malsfeld, Germany) and exposed to X-rays of Cu wavelength (1.541 Å). 
Scattered X-rays were recorded on SC-70S scintillation counter detector (Rigaku Corporation, Tokyo, 
Japan) in range of 0 – 0.5 2θ scattering angle. Sample to detector distance was 300 mm. The optics 
were set as follow: parallel beam slit, 2-bounce Ge (220) monochromator, incident parallel open soller 
slit, 1 mm incident slit, 10 mm length limiting slit on the incident arm of the goniometer and 2 mm 
receiving slit #1, U-SAXS analyser, receiving parallel 5.0 deg soller slit, 20 mm receiving slit #2 on the 
receiving arm of the goniometer. Recorded data were analysed with Particle-/Pore-size Analysis 
Software NANO-Solver 3.7 (Rigaku Corporation, Tokyo, Japan). Results are shown of n = 1 
experiments.  
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S3. Langmuir through 
 
Figure S3 Determination of the critical aggregation concentration (CAC) by surface activity measurments. The CAC is 
indicated with a red triangle at a PEG-PCL concentration of 0.5 μg/mL (2.8 x 10-7 M). 
 
Experimental section. 
Measurement of surface activity were performed on a round Teflon trough designed by Fromherz 
[222]. Measurement was performed at room temperature and 20 mL filling volume compartment was 
used. The surface pressure was measured by the Wilhelmy method by using plates cut from filter 
paper (Whatman no. 1). Before each measurement, the trough and the filter paper were cleaned with 
ethanol and nanopure water. The filter paper was left to equilibrate in water until a constant surface 
tension was reached. The surface tension, γ0, of water was set to zero and the surface pressure, π, of 
the PEG-PCL, which is the difference between the surface tension of pure water, γ0, and the surface 
tension of water containing the PEG-PCL, γ, was recorded – i.e. π = γ0 – γ. 
Water was stirred with a tiny magnet and small aliquots of the PEG-PCL solution in THF (5 mg/mL) 
were added. The surface pressure was monitored until the equilibrium was reached. Results are 
shown of n = 1 experiment. 
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S4. Filomicelles 
 
Figure S4 Transmission electron micrograph of PEG-PCL filomicelles after negative staining with uranylacetate. Scale bar: 
500 nm. 
 
 
Experimental section.  
PEG-PCL filomicelles were prepared as described previously [179]. In brief, 10 mg of PEG-PCL were 
dissolved in 1 mL of THF. Then, 10 mL of water were added dropwise under constant stirring at 
700 rpm. After 30 min, the suspension was dialyzed (12-14 kDa MWCO) against water for 24 h. Water 
was exchanged every 8 h to remove traces of THF. NP size and shape was analyzed by transmission 
electron microscopy (TEM) using a CM-100 (Philips, Eindhoven, Netherlands) operating at 80 kV. 
Samples were mounted on a 400-mesh carbon copper grid that was pre-exposed to plasma (10 sec) 
for increased sample binding.  Samples were negatively stained unsing a 2% uranylacetate solution 
(Sigma Aldrich, Buochs, Switzerland) and were dried at room temperature over night.  
 
 
S5. Lyophilization of Dox-PEG-PCL micelles 
 
Figure S5 Lyophilizates of Dox-PEG-PCL micelles.  
 
Experimental section and results are summarized in [207].  
 
 
